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ABSTRACT 
Vincent S. Tagliabracci 
METABOLISM OF THE COVALENT PHOSPHATE IN GLYCOGEN 
 Glycogen is a highly branched polymer of glucose that functions to store 
glucose residues for future metabolic use.  Skeletal muscle and liver comprise 
the largest glycogen reserves and play critical roles in maintaining whole body 
glucose homeostasis.  In addition to glucose, glycogen contains small amounts 
of covalent phosphate of unknown function, origin and structure.  Evidence to 
support the involvement of glycogen associated phosphate in glycogen 
metabolism comes from patients with Lafora Disease.  Lafora disease is an 
autosomal recessive, fatal form of progressive myoclonus epilepsy.  
Approximately 90% of cases of Lafora disease are caused by mutations in either 
the EPM2A or EPM2B genes that encode, respectively, a dual specificity 
phosphatase called laforin and an E3 ubiquitin ligase called malin.  Lafora 
patients accumulate intracellular inclusion bodies, known as Lafora bodies that 
are primarily composed of poorly branched, insoluble glycogen-like polymers.  
We have shown that laforin is a glycogen phosphatase capable of releasing 
phosphate from glycogen in vitro and that this activity is dependent on a 
functional carbohydrate binding domain.  In studies of laforin knockout mice, we 
observed a progressive change in the properties and structure of glycogen that 
paralleled the formation of Lafora bodies.  Glycogen isolated from these mice 
showed increased glycogen phosphate, up to 6-fold (p< 0.001) compared to WT, 
providing strong evidence that laforin acts as a glycogen phosphatase in vivo.  
Furthermore we have demonstrated that glycogen synthase introduces 
phosphate into glycogen during synthesis by transferring the -phosphate of 
UDP-glucose into the polymer and that laforin is capable of releasing the 
phosphate incorporated by glycogen synthase.  Analysis of mammalian glycogen 
revealed the presence of covalently linked phosphate at the 2 hydroxyl and the 3 
hydroxyl of glucose residues in the polysaccharide, providing the first direct 
evidence of the chemical nature of the phosphate linkage.  We envision a 
vii 
glycogen damage/repair process, analogous to errors during DNA synthesis that 
are subsequently repaired.  We propose that laforin action parallels that of DNA 
repair enzymes and Lafora disease results from the inability of the phosphatase 
to repair damaged glycogen, adding another biological polymer to the list of 
those prone to errors by their respective polymerizing enzymes. 
 
Peter J. Roach, Ph.D. -Chair 
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1 
INTRODUCTION 
 
1.  Glycogen Structure  
 
Glycogen is a highly branched polymer of glucose that functions to store 
glucose residues for future metabolic use.  The large majority of glycogen in 
animals is found in the liver and skeletal muscle, but heart, brain, adipose, as 
well as many other tissues are capable of synthesizing the polymer (1).  The 
mobilization of glucose from glycogen deposits in the liver provides a constant 
supply of glucose for tissues, such as the brain, which depends on this sugar for 
an energy source.  Skeletal muscle, on the other hand, lacks the enzymatic 
machinery for mobilization of glucose to the blood stream and glucose released 
from glycogen is catabolized locally.  Polymerization of glycogen occurs by the 
formation of -1,4-glycosidic linkages between glucose residues, forming an 
elongated polymer.  Branch points are introduced at the C6 hydroxyl of a glucose 
residue in the chain forming an -1,6-glycosidic linkage (Figure 1).  The 
frequency of -1,6-glycosidic linkages (about 1 every 8-12 glucose residues), 
determines the topology, structure and solubility of glycogen and distinguishes it 
from the carbohydrate moiety of plant starch.  A unique three dimensional 
structure of glycogen cannot be determined experimentally due to the fact that 
glycogen is polydisperse.  However much is known about the branching structure 
of glycogen and a widely accepted model has been proposed (2) (Figure 2).  In 
this model the average chain consists of 13 glucose residues where the inner B 
chains contain two branch points and the outer A chains are unbranched.  A full 
size glycogen molecule would consist of 12 tiers, have Mr ~107, a diameter of 
~40 nm and contain about 55,000 glucose residues (2).  Based on this model 
there is an equal number of A chains and B chains with a uniform distribution of 
chain lengths.  Furthermore, each B chain has two chains attached to it, and all 
the A chains are on the outermost tier.  The branching frequency of 1 branch 
point every 8-12 glucose residues is somewhat misleading, as it is the average 
over the entire glycogen molecule.  Given that the A chains are unbranched, the
2 
A
B
 
Figure 2.  Glycogen structure.  A portion of a molecule is shown, indicating the 
branching pattern, the tiered structure and the A and B chains.  The unbranched A 
chains account for about 50% of the total number of glucoses in the glycogen 
molecule. 
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Figure 1.  Glycosidic linkages in glycogen.  The traditional -1,4- and -1,6-
glycosidic linkages account for the bulk of the polymerization of glycogen (left).  
The structure of glucose, indicating the numerical nomenclature of the carbons 
(right). 
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average distance between branches would only apply to the B chains.  However, 
the A chains account for about 50% of the entire glycogen molecule, assuming 
they are of full length, so the distance between branch points on the B chains 
would be about 4 glucoses.   
In addition to glucose, glycogen also contains small amounts of covalently 
linked phosphate whose function and origin, until recently, was not well 
understood (3-7).  Rabbit skeletal muscle glycogen for example contains 0.064% 
by weight of phosphate or 0.12% mol phosphate/mol glucose.  This value 
corresponds to about 1 phosphate molecule for approximately every 650 glucose 
residues.  Covalently bound phosphate has been proposed to exist as a 
phosphomonoester at the C6-OH and a phosphodiester, linking C1 of one 
glucose residue to C6 of another residue forming an alternative branch point (4).  
Lomako et al. (4) proposed that a specific enzyme, termed UDP-glucose: 
glycogen glucose-1-phosphotransferase introduces this diester linkage, with the 
source of the phosphate from UDP-glucose.  The enzyme was not, however, fully 
characterized at the molecular level.  Covalently bound phosphate in plant 
amylopectin, a complex carbohydrate similar in structure to mammalian glycogen, 
is well accepted and alterations in starch phosphate levels have profound impact 
on starch metabolism (8).  Specific protein dikinases, unique to plants, are known 
to catalyze this phosphorylation (9).  Glucan water dikinase and phosphoglucan 
water dikinase transfer the  phosphate of ATP to C6 and C3 hydroxyl residues 
in amylopectin respectively.  Phosphorylation at C6 is thought to prime the 
polysaccharide for phosphorylation at the C3 hydroxyl (9).  Extensive analysis of 
mammalian genomes reveals no mammalian homologues of the dikinases 
identifiable by sequence comparison.  Furthermore, the starch phosphatase, 
starch excess 4 (SEX4), hydrolyzes both C6 and C3 phosphate from amylopectin.  
Genetic depletion of SEX4 in Arabidopsis leads to the accumulation of starch 
(10), presumably by preventing the degradation of the starch granule due to 
excessive phosphate (11).  
Besides phosphate, trace amounts of glucosamine have also been 
detected in rabbit liver glycogen, but not in skeletal muscle and heart glycogen 
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(12).  The glucosamine in liver glycogen has not been studied thoroughly and its 
importance in glycogen structure and metabolism, if any, is not understood.  
Glucosamine is thought to be incorporated into glycogen by glycogen synthase 
using UDP-glucosamine as the glucosyl donor (12).  Glucosamine is present as 
an -1,4-linkage and liver glycogen purified from rats injected with galactosamine 
contained as much as 10% glucosamine in the polysaccharide (12).   
The physiological relevance of these atypical, covalent structural 
components of glycogen is unknown.  Nevertheless emerging evidence points to 
a particularly important role for covalent phosphate in maintaining glycogen 
structure and solubility. 
 
2.  Glycogen Metabolism  
 
2.1  Preamble 
Glycogen metabolism is regulated largely by the coordinated action of 
glycogen synthase and glycogen phosphorylase, the rate limiting enzymes in 
glycogenesis and glycogenolysis, respectively.  The synthesis of glycogen can 
be initiated once sufficient uridine diphosphate glucose (UDP-glucose) is formed 
from the combined actions of a series of enzymes that convert glucose to UDP-
glucose.  This conversion is highly dependent on the nutritional status of the 
organism.  For example, when nutrients are limiting, the majority of ingested 
glucose will be oxidized through glycolysis and oxidative phosphorylation.  In 
times of nutritional abundance glucose can be converted to UDP-glucose and 
stored as glycogen.  In muscle, glucose is taken from the bloodstream by 
facilitated diffusion mediated by the GLUT4 transporter, whose translocation to 
the plasma membrane is dependent on the hormone insulin.  In liver, the 
constitutively active GLUT2 transporter facilitates glucose entry into hepatocytes, 
a process that is not dependent on insulin.  The intracellular glucose is rapidly 
converted to glucose-6-phosphate (glucose-6P) by glucokinase in the liver and 
hexokinase in muscle, at which time the cell’s nutritional status decides the fate 
of glucose-6P.  In times of low nutrient availability, glucose is oxidized whereas in 
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times of nutritional abundance, the glucose-6P is converted to glucose-1-
phosphate (glucose-1P) by phosphoglucomutase (PGM).  Glucose-1P is a 
substrate for UDP-glucose pyrophosphorylase (UGP), a uridylyltransferase that 
catalyzes the formation of UDP-glucose from UTP and glucose-1P.  Glycogen 
synthase then initiates bulk glycogen biosynthesis from a short oligosaccharide 
primer covalently linked to and synthesized by glycogenin.   
 
2.2  Glycogenin 
The necessity for a ‘primer’ in polysaccharide synthesis was suggested by 
the Cori’s in the early 1930’s (13), with the observation that glycogen synthesis 
by phosphorylase and glucose-1P proceeded only in the presence of a trace of 
glycogen.  Work by Whelan and Krisman (14, 15) led to the discovery of a 
specialized self glycosylating protein, glycogenin, that was found to be necessary 
for the initiation of glycogen biosynthesis.  Primates have two glycogenin genes, 
glycogenin-1, corresponding to the originally described enzyme, and glycogenin-
2.  In humans, glycogenin-1, encoded by the GYG1 gene, is widely expressed 
and predominates in muscle.  Glycogenin-2 is restricted to liver, heart, and to a 
lesser degree, pancreas. (16).  A patient has been described with a mutation in 
the GYG1 gene, resulting in the depletion of glycogen in skeletal muscle, and 
cardiac arrhythmia, associated with the accumulation of abnormal storage 
material in the heart (17). Glycogenin is a member of the family 8 retaining 
glycosyltransferases (GT8) and initiates the synthesis of glycogen through 
repeated self glycosylation reactions using UDP-glucose as a substrate to form a 
short glucose polymer approximately ten residues long (18, 19).  Two chemically 
distinct reactions are catalyzed by glycogenin, the first involving glucosylation of 
Tyr194 through the formation of a C1-O-tyrosyl linkage and the second involving 
the subsequent formation of the -1,4-glycosidic linkages.  The resulting -1,4-
linked oligosaccharide acts as a primer for bulk glycogen synthesis (20, 21).  
Glycogenin is an unusual enzyme, since it is the catalyst, a substrate and a 
product of the reaction.  The crystal structure of rabbit muscle glycogenin has 
been solved revealing the basic functional unit as a dimer (22).   
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2.3  Glycogen synthase 
The rate limiting intracellular enzyme in glycogen biosynthesis is glycogen 
synthase.  Glycogen synthase catalyzes the formation of the -1,4-glycosidic 
linkages in glycogen by transferring a glucosyl moiety from UDP-glucose to the 
non-reducing end (C4-OH) of a glycogen molecule with the release of UDP 
(Figure 3).  Although the mechanism of this reaction is not completely understood, 
it has been proposed that an unstable oxonium ion intermediate is formed, giving 
the anomeric carbon on the glucosyl moiety positive character, allowing for attack 
of the C4-OH at the non-reducing end of the glycogen particle (23).  Glycogen 
synthase belongs to the family 3 retaining glycosyltransferases (GT3) and 
mammals express two isoforms, one of which is liver specific and the other 
expressed in muscle and other tissues (1).  The regulation of glycogen synthase 
is complex, as both phosphorylation and allosteric regulation play major roles in 
controlling enzyme activity.  In fact, glycogen synthase was the third enzyme 
shown to be controlled by reversible phosphorylation (24).  Normally, 
phosphorylation by protein kinases inactivates the enzyme but this inactivation 
can be overcome by the potent allosteric activator glucose-6P (25).  In the 
laboratory, glycogen synthase activity is measured in the absence and presence 
of glucose-6P. The ratio of the two activities, (minus glucose-6P divided by plus 
glucose-6P), generates an activity ratio which is used as a kinetic index of the 
state of activation of the enzyme due to its covalent phosphorylation status (25).  
For example, a low activity ratio would be indicative of a highly phosphorylated 
and inactivated enzyme, whereas a high activity ratio is indicative of an active, 
dephosphorylated enzyme.  Rabbit muscle glycogen synthase contains at least 9 
different serine residues located at the N and C termini that can be 
phosphorylated in vivo (1).  In vitro, a number of protein kinases phosphorylate 
glycogen synthase, including glycogen synthase kinase-3 (GSK3) (26, 27), 
phosphorylase kinase (PhK) (28), cAMP dependent protein kinase (PKA) (29), 
casein kinase 1 (CK1) (30, 31), casein kinase 2 (CK2) (32), AMP activated 
protein kinase (AMPK) (33), PAS kinase (34), DYRK1A (35) and p38 MAPK (36). 
The phosphorylation sites of glycogen synthase were named before the 
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sequence of the protein was determined.  Sites 1a, 1b, 2, 2a, 3a, 3b, 3c, 4 and 5 
correspond, respectively to residues 697, 710, 7, 10, 640, 644, 648, 652, and 
656 in rabbit muscle glycogen synthase (Figure 4).  The mammalian N terminus 
contains two sites that are phosphorylated in vivo, sites 2 and 2a (Figure 4).  In 
vitro, site 2 is phosphorylated by cyclic AMP-dependent protein kinase (29) and 
phosphorylase kinase (28).  Site 2a is phosphorylated by casein kinase 1 in vitro, 
but only when site 2 has been phosphorylated (30).  Consistent with this idea, 
mutation of site 2 eliminates phosphorylation of site 2a in COS cells (37).  These 
phosphorylation events inactivate the enzyme and exemplify a phenomenon 
termed hierarchal phosphorylation, a mechanism in which a phosphorylation 
event at one residue is a prerequisite for phosphorylation of another residue (38).  
The C terminus of glycogen synthase contains 7 phosphorylation sites in the 
muscle isoform and 5 in the liver isoform, as sites 1a and 1b are absent in the 
liver enzyme.  Phosphorylation of sites 3a and 3b in the C termini have the most 
influence on enzyme activity (1).  GSK-3 phosphorylates these regulatory sites 
and, in vitro, catalyzes sequential phosphorylation of sites 4, 3c, 3b, and 3a (26, 
32).  These sites are phosphorylated in a hierarchal manner involving GSK3 and 
casein kinase II.  Casein kinase II phosphorylates site 5, creating a recognition 
motif –S-X-X-X-S(P), (where X is any amino acid) for GSK3.  This primes 
glycogen synthase for sequential phosphorylation at sites 4, 3c, 3b, and 3a by 
GSK3 (26, 32, 39).  GSK-3, however, is not the only kinase that phosphorylates 
the C terminal regulatory sites 3a and 3b.  This is based on the observations that 
glycogen synthase expressed in COS cells or Rat1 fibroblasts can still be 
phosphorylated and inactivated when site 2 and site 2a are mutated to alanine, 
and the GSK-3 recognition motif is disrupted by serine-to-alanine substitutions at 
sites 3c, 4, and/or 5 (40).  The mutant enzyme could still be phosphorylated at 
site 3a and/or 3b suggesting the presence of another site 3a and/or 3b kinase.  A 
site 3a kinase was originally purified from rabbit skeletal muscle and identified as 
DYRK1A, a member of the dual-specificity tyrosine phosphorylated and regulated 
protein kinase family (35).  Another site 3a kinase was identified as PAS kinase, 
(34), after the identification of orthologues in S. cerevisiae that were genetically  
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Figure 3.  The glycogen synthase reaction.  Glycogen synthase transfers a 
glucosyl moiety (red) from UDP-glucose to the non-reducing end (C4-OH) of a 
glycogen particle. 
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required for the maintenance of normal glycogen stores (41).  In vitro, site 3b and 
4 can be phosphorylated by the stress activated protein kinase p38 MAPK (36) 
 Activity can be restored to glycogen synthase by the action of the 
glycogen associated phosphatases (PP1G) that remove the inhibitory 
phosphates (see Introduction Section 2.8).  In muscle, PP1G is composed of the 
type 1 protein phosphatase catalytic subunit (PP1c) and the regulatory subunits 
PTG, R6, and RGL. The regulatory subunits have carbohydrate binding domains 
that localize the phosphatase to glycogen to dephosphorylate enzymes involved 
in glycogen metabolism (42).  
Activation of glycogen synthase leads to the formation of an elongated 
polymer of glucose that would eventually become insoluble and perhaps toxic to 
the cell.  Keeping the polymer soluble by the formation of branch points 
necessitates the action of another glycogen metabolic enzyme, the branching 
enzyme. 
 



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

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


 
1a 1b3a 3b 3c 4 52 2a
PKA
PhK
CK1
PKACK2
GSK3
 
 
Figure 4.  Schematic of glycogen synthase.  Vertical lines indicate the 
phosphorylation sites associated with different protein kinases.  PKA; protein 
kinase A (cAMP dependent protein kinase); PhK, phosphorylase kinase; CK1, 
casein kinase-1; CK2, casein kinase-2; GSK3, glycogen synthase kinase-3.  
Modified from Roach. 2, 101-120. (2002) Curr Mol Med. 
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2.4  The branching enzyme  
The branching enzyme adds branch points to a growing glycogen particle 
in the form of -1,6-glycosidic linkages, thereby influencing the structure and 
solubility of the polysaccharide.  These branch points are introduced by cleavage 
of an -1,4-glycosidic linkage, excising a segment of existing oligosaccharide, 
and reforming an -1,6-linkage (43) (Figure 5).  The mammalian enzyme is a 
monomer with Mr of 77 kDa (44) and shares sequence similarity with -amylase 
and other polysaccharide modifying enzymes that act on branched structures.  
The degree of branching of polysaccharides determines the solubility of the 
polymer.  For example, a polysaccharide with frequent branches, like glycogen, 
is soluble in aqueous solution.  A polysaccharide with less frequent branch points, 
like the amylopectin found in starch, is far less soluble in aqueous solution.  
Glycogen branching is therefore a central feature in the maintenance of a 
functional, non toxic polymer; indeed, defects in the human branching enzyme 
are found in type IV glycogen storage disease (see Introduction Section 4.6).  
Common to all patients is the formation of poorly branched insoluble glycogen 
particles or polyglucosans that can have devastating effects due to their lack of 
solubility.  Unlike glycogen synthase, not much is known about the regulation of 
the branching enzyme. 
The synthesis of glycogen thus requires the combined action of three 
enzymes, glycogenin, glycogen synthase and the branching enzyme.  In times of 
metabolic demand, such as fasting or exercise, glycogen is broken down and the 
stored glucose can be oxidized and used as fuel.  The degradation of glycogen is 
mediated by the combined actions of glycogen phosphorylase and the 
debranching enzyme.  
 
2.5  Glycogen phosphorylase 
A key enzyme in glycogenolysis is glycogen phosphorylase.  Glycogen 
phosphorylase catalyzes the phosphorolysis of the -1,4-glycosidic linkages of 
glycogen producing glucose-1-phosphate and glycogen(n-1) (Figure 6).  
Phosphorylase uses pyridoxal phosphate as a necessary cofactor and three 
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Figure 5.  The branching enzyme reaction.  The reaction catalyzed by the 
branching enzyme (BE) involves excising a segment of existing oligosaccharide 
by cleavage of an existing -1,4-glycosidic linkage followed by the formation of an 
-1,6-linkage.  
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isoforms of the enzyme, expressed in skeletal muscle, liver and brain are present 
in mammals.  The most active form of the enzyme is thought to be a homodimer 
with a subunit of 97,000 Da (45) which undergoes transitions between an active 
R state and a less active T state.  The transition between these 2 states is 
dependent on the phosphorylation state of the enzyme and its interaction with 
allosteric ligands.  The phosphorylated form of the enzyme, phosphorylase a, has 
a single phosphorylated serine, Ser14.  Phosphorylation by phosphorylase kinase 
activates the enzyme by promoting a large conformational change and shifting 
the enzyme’s equilibrium from the less active T state to the more active R state.  
The allosteric activator AMP also shifts the equilibrium in favor of the R state and 
can restore activity to the dephosphorylated form of the enzyme, phosphorylase 
b.  As for glycogen synthase, phosphorylase activity is measured in the absence 
and presence of its allosteric regulator AMP.  The resulting activity ratio is used 
as a kinetic index on the state of activation of the enzyme due to its covalent 
phosphorylation status (46).  The protein phosphatase that dephosphorylates 
phosphorylase is PP1G, containing the RGL, PTG/R5 or R6 regulatory subunits in 
skeletal muscle and PTG/R5, R6 or GL in liver (47).  
 
2.6  The debranching enzyme  
 Mechanistically, phosphorylase stalls four glucose residues from an -1,6-
glycosidic linkage necessitating the action of another enzyme, the glycogen 
debranching enzyme.  The glycogen debranching enzyme or amylo-1,6-
glucosidase, 4--glucanotransferase, (AGL), is a relatively large protein with Mr 
of 165 kDa.  The substrate for AGL is a branch with 4 glucose residues formed 
by phosphorylase.  AGL has two separate catalytic activities and two different 
active sites.  The N terminal domain catalyzes the hydrolysis of an -1,4-linkage 
to leave a single branched residue in an -1,6-linkage, and reforms an -1,4-
linkage between the detached glucose residues and the main chain (Figure 7).  
The C terminus of AGL contains a domain with amylo-1,6-glucosidase activity 
that removes the remaining branched glucose residue.  Mutations in AGL lead to  
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Figure 6.  The glycogen phosphorylase reaction.  Glycogen phosphorylase 
transfers a molecule of inorganic phosphate to the terminal glucose residue in 
a glycogen chain and subsequent cleavage of the -1-4 glycosidic linkage. 
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Figure 7.  The glycogen debranching enzyme (AGL) reaction.  AGL has 2 
separate catalytic activities that work sequentially to debranch a glycogen 
molecule.  After phosphorylase stalls 4 glucoses from a branch point, AGL 
excises three glucoses of existing oligosaccharide by cleavage of an -1,4- 
glycosidic linkage followed by the formation of a new -1,4-linkage at the non-
reducing end of the main chain (a).  The second reaction involves hydrolysis of 
the -1,6-linkage with the release of glucose (b). 
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a type III glycogen storage disease or Cori’s disease, characterized by abnormal 
glycogen structure with very short outer chains.   
 
2.7  Acid--glucosidase 
Glycogen resides and is metabolized by the above enzymes in the cytosol. 
However, a small fraction of glycogen makes its way to the lysosomes where it is 
degraded by another glycogen metabolizing enzyme, acid--glucosidase.  Acid-
-glucosidase is the enzyme responsible for the breakdown of lysosomal 
glycogen by catalyzing the hydrolysis of both the -1,4- and -1,6-linkages to 
produce glucose.  Although the mechanism of glycogen transfer to the 
lysosomes for degradation is still not well understood, the importance of 
lysosomal glycogen degradation is highlighted in patients with Pompe’s disease.  
Pompe’s patients have defects in acid--glucosidase and hyperaccumulate 
lysosmal glycogen resulting in a severe phenotype in heart and muscle that 
usually results in death within the first year of life.  There is evidence for the 
transcriptional regulation of the human acid -glucosidase gene (48) but 
regulation of acid--glucosidase activity for the most part seems to be strictly 
dependent on pH.  
 
2.8  Glycogen associated phosphatases 
 The glycogen associated phosphatases (PP1G) consist of the catalytic 
subunit of protein phosphatase 1 (PP1c) and a regulatory or targeting subunit 
that binds glycogen with high affinity.  These targeting subunits localize PP1c to 
glycogen in the vicinity of glycogen metabolizing enzymes.  The result is 
dephosphorylation of target substrates leading to a net accumulation of glycogen, 
mainly through activation of glycogen synthase and inactivation of phosphorylase.  
Common to all glycogen targeting subunits is a PP1 binding motif (RVXF) and a 
glycogen binding domain (49).  Mammalian genomes contain no fewer than 
seven glycogen targeting subunits but only four have been extensively 
characterized, PTG/R5, RGL R6 and GL (49).  Ceulemans et al. (50) undertook a 
bioinformatic approach to trace the evolution of regulatory subunits of PP1. By 
16 
searching completed genome sequences, they identified three novel regulatory 
subunits of PP1 that were named PPP1R3E, PPP1R3F and PPP1R3G. These 
putative proteins all contained the canonical RVXF motif that mediates interaction 
with PP1, as well as putative glycogen binding domains.  RGL/ GM, (PPP1R3A) 
was the first glycogen-binding subunit of PP1 identified (51).  The RGL/Gm subunit 
is expressed only in striated muscle and is necessary for the activation of 
glycogen synthase in response to exercise (52).  Furthermore, RGL knockout 
mice have decreased glycogen levels as well as a decrease in the activity ratio of 
glycogen synthase (53).  GL, (PPP1R3B), a 33 kDa protein, is expressed 
predominantly in liver and skeletal muscle in humans but only in liver of rodents 
(54).  PP1G/GL is controlled allosterically by glucose and phosphorylase (55, 56).  
R5/PTG (PPP1R3C) interacts with glycogen metabolizing enzymes and has 
been suggested to control glycogen synthase activity in response to insulin 
stimulation (57, 58).  Crosson et al. (58) reported that genetic depletion of PTG in 
mice is embryonically lethal.  Heterozygous deletion of the PTG gene resulted in 
mice with reduced glycogen stores in adipose tissue, liver, heart, and skeletal 
muscle, correlating with decreased glycogen synthase activity and glycogen 
synthesis.  Furthermore, these mice were glucose intolerant, hyperinsulinemic, 
and insulin resistant, conditions that worsened as the mice aged (58).  
Distruption of the PTG gene, in the laboratory of Dr. Anna DePaoli-Roach, leads 
to viable mice that have a decrease in the glycogen synthase -/+ glucose-6P 
activity ratio and a corresponding 30% decrease in skeletal muscle glycogen.  
Fold activation of glycogen synthase activity in response to insulin is unchanged 
in these mice suggesting that PTG is not required for the activation of glycogen 
synthase in response to insulin.  Most importantly, and contrary to the report by 
Crosson et al. (58), the homozygous null mice are viable and more insulin 
sensitive as judged by insulin tolerance tests and by hyperinsulinemic-
euglycemic clamp studies (DePaoli-Roach, unpublished data).  There is a clear 
increase in PTG protein levels in response to exercise, suggesting that PTG, like 
RGL, may be essential for the activation of glycogen synthase in response to 
exercise (see Results).  Recently, PTG has been implicated in a fatal form of 
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progressive myoclonus epilepsy known as Lafora Disease (see Introduction 
Section 5).  R6 is a 33kDa protein that is ubiquitously expressed, with highest 
levels in heart and skeletal muscle and much lower levels in the liver (59).  
PP1/PPP1R3E activity has been proposed to be under long-term control by 
insulin in rodent liver yet absent from skeletal muscle.  However, PPP1R3E 
mRNA is found at appreciable levels in human skeletal muscle (60). 
There is strong evidence to support critical roles for these targeting 
subunits in controlling glycogen accumulation also in humans, as a prevalent 
variant in PPP1R3A, the gene encoding human RGL, impairs glycogen synthesis 
and decreases glycogen levels in human, as well as mouse, skeletal muscle (61). 
 
3.  Hormonal Regulation of Glycogen Metabolism 

3.1  Insulin regulation of glycogen metabolism 
Skeletal muscle and liver comprise the largest glycogen reserves and play 
critical roles in whole body glucose homeostasis. The mobilization of glucose 
from glycogen deposits in the liver provides a constant supply of glucose for 
tissues, such as the brain, which depend primarily on this sugar as an energy 
source.  In the fasted state, the enzyme-catalyzed isomerization of glucose-1P 
released by phosphorolysis of glycogen, results in the production of glucose-6P.  
The liver expresses glucose-6-phosphatase, which converts glucose-6P to 
glucose that can enter the blood stream and supply other organs with a source of 
energy.  Skeletal muscle lacks glucose-6-phosphatase and glucose released 
from glycogen is catabolized locally.  The metabolism of glycogen in these 
tissues is linked hormonally to nutritional status by regulation of the enzymes that 
participate in both the synthesis and degradation of the polymer.   
Insulin is the primary hormone responsible for promoting the conversion of 
glucose into glycogen in the muscle.  In the diabetic state, impairment of insulin 
action is associated with defective muscle glycogen metabolism (1).  Insulin 
stimulates glucose uptake in the muscle, leading to an increase in glucose-6P 
levels, which drives glycogen synthesis by allosterically activating glycogen 
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synthase.  Insulin also triggers a signaling cascade in both muscle and liver 
involving phosphatidylinositol-3-kinase (PI3K).  Binding of insulin to the 
extracellular -subunit of the insulin receptor tyrosine kinase results in activation 
of tyrosine kinase activity.  Autophosphorylation of a series of tyrosine residues in 
the intracellular -subunit activates the kinase towards intracellular substrates, 
including the insulin receptor substrate-1 (IRS-1).  Phosphorylation of IRS-1 by 
the insulin receptor signals to PI3K, which in turn phosphorylates the 3’ position 
of phosphatidylinositol-4,5-bisphosphate producing phosphatidylinositol-3,4,5-
bisphosphate.  Recruitment of 3’-phosphatidylinositol dependent kinase 1 (PDK1) 
activates protein kinase B (PKB/AKT) which phosphorylates an N terminal serine 
of GSK3, inhibiting the enzyme.  The phospho-serine occupies the region of the 
active site of GSK3 that would interact with the ‘primed’ phosphate groups in a 
target substrate (62).  The inactivation of GSK3 prevents phosphorylation of sites 
3a, 3b, 3c and 4 in glycogen synthase and activates the enzyme.  Not all of the 
insulin control of glycogen synthase can be explained by the regulation of GSK-3, 
because insulin stimulation causes dephosphorylation of both the N and C 
terminal phosphorylation sites; GSK3 phosphorylates 3a, 3b, 3c and 4 all in the C 
terminus.  The glycogen-associated phosphatases have been implicated in 
hormonal control of glycogen synthase activity.  An obvious mechanism to 
explain the dephosphorylation of glycogen synthase in response to insulin 
stimulation would be activation of an insulin-stimulated glycogen synthase 
phosphatase.  In muscle, it has been proposed that stimulation with insulin 
activates a PP1G containing the striated muscle specific glycogen targeting 
subunit RGL (63) or PTG (57, 64).  However, mice lacking the RGL subunit are still 
capable of activating glycogen synthase in response to insulin (53), suggesting 
that another targeting subunit of PP1 may be involved in insulin stimulated 
dephosphorylation of glycogen synthase in muscle.  An alternate proposal is the 
inactivation of cAMP dependent protein kinase, (PKA) by insulin-stimulated 
activation of cAMP phosphodiesterases which has been observed in adipocytes 
(65).  In liver, a rise in blood glucose and the subsequent increase in plasma 
insulin levels promotes glycogenesis by allosteric mechanisms mediated by 
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glucose and phosphorylase a.  Binding of glucose to an allosteric site on the 
phosphorylated form of glycogen phosphorylase causes a conformational change 
that makes phosphorylase a better substrate for PP1G/GL and provides a 
mechanism for negative feedback control by glucose upon its own production by 
glycogen degradation (66).  Furthermore, the glucose induced conversion of 
phosphorylase into its b form indirectly promotes dephosphorylation and 
activation of glycogen synthase.  Phosphorylase a is an allosteric inhibitor of 
PP1G/GL, and the transition of phosphorylase a to phosphorylase b relieves the 
inhibition on PP1G/GL resulting in dephosphorylation and activation of glycogen 
synthase (66). 
 
3.2  Epinephrine and glucagon regulation of glycogen metabolism 
In contrast to insulin, epinephrine promotes glycogenolysis in muscle, and 
glucagon is the main hormone inducing glycogen degradation in the liver.  Acting 
through -adrenergic receptors, epinephrine initiates a signaling cascade that 
activates adenyl cyclase catalyzing the conversion of ATP to cAMP.  cAMP 
activates PKA by binding the regulatory subunit and releasing the active catalytic 
subunit to phosphorylate target substrates.  Phosphorylation of the  and  
subunits of phosphorylase kinase by PKA in response to epinephrine relieves the 
inhibitory effects of these subunits on the catalytic subunit.  Active phosphorylase 
kinase phosphorylates glycogen phosphorylase at Ser14 shifting the equilibrium 
from the less active T state to the more active R state, thus promoting 
glycogenolysis.  Inhibition of glycogen synthesis is mediated by PKA dependent 
phosphorylation of glycogen synthase at sites 2, 1a and 1b (1), as well as 
phosphorylase kinase dependent phosphorylation of site 2.  It has been 
proposed that epinephrine signalling through PKA decreases the activity of PP1G 
by PKA dependent phosphorylation of RGL, leading to dissociation of the catalytic 
subunit PP1c (67).  PKA also phosphorylates the PP1 inhibitory protein, inhibitor-
1 in response to epinephrine stimulation (68).  In the liver, glucagon activates 
liver adenyl cyclase, which increases cAMP levels and stimulates PKA 
dependent phosphorylation and inactivation of glycogen synthase.  
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Phosphorylation of phosphorylase kinase by PKA results in phosphorylation and 
activation of phosphorylase.  In addition to degrading glycogen, activated 
phosphorylase (phosphorylase a) prevents glycogen synthesis by binding GL and 
altering its glycogen synthase phosphatase activity, thereby inhibiting glycogen 
synthase activity (56, 69).  
 
4.  Glycogen Storage Diseases 

4.1  Preamble  
The overall importance of glycogen is illustrated by the physiological 
effects of deficiencies in the enzymes involved in its metabolism (Figure 8).  
Glycogen storage diseases are inherited metabolic disorders of glycogen 
metabolism affecting either the synthesis or degradation of the polysaccharide.  
These disorders result in a polysaccharide that is altered either in quantity and/or 
quality.   

4.2  Glycogen storage disease type 0 
Glycogen storage disease type 0 (GSD0) is a rare autosomal recessive 
form of fasting hypoglycemia that presents in infancy.  GSD0 is caused by 
mutations in the GYS2 gene, which encodes the liver isoform of glycogen 
synthase and results in an almost complete loss of liver glycogen.  Patients have 
high blood ketones, low alanine and lactate concentrations and postprandial 
hyperglycemia, hyperlactatemia and hyperlipidemia (70).  Mice lacking the Gys2 
gene have a 95% reduction in liver glycogen content, develop mild hypoglycemia, 
with an elevated rate of basal gluconeogenesis and an impairment in insulin 
suppression of endogenous glucose production (71).  Recently, a mutation in the 
GYS1 gene was described that resulted in sudden cardiac death of an 8 year old 
patient after collapsing during a bout of exercise (72).  Similarly, approximately 
90% of Gys1 null mice died soon after birth due to impaired cardiac function (73). 
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Figure 8.  Glycogen metabolism.  The asterisks indicate enzymes implicated in 
glycogen storage disorders.  HK, hexokinase/glucokinase; PGM, 
phosphoglucomutase; UGP, UDP-glucose pyrophosphorylase; GN, glycogenin; 
GS, glycogen synthase; BE, branching enzyme; GP, glycogen phosphorylase; 
AGL, debranching enzyme; GAA, lysosomal acid -glucosidase; G6Pase, 
glucose-6-phosphatase; PGI, phosphoglucose isomerase; PFK, 
phosphofructokinase. 
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4.3  Glycogen storage disease type I:  von Gierke’s disease 
Glycogen storage disease type I (GSDI) or von Gierke’s disease is 
characterized by the accumulation of glycogen and fat in the liver and kidneys, 
resulting in hypoglycemic seizures, hepatomegaly, growth retardation and life-
threatening lactic acidosis (74). GSD1 is caused by mutations in the G6PC and 
G6PT genes and is the most common type of glycogenosis.   G6PC and G6PT 
encode glucose-6-phosphatase and glucose-6P translocase (G6PT) respectively.  
Glucose-6-phosphatase hydrolyzes phosphate from glucose-6-P, a product of 
glycogenolysis or gluconeogenesis, to allow mobilization of glucose from the liver 
to the blood stream in the fasting state.  Similarly, loss of the G6PT results in the 
same phenotype (75).  In the terminal steps of gluconeogenesis and 
glycogenolysis, cytoplasmic glucose-6P is translocated into the lumen of the 
endoplasmic reticulum by G6PT, where glucose-6-phosphatase resides (75).  
The inability to dephosphorylate glucose-6P results in severe hypoglycemia with 
a concomitant increase in the intracellular glucose-6P concentrations driving 
excessive glycogen accumulation (76).   
 
4.4  Glycogen storage disease type II:  Pompe’s disease 
Glycogen storage disease type II or Pompe’s disease is an autosomal 
recessive disorder caused by a deficiency in the lysosomal acid--glucosidase.  
Pompe’s patients have mutations in the GAA gene, resulting in the most 
devastating form of the glycogen storage disorders (77).  Pompe’s patients 
overeraccumulate glycogen in the lysosomes of the heart and skeletal muscle 
leading to death usually within a year after birth (78).  Acid--glucosidase is 
restricted to glycogen catabolism in the lysosomes and does not appear to play a 
role in the cytosolic degradation of the polysaccharide.  The phenotype of the 
gaa-/- mice resembles the human disease closely, with the exception that 
pathological symptoms develop late relative to the onset of the human disease 
(79).  Crossing Gaa-/- mice with a transgenic mouse overexpressing a 
hyperactivated form of glycogen synthase accelerated the course of the disease 
and  resulted in the formation of abnormally structured polyglucosan, reminiscent 
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of that observed in patients with Lafora disease, glycogenosis type IV, and 
glycogenosis type VII (80).  Douillard-Guilloux et al. (81) generated a Gaa/Gys1 
double knockout mouse model that exhibited a profound reduction in the amount 
of heart and skeletal muscle glycogen, a significant decrease in lysosomal 
swelling and autophagic build-up as well as a complete correction of 
cardiomegaly.  These data suggest that long-term elimination of muscle glycogen 
synthesis may lead to a significant improvement of the structural, metabolic and 
functional defects in patients with Pompe’s disease. 
 
4.5  Glycogen storage disease type III:  Cori’s disease 
Glycogen storage disease type III or Cori’s disease is an autosomal 
recessive disorder caused by mutations in the AGL/DBE gene leading to defects 
in the glycogen debranching enzyme, AGL (82).  Symptoms usually present 
during infancy with hypoglycemia and failure to thrive (82).  Since the removal of 
branch points is required for complete phosphorolysis by phosphorylase, patients 
accumulate glycogen with very short outer chains. 
 
4.6  Glycogen storage disease type IV:  Andersen’s disease 
Glycogen storage disease type IV or Andersen’s disease is one of the 
most severe of the glycogen storage disorders.  It is caused by mutations in the 
GBE1 gene, whose protein product is the branching enzyme (83).  Patients 
present with hepatosplenomegaly, failure to thrive, and progressive liver cirrhosis, 
and the severity of the disease is related to the degree of accumulation of 
polyglucosan (84).  The polyglucosan in Andersen’s patients has long stretches 
of unbranched chains resulting in a loss of solubility of the polysasccharide, 
eventually leading to cellular dysfunction and degeneration. 
 
4.7  Glycogen storage disease type V:  McArdle’s disease 
Glycogen storage disease type V or McArdle’s disease is caused by 
mutations in the PYGM gene encoding the muscle form of glycogen 
phosphorylase.  Symptoms are surprisingly mild and begin in young adulthood 
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with exercise intolerance and muscle cramps due to the inability to breakdown 
glycogen and use the released glucose as fuel (85). 
 
4.8  Glycogen storage disease type VI:  Hers’ disease 
Glycogen storage disease type VI or Hers’ disease is caused by mutations 
in the PYGL gene which encodes the liver isoform of glycogen phosphorylase. 
Patients experience mild hypoglycemia, hepatomegaly and growth retardation 
(86). 
 
4.9  Glycogen storage disease type VII:  Tarui’s disease  
Glycogen storage disease type VII or Tarui’s disease is caused by 
mutations in the PFKM gene, encoding the muscle form of phosphofructokinase.  
Phosphofructokinase catalyzes a rate limiting step in glycolysis by 
phosphorylating fructose-6P to fructose-1,6-bisphosphate.  Loss of function 
mutations in PFKM  causes a a build up of glycolytic intermediates which are 
thought to drive excessive glycogen synthesis through elevation of the allosteric 
activator of glycogen synthase, glucose-6-P (87).   
 
5.  Lafora Disease 
 
5.1  Etiology 
Lafora Disease (LD) is an autosomal recessive neurodegenerative 
disorder that falls into the category of progressive myoclonus epilepsies with 
onset typically in the teenage years followed by death within ten years (88, 89).  
Although not thought of as a classical example of a glycogen storage disorder, 
characteristic to all Lafora patients is the presence of periodic acid-Schiff (PAS) 
positive staining intracellular inclusion bodies that are composed of poorly 
branched, insoluble glycogen-like polymers known as Lafora bodies (Figure 9).  
The detection of Lafora bodies in biopsies from the sweat glands in the arm pit is 
used diagnostically.  Lafora bodies are most commonly found in organs with the 
highest rate of glucose metabolism, including the brain, skeletal muscle, heart 
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and liver.  Lafora patients experience symptoms starting in early adolescence as 
stimulus sensitive grand mal tonic-clonic, absence, visual and myoclonic seizures.  
Rapid progressive dementia ensues with psychosis, cerebellar ataxia, dysarthria, 
amaurosis, mutism, muscle wasting and respiratory failure leading to death within 
ten years of first symptom (90).  Lafora disease is relatively rare in the outbred 
populations of the United States, Canada, China and Japan, and it most 
commonly found in parts of the world where a high rate of consanguinity is 
practiced.  This would include ethnic isolates in the United States, Canada, Spain, 
France and Italy, and in isolated regions of Asia, India, Pakistan, Africa, and in 
the Middle East (91).  To date no preventative or curative treatment is available.  
Mutations in two genes, Epilepsy progressive myoclonus type 2A (EPM2A) and 
Epilepsy progressive myoclonus type 2B (EPM2B), account for approximately 
90% of Lafora cases (89, 91).  The remaining cases could result from mutations 
in a third, yet to be identified gene, or could be mutations in promoter or 
enhancer regions of the two known genes (92).  The EPM2A gene is composed 
of 4 exons encoding, by sequence similarity, a dual specificity protein 
phosphatase termed laforin (Figure 10A).  Laforin also contains an N terminal 
carbohydrate binding domain that binds tightly to glycogen.  The second gene, 
EPM2B (NHLRC1), encodes malin, an E3 ubiquitin ligase, containing an N 
terminal RING finger domain, common to all E3 ubiquitin ligases, followed by 6 
NHL domains thought to be involved in protein-protein interactions (93) (Figure 
10B).   Most recent Lafora research has focused on understanding the functions 
of laforin and malin, and their relationship to the development of the disease.  
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Figure 9.  Lafora bodies.  An electron micrograph depicting a Lafora body in a 
neuropil of an Epm2a-/- mouse.  Courtesy of Cameron Ackerley, The Hospital 
for Sick Children, University of Toronto. 
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5.2  Mouse models of Lafora disease 
 Three mouse models of Lafora disease have been developed (94-96).  
Disruption of the mouse Epm2a gene resulted in viable homozygous null mice 
that had many, but not all, the features of the human disease (94).  Neuronal 
degeneration was observed at two months, when relatively few Lafora bodies 
were present, followed by a much more robust accumulation of the polyglucosan 
after 4 months.  The second mouse model utilized transgenic over-expression of 
a dominant negative form of laforin generated by mutating the catalytic Cys266 to 
Ser inactivating the phosphatase activity of the enzyme and driving expression 
under the control of the chicken -actin promoter (95).  The mutant human laforin 
was overexpressed in skeletal muscle to a level of 150 times that of the 
endogenous protein (97).  The mice developed Lafora bodies in muscle, liver and 
neurons and, by immunogold electron microscopy, laforin was shown to be in 
proximity of the polyglucosan deposits.  Our laboratory has recently generated 
and initially characterized the malin knockout mouse.  Disruption of the Epm2b 
gene resulted in viable animals with homozygotes produced at the expected 
frequency for Mendelian inheritance.  The animals developed Lafora bodies at 3 
months of age in brain, and to a lesser degree in skeletal muscle and heart (96) 
(see Results). 
 
5.3  Laforin 
Laforin was first identified by Minassian and colleagues using a positional 
cloning approach. They identified EPM2A on chromosome 6q24 that encodes 
laforin (98) (Figure 10A).  Laforin is a ubiquitously expressed protein with highest 
expression level in skeletal muscle, liver, kidney, heart, and brain (99).  Laforin 
contains the signature dual specificity phosphatase (DSP) motif HCXXGXXRS/T 
and can dephosphorylate phospho-serine/threonine and phospho-tyrosine as 
well as the generic phosphatase substrate p-nitrophenyl phosphate (pNPP) in 
vitro (100).  Additionally, laforin contains a highly conserved carbohydrate binding 
domain (CBM20) that can bind complex carbohydrates including glycogen, 
amylopectin and polyglucosan (95, 101).  Laforin is conserved in all vertebrates 
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and in a small, defined group of protists including Toxoplasma gondii (102) 
(Figure 11).  Niittyla et al. (10) described a gene in plants called starch excess 4 
(SEX4) whose protein product contains an N terminal DSP and a C terminal 
CBM, the same domains as laforin but in the opposite orientation. SEX4 has a 
well established role as a starch phosphatase that hydrolyzes C3 and C6 
phosphate from amylopectin (11) and genetic depletion of SEX4 in Arabidopsis 
results in the accumulation of insoluble polysaccharide (10).  Furthermore, laforin 
complements the SEX4 phenotype in Arabidopsis providing evidence that laforin 
and SEX4 are functional equivalents (102).  In mammals, laforin has been 
proposed to bind many proteins involved in glycogen metabolism including 
glycogen synthase, GSK3, PTG and malin (90, 103-105).  Two other proteins 
HIRIP5, a cytosolic protein involved in iron metabolism and Epm2a interacting 
protein 1 (106), a protein with unknown function, have also been reported to 
interact with laforin.  Fifty six mutations in the EPM2A gene have been found and 
the large majority of these mutations affect either the polysaccharide binding 
and/or the dual specificity phosphatase activities of laforin (The Lafora  
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Figure 10.  Lafora disease proteins, laforin and malin.  A. Schematic of 
laforin depicting its N terminal carbohydrate binding module (CBM) and its C 
terminal dual specificity phosphatase domain (DSP).  B. Schematic of malin 
depicting its N terminal RING finger domain followed by 6 NHL domains.
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Progressive Myoclonus Epilepsy Mutation and Polymorphism Database, 
http://projects.tcag.ca/lafora/).  One mutation was also described that had no 
effect on phosphatase and polysaccharide binding activity but did affect 
interaction with PTG (103).  Laforin is very sensitive to inhibition by 
polysaccharides, when assayed using the generic phosphatase substrate p-
nitrophenyl phosphate (pNPP) (107).  One disease mutation, W32G (91), is 
located in the conserved carbohydrate binding domain and, when transferred to 
recombinant laforin, eliminates glycogen binding by laforin without completely 
abolishing pNPPase activity (101, 107).  Thus impaired glycogen binding by 
laforin may be sufficient to cause disease.  Another link between laforin and 
glycogen comes from the observation that the laforin protein levels correlate with 
the amount of glycogen in a series of mouse models in which the muscle 
glycogen content was genetically manipulated (108). 
 A prominent hypothesis in Lafora research has been that the polyglucosan 
might result from an imbalance between the activities of glycogen synthase and 
branching enzyme.  There is precedent for this proposal.  Andersen’s disease, 
caused by mutations in the branching enzyme gene, leads to the accumulation of 
polyglucosan (109).  A somewhat similar situation exists in glycogen storage 
disorder type VII, Tarui’s disease, in which mutation of the phosphofructokinase 
gene causes a build up of glycolytic intermediates which are thought to drive 
excessive glycogen synthesis through elevation of the allosteric activator of 
glycogen synthase, glucose-6-P (87).  In addition, our laboratory previously 
observed that a mouse in which hyperactive glycogen synthase is overexpressed 
in muscle overaccumulated glycogen and developed structures reminiscent of 
Lafora bodies (80, 110).  Therefore, several groups have looked for ways by 
which laforin could affect glycogen synthesizing enzymes.  Glycogen synthase is 
inactivated through phosphorylation by the protein kinase GSK-3 which itself 
contains an inhibitory phosphorylation site (111).  Two groups have proposed 
that the inhibitory phosphate of GSK-3 can be removed by laforin (104, 112), 
thus potentially leading to activation of glycogen synthase to cause the 
biosynthetic imbalance.  Lohi et al. (104) suggested that laforin's role is to detect 
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polyglucosan appearance during glycogen synthesis and to initiate mechanisms 
to down-regulate glycogen synthase.  They reported that laforin is capable of 
dephosphorylating glycogen synthase kinase 3 (GSK3), thereby activating it to 
phosphorylate and inhibit glycogen synthase.  Loss of function of laforin should 
result in a hyperphosphorylated GSK3 and a hyperactivated glycogen synthase.  
This would lead to an imbalance between glycogen synthase and the branching 
enzyme resulting in insufficient branching and the formation of polyglucosan.  
More recently, these same groups have reported that laforin is a regulator of the 
cellular response to energy deprivation and that it confers cancer resistance to 2-
deoxyglucose induced apoptosis via dephosphorylation of GSK3.  However, 
several studies argue against GSK-3 being a laforin substrate (3, 7, 97, 113).  
Perhaps most important is the observation that the GSK3 phosphorylation state 
is unchanged in two different genetic mouse models of Lafora disease in which 
the Epm2a gene is either disrupted (3) or the dominant-negative laforin is over-
expressed (97).  Measurements of glycogen synthase and branching enzyme 
activities in these mice also argued against the “branching imbalance” hypothesis.
 An emerging hypothesis in Lafora research was first introduced by Worby 
et al. (113), who showed that laforin was capable of dephosphorylating 
amylopectin, the major component of plant starch with similar chemistry to 
glycogen (-1,4-glycosidic linkages with less frequent -1,6-branch points).  This 
hypothesis was further supported by Gentry et al. (102) who demonstrated that 
laforin was a functional equivalent to SEX4, the phosphatase responsible for 
removing phosphate from plant starch.  Further insight was provided by our 
laboratory, demonstrating that laforin was able to dephosphorylate mammalian 
glycogen and more notably, Epm2a-/- mice contained elevated levels of glycogen 
phosphate, supporting the hypothesis that laforin is a physiological glycogen 
phosphatase (3) (see Results).  It should also be noted that laforin activity to 
dephosphorylate glycogen was dependent not only on a functional dual 
specificity phosphatase domain but also a functional carbohydrate binding 
domain (3).   
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Figure 11.  Sequence alignment of Laforin.  Laforin is found in all vertebrates and a small subset of protists including T. gondii.  
The red, blue and green amino acids demonstrate 100%, 75% and 50% conservation across the shown species respectively.  The 
CBM is highlighted in yellow and the DSP in grey.  The catalytic HCXXGXXRS/T motif is in bold.   
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5.4  Malin  
The EPM2B gene (also called NHLRC1) encodes malin, a 395 residue 
protein that contains an NH2-terminal RING finger domain followed by six NHL 
domains (114).  Fifty eight disease causing mutations in the EPM2B gene have 
been identified (The Lafora Progressive Myoclonus Epilepsy Mutation and 
Polymorphism Database, http://projects.tcag.ca/lafora/).  The RING finger 
domain is characteristic of E3 ubiquitin ligases (115) and Gentry et al. (105) 
reported that malin interacts with laforin and catalyzes its polyubiquitination in 
vitro and in cultured cells.  In cells, the result is proteosome-dependent 
degradation of laforin.  Furthermore, Chan et al. (95) were unable to detect 
endogenous laforin in tissue from non-Lafora disease patients by using multiple 
polyclonal antibodies to laforin.  However, they were able to detect endogenous 
laforin surrounding Lafora bodies in tissue from Lafora patients with malin 
mutations.  Nevertheless, laforin protein levels correlate with glycogen in a series 
of mouse models in which the muscle glycogen content was genetically 
manipulated (108).  Disruption of the Gys1 gene in mice, which encodes the 
muscle isoform of glycogen synthase, and whose skeletal muscle is completely 
devoid of glycogen, have a 60% reduction in laforin protein levels.  
Overexpression of a hyperactive form of glycogen synthase results in a massive 
overaccumulation of glycogen and a subsequent 7-fold elevation in laforin protein 
levels (108).  So it is unclear whether the increase in laforin protein levels in 
patients with malin mutations is a cause of over accumulation of glycogen, lack of 
laforin degradation due to malin mutations or a combination of both.  
Nonetheless, if the physiological function of malin is to mediate the destruction of 
laforin, then it is hard to reconcile with the fact that Lafora disease is caused by 
recessive mutations in either EPM2A or EPM2B.  Based on the model of Gentry 
et al. (105), defective malin should up-regulate laforin.   
Recent studies using cell culture overexpression systems have reported 
that several proteins involved in glycogen metabolism are substrates for malin, 
including glycogen synthase, PTG and AGL (116-118).  Two independent 
laboratories have reported that co-expression of malin and laforin resulted in the 
33 
ubiquitination and proteosome-dependent degradation of the regulatory subunit 
of protein phosphatase 1, PTG (117, 118).  They proposed that laforin, via its 
glycogen binding domain, could recruit malin to the glycogen particle to promote 
the degradation of PTG and glycogen synthase thereby inhibiting glycogen 
synthesis.  They also suggest that neurons contain the enzymatic machinery 
capable of synthesizing glycogen, yet do not do so because glycogen synthase is 
in an inactivated, hyperphosphorylated form (117).  Loss of laforin or malin would 
inhibit malin-mediated degradation of PTG and glycogen synthase, driving 
excessive glycogen accumulation by dephosphorylation of glycogen synthase.  
Interestingly, co-expression of the catalytically inactive form of laforin had the 
same effect on the degradation of PTG.  It is hard to envision control of PTG as a 
key event in the formation of Lafora bodies since patients with mutations in 
laforin that abolish phosphatase activity still develop Lafora bodies and the 
neurological sequalae, unless the phosphatase domain is required for an 
independent but interrelated function.  Another proposal for the formation of 
Lafora bodies comes from work in cell culture overexpression systems with the 
identification of the  glycogen debranching enzyme (AGL) as a substrate for 
malin-mediated ubiquitination and proteosome-dependent degradation (119).  
This ubiquitination event, unlike the ones discussed above, was independent of 
laforin.  The authors proposed that mutations in malin would prevent the 
ubiquitination and proteosome-dependent degradation of AGL resulting in 
increased AGL protein promoting the removal of -1,6-glycosidic linkages and 
resulting in polyglucosan formation.  However, based on the two stage 
degradation of glycogen by phosphorylase and debranching enzyme, excessive 
AGL activity should only reduce branching frequency if phosphorylase, normally 
an abundant enzyme, becomes limiting.  Solaz-Fuster et al. (116) have proposed 
that AMPK phosphorylates laforin, controls its association with malin and thereby 
regulates laforin and malin targets.  AMPK was also reported to phosphorylate 
the PTG protein phosphatase subunit and target it for degradation by the malin-
laforin complex (120).  Other studies have suggested that laforin and malin are 
recruited to aggresomes upon proteosomal inhibition (121).  The authors 
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proposed that the centrosomal accumulation of malin and laforin enhances the 
ubiquitination of malin substrates, facilitating their efficient degradation by the 
proteosome. (121).  Furthermore, laforin and malin were shown to form a 
functional complex with HSP70 to suppress the cellular toxicity of misfolded 
proteins by promoting their degradation through the unfolded protein response 
(122).   
Our laboratory has recently generated the malin knockout mouse (Epm2b-
/-) and analyses of these mice have refuted many of the proposed mechanisms 
of action of malin (96) (see Results). 
 
6.  Glycogen in the Brain 
 
6.1  Location 
 Although Lafora bodies are present in many tissues, their formation in 
neurons likely contributes to the neurological deterioration and subsequent death 
in patients with Lafora disease (123, 124).  The brain contains low levels of 
glycogen relative to muscle and liver.  In mice for example, brain glycogen 
concentrations are about 5-10 times lower than muscle and ~100 times lower 
than liver.  It is thought that brain glycogen is almost exclusively produced in 
astrocytes in the adult animal, whereas in the embryo, glycogen is produced in 
both neurons and glial cells, but as animals age neuronal glycogen disappears 
and polysaccharide synthesis is predominantly restricted to astrocytes, a subtype 
of glial cells (125, 126).  Electron microscopy studies of glycogen granules 
suggests that the polysaccharide is not uniformly distributed throughout the brain 
but concentrated in areas with the greatest synaptic density (127), suggesting a 
role for glycogen in the energy-dependent process of synaptic transmission.  
However, white matter, which is devoid of synapses has also been reported to 
contain significant amounts of glycogen (128).    
 Since Lafora bodies are primarily composed of glycogen, how is it that 
Lafora patients accumulate the polymer in neurons if these cells do not 
synthesize glycogen?  Most studies on the location of brain glycogen have been 
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performed with cultured tissue cells, conditions not always conducive for 
glycogen accumulation.  Neurons in culture may not produce detectable levels of 
glycogen, but may still produce the polysaccharide in vivo.  Furthermore, brain 
glycogen is rapidly depleted after the death of an animal (129), much more so 
than that of muscle and liver glycogen.  Perhaps neurons do accumulate 
glycogen in vivo, but detection goes unnoticed due to the rapid degradation of 
the polymer post mortem.  Neurons do express the muscle isoform of glycogen 
synthase which based on cell culture studies, has been proposed to be 
hyperphosphorylated and thus inactive (117).  However, considering that 
glycogen synthase is activated allosterically by glucose-6P, which overcomes the 
inactivation by phosphorylation, it is not unreasonable to assume that neuronal 
glycogen synthase in vivo would have the capacity to synthesize glycogen.   
 
6.2  Brain glycogen metabolism 
 Glycogen in astrocytes is thought to serve as an energy reserve for 
neighboring neurons.  The degradation of glycogen by the brain isoform of 
glycogen phosphorylase produces glucose-1P which is isomerized to glucose-6P 
by PGM.  The resulting glucose-6P is oxidized through glycolysis forming 
pyruvate, which is subsequently converted to lactate by lactate dehydrogenase 
(Figure 12).  Several lines of evidence suggest that lactate exits the astrocytes 
and is then taken up by neurons to be used as a fuel.  For example, neurons 
operate normally if lactate is substituted for glucose (130, 131) and during 
hypoglycemia, glycogen is rapidly degraded and appears mainly as extracellular 
lactate (132).  Furthermore, astrocytes do not express glucose-6-phosphatase 
and therefore cannot make free glucose from glycogen phosphorolysis to be 
transported to neurons.  Astrocytes do however, express lactate dehydrogenase 
and readily oxidize glucose-6P to lactate via glycolysis.  Lactate is exported from 
astrocytes by the monocarboxylate transporter-1 (MCT1) (133, 134) and enters 
neurons via MCT2 where it is aerobically metabolized by oxidative 
phosphorylation (Figure 12). 
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 The concentration of brain glycogen seems to be sensitive to brain 
glucose levels.  In rats, an episode of hypoglycemia resulted in glycogenolysis 
but only after glucose levels in the brain had fallen to zero (135).  These data 
imply that glycogen is rapidly metabolized in the brain when glucose transport 
becomes rate limiting and provides a significant source of energy during 
hypoglycemia.  Moreover, re-establishment of euglycemia resulted in an increase 
in glycogen well above basal levels.  This super-compensation phenomenon has 
been implicated as a possible mechanism for hypoglycemia unawareness (136).  
Further insight into the metabolic importance of brain glycogen was 
demonstrated by Suh et al. (137).  Manipulation of brain glycogen levels by the 
glycogen phosphorylase inhibitor CP316819 resulted in an increase in brain 
glycogen levels that prevented the pathological effects of insulin-induced 
systemic hypoglycemia by delaying the onset of isoelectric encephalogram, a 
recognizable sign of transmembrane ion gradient failure.  The glycogen stores 
preserved brain function for up to 90 minutes during an episode of severe 
hypoglycemia.  
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Figure 12.  Brain glycogen metabolism.  Glycogen is synthesized and stored 
in astrocytes.  The degradation of glycogen by phosphorylase produces 
glucose-1P which is isomerized to glucose-6P by PGM.  The resulting glucose-
6P is oxidized through glycolysis forming pyruvate, which is subsequently 
converted to lactate by lactate dehydrogenase (LDH).  The lactate is exported 
from the astrocytes by the monocarboxylate transporter-1 (MCT1) and taken up 
by the neuron via monocarboxylate transporter-2 (MCT2).  The neuronal lactate 
is further oxidized by the tricarboxylic acid cycle (TCA) and the electron 
transport chain (ETC) producing ATP to fuel the neuron. 
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RESEARCH OBJECTIVE 
 
Since the discovery that mutations in the EPM2A and EPM2B genes 
caused Lafora disease, most Lafora research has focused on understanding the 
functions of these two proteins, and their relationship to the development of 
Lafora bodies.  When I started my studies, the majority of work had focused on 
ways in which laforin and malin might down-regulate glycogen synthesis, with the 
hypothesis that a biosynthetic imbalance between glycogen synthase and the 
branching enzyme leads to the formation of Lafora bodies.  The search for 
protein substrates of laforin led to a proposal that it dephosphorylated the 
inhibitory N terminal phosphorylation site of GSK3 (104), a negative regulator of 
glycogen synthase.  If laforin was a GSK3 phosphatase it would act as a 
negative regulator of glycogen synthesis, dephosphorylating GSK3, which in turn 
would phosphorylate and inhibit glycogen synthase.  So in patients with EPM2A 
mutations, GSK3 would remain phosphorylated and inactivated, resulting in 
activation of glycogen synthase.  Work from a previous graduate student in our 
laboratory found no changes in the phosphorylation status of GSK3 in two mouse 
models of Lafora disease (138) and furthermore found no differences in the 
activity of glycogen synthase and the branching enzyme in these mice, providing 
strong evidence that laforin was not a GSK3 phosphatase.  These negative 
results prompted us to begin looking for other laforin substrates when a report  
from the Dixon laboratory (113) demonstrated that laforin was capable of 
dephosphorylating amylopectin.  This group was unable to detect activity towards 
rabbit liver glycogen however (113).  Earlier reports from the 1990’s by Whelan 
and colleagues had demonstrated that rabbit liver glycogen contains significantly 
less phosphate than muscle glycogen (5).  My original goal was to determine if 
laforin was a physiological glycogen phosphatase and what role covalent 
phosphate plays in glycogen structure and metabolism.  More specifically, how is 
phosphate incorporated into glycogen?  Which hydroxyl in glucose is it attached 
to?  Can excessive glycogen phosphate cause Lafora disease?  Therefore, my 
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research objective was to understand how phosphate in glycogen is metabolized 
and the possible role it plays in the etiology of Lafora disease. 
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EXPERIMENTAL PROCEDURES 
 
1.  Purification of rabbit skeletal muscle glycogen  
Two male rabbits were sacrificed by injection with pentobarbital and 
decapitation.  The back and hind limb muscles were immediately removed and 
placed on ice.  The muscle was cut up into small pieces and homogenized in a 
Waring blender with 3 volumes of 4 mM EDTA pH 7.8.  The homogenate was 
centrifuged at 9,000 x g for 45 minutes.  The supernatant was passed through 
Miracloth to remove the floating fat and 100% trichloracetic acid (TCA) added to 
a final concentration of 10%.  The solution was cleared by centrifugation at 9,000 
x g and 1 volume of -80oC 100% ethanol was added to the supernatant to 
precipitate the glycogen.  The glycogen was collected by centrifugation at 8,000 x 
g for 45 minutes and resuspended in ~80mL of water purified by reverse osmosis 
(H2O).  Nonpolar contaminants were extracted twice with an equal volume of 
chloroform:octanol (3:1).  To the aqueous phase was added 1 volume of ethanol 
and the glycogen was allowed to precipitate overnight at -20oC.  The glycogen 
was again collected by centrifugation at 12,000 x g for 30 minutes and 
resuspended in 45 mL of 1% sodium dodecyl sulfate (SDS).  After high speed 
centrifugation at 196,000 x g for 2 hours, the glycogen pellet was resuspended in 
H2O and placed in an ice bath for 1 hour to precipitate the SDS that had come 
out of solution and pelleted during the high speed centrifugation.  After 
centrifugation to remove SDS, the glycogen was precipitated with 2 volumes of 
100% ethanol, collected by centrifugation at 12,000 x g and again resuspended 
in H2O at which time it was dialyzed against 2 changes of 3 L H2O.  The glycogen 
was precipitated with 1 volume of 100% ethanol, collected by centrifugation and 
washed with 100% ethanol.  After evaporation of residual ethanol at room 
temperature for several days, the glycogen, (yield ~3.5 g) was stored at -20oC 
until use.  
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2.  Preparation of the Malachite green reagent  
The Malachite green reagent was prepared essentially as described in 
(139).  All solutions were made in polypropylene conical screw cap tubes as used 
glassware had contaminating phosphate.  Briefly, 13.5 mg of Malachite green 
oxalate was dissolved in 30 mL of H2O.  Ten mL of a 4.2% (w/v) ammonium 
molybdate in 4 M HCl was added and the solution incubated at 4oC on a nutator 
for a minimum of 45 minutes.  Immediately before use, the solution was filtered 
through a 22 m filter and Tween 20 added to a final concentration of 0.01%. 
 
3.  Laforin phosphatase activity assays  
Recombinant His-tagged laforin was expressed in Escherichia Coli and 
purified by affinity chromatography using Ni-NTA agarose as described 
previously (107).  To measure laforin phosphatase activity with amylopectin 
and/or rabbit skeletal muscle glycogen as substrate, a 100 L reaction mix 
consisting of phosphatase buffer (100 mM sodium acetate, 50 mM bis-Tris, 50 
mM Tris HCl, 2 mM DTT, pH 6.5), 25 g/mL laforin and varying concentrations of 
polysaccharide substrate were incubated at 37oC for the indicated time points.  
The reaction was terminated by the addition of 100 L N-ethyl maleimide at 
which time 400 L of Malachite green reagent was added.  The samples were 
mixed and the OD at 620 nm recorded to assess inorganic phosphate levels by 
comparison to a standard curve generated using KH2PO4.  The Malachite green 
reagent prepared under these conditions had a linear range from 0.5-7 nmoles 
KH2PO4. 
Hydrolysis of p-nitrophenyl phosphate (pNPP) was performed in a 100 L 
reaction volume containing 1X phosphatase buffer with 25 g/mL recombinant 
laforin and varying amounts of pNPP.  The reaction was terminated by the 
addition of 400 L of 0.25 M NaOH and the absorbance was read at 410 nm.  
Activity was measured taking the extinction coefficient of p-nitrophenolate to be 
18.3 mM-1cm-1. 
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4.  Purification of mouse skeletal muscle and liver glycogen for covalent 
phosphate determination 
Frozen mouse muscle (minimum 500-600 mg) or liver (minimum 150 mg, 
for fed animals) was pulverized under liquid nitrogen and hydrolyzed in 10 
volumes (w/v) of 30% KOH at 100oC for 1 hour in a sterile 15 mL polypropylene 
conical screw cap tube.  The solution was cooled, centrifuged at 10,000 x g for 
10 minutes, the supernatant passed through Miracloth to remove the floating fat 
and collected in a 15 mL polypropylene conical tube.  The filtrate was 
precipitated with 2 volumes of -20oC 100% ethanol with addition of approximately 
25 L of 1 M LiCl and allowed to stand at -20oC overnight.  The glycogen was 
recovered by centrifugation at 10,000 x g for 30 minutes, redissolved in 500 L of 
H2O (occasionally with heat), transferred to an Eppendorf tube and centrifuged at 
17,500 x g at 4oC on a table top centrifuge to remove insoluble material.  The 
supernatant was transferred to a clean Eppendorf tube, precipitated with 2 
volumes of -20oC 100% ethanol and LiCl added after the ethanol to a final 
concentration of 6.7 mM (10 L of 1M LiCl).  The glycogen was allowed to 
precipitate at -20oC for a minimum of 1 hour, recovered by centrifugation at 
17,500 x g for 20 minutes and resuspended in 100 L of H2O (occasionally with 
heat).  Ten volumes of a 4:1 methanol:chloroform solution were added and the 
solution heated at 80oC for 5 minutes.  The methanol:chloroform solution was 
prepared in an extensively water-washed glass beaker using clean glass pipettes.  
After cooling, the precipitated glycogen was recovered by centrifugation at 
17,500 x g for 20 minutes.  For liver glycogen, the pellet was resuspended in 100 
L of H2O and the methanol:chloroform extraction repeated.  The glycogen pellet 
was dried in a Speed Vac and resuspended in 500 L of H2O and precipitated 
again with 2 volumes -20oC 100% ethanol and 6.7 mM LiCl, and allowed to 
precipitate at -20oC for a minimum of 1 hour.  The glycogen was again collected 
by centrifugation at 17,500 x g for 20 minutes and redissolved in 400 L of H2O.  
To ensure that all the glycogen was resuspended, the sample was placed in a 
boiling water bath for 5 minutes, cooled and 100 L of 50% TCA was added (final 
concentration of 10%).  The solution was centrifuged at 17,500 x g for 20 minutes, 
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the supernatant transferred to a new clean Eppendorf tube and precipitated with 
2 volumes of -20oC 100% ethanol.  The glycogen was allowed to precipitate for a 
minimum of 1 hour at -20oC and collected again by centrifugation at 17,500 x g 
for 20 min at 4oC.  The glycogen pellet was dried in a speed vac and 
resuspended in 500 L of H2O and dialyzed using Spectra/Por®Dialysis 
Membrane (MWCO: 12-14,000Da, Vol/length: 0.32 mL/cm) overnight against 4 L 
of H2O with constant stirring.  The glycogen was transferred from the dialysis 
tubing to a clean Eppendorf tube, precipitated with 2 volumes of -20oC 100% 
ethanol and allowed to stand at -20oC for a minimum of 1 hour.  Occasionally 
LiCl was omitted from this step in order to assess glycogen solubility in the 
absence of chaotropic salts.  However, after some time 10 L of 1 M LiCl was 
added and the glycogen was allowed to stand at -20oC for an additional 1 hour.  
After collection by centrifugation at 17,500 x g for 20 minutes, the glycogen was 
dried in a Speed Vac until the pellet became dislodged from the side of the 
Eppendorf tube.  The pellet was transferred into a tared, clean Eppendorf tube 
and the mass recorded.  The glycogen was redissolved to 5 mg/mL for skeletal 
muscle and 10 mg/mL for liver with H2O.  An aliquot was used to measure 
glucose equivalents after digestion with -amylase and amyloglucosidase (see 
below).  Glycogen phosphate was measured according to the protocol of Hess 
and Derr (140).  For skeletal muscle glycogen, 250-400 g and for liver glycogen, 
750-1,000g was dried in a speed vac and hydrolyzed with 10 µL of 10N HCl 
and 30 µL of 60% perchloric acid at 190oC for 2 hours in clean borosilicate glass 
tubes (VWR).  After hydrolysis, 100 L of H2O was added followed by 400 L of 
the Malachite green reagent.  The solution was transferred with a clean Pasteur 
pipette into a 1 mL disposable cuvette and the OD 620 nm recorded and 
compared to a standard curves using glucose-6P subjected to the same 
hydrolysis conditions and KH2PO4.  Under these conditions the standard curve 
was linear in the range of 0.5-7 nmoles KH2PO4 or glucose-6P.  By this 
procedure, lipids were removed by the methanol:chloroform extraction.  Proteins 
and nucleic acids were absent as determined by the Bradford protein 
determination assay (141) and by A260 absorbance, respectively.  The recovery 
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of glycogen was ~75-80% of that obtained by the KOH protocol (see 
Experimental Procedures Section 9) used for the isolation and determination of 
glycogen from mouse skeletal muscle (53).   
 
5.  Preparation of mouse tissue samples for Western blot analysis  
Animals were sacrificed by cervical dislocation and the heads immediately 
decapitated into liquid nitrogen.  The hind limb skeletal muscle and liver was 
immediately excised and frozen in liquid nitrogen.  The frozen tissues were 
stored at -80oC for later use.  Tissues were pulverized under liquid nitrogen and 
stored at -80oC until use.  Brains were dissected from the frozen heads under 
liquid nitrogen, powdered as above and stored at -80oC until use.  Frozen tissue 
samples (30-100 mg) were homogenized in 10 volumes (w/v) of a buffer 
containing 50 mM Tris HCl, pH 7.8, 10 mM EDTA, 2 mM EGTA, 100 mM NaF, 2 
mM benzamidine, 0.1 mM N-p-tosyl-L-lysine chloromethyl ketone, 50 mM -
mercaptoethanol, 0.5 mM PMSF, 10 g/ml leupeptin and 1 mM sodium 
orthovanadate) (0.1-0.2% Triton X-100 was included for brain samples) with a 
tissue Tearer at maximal speed for 20-30 sec.  Muscle homogenates were 
centrifuged at 6,500-8,000 x g and brain homogenates at 8,000-10,000 x g for 10 
minutes. The supernatant, denoted LSS (low speed supernatant), was used for 
Western blot analysis, measurement of enzyme activities and quantitation of 
glycogen (see below).  The pellet denoted LSP (low speed pellet) was 
resuspended in the same or two thirds to half the original homogenization volume 
for skeletal muscle and brain, respectively.  The resuspended LSP was used for 
Western analyses, measurement of enzyme activities, and quantitation of 
glycogen in parallel with the LSS.  In some cases, the LSS was subjected to high 
speed centrifugation (100,000 x g for 90 minutes) to generate a glycogen pellet.  
The glycogen pellet was enriched, usually 5 fold compared to the high speed 
supernatant, and used for Western analyses.   
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6.  Glycogen synthase and glycogen phosphorylase activity assays 
Tissues were homogenized as above and the LSS and the LSP were used 
to measure glycogen synthase and glycogen phosphorylase activity.  Glycogen 
synthase activity was measured by the incorporation of [U-14C]-glucose into 
glycogen using UDP-[U-14C]glucose as the glucosyl donor in the presence or 
absence of 7.2 mM glucose-6-P (142).  A reaction mixture (60 L) consisting of 
50 mM Tris-HCl pH 7.8, 20 mM EDTA, 25 mM KF, 6.67 mM UDP-glucose, 10 
mg/mL treated rabbit liver glycogen (Type III) (see Experimental Procedures 
Section 7), -/+ 10.9 mM glucose-6P pH 7.6-7.8 and UDP-[U-14C]glucose for a 
specific activity of ~1100 cpm/nmol (usually ~15 Ci in 12 mL) was preheated for 
5 minutes at 30C.  Thirty L of either the LSS or the LSP appropriately diluted 
(see below) was added and the reaction mix incubated at 30oC for various times 
depending on tissue and fraction.  Typically for muscle, the LSS was diluted 1:4 
in homogenization buffer and the LSP, which was resuspended in the original 
volume, was diluted 1:2.  The reaction time was 15 minutes.  For brain, the LSS 
was used undiluted and the LSP, resuspended in ½ the original volume, was also 
undiluted.  The reaction time was 45 minutes.  All reactions were stopped by 
spotting 75 L onto 2 cm x 2 cm square 31ET filter paper and immediately 
immersed in -20oC 66% ethanol under stirring.  The filter papers were allowed to 
wash for ~10-15 minutes with stirring, at which time the ethanol was discarded 
and fresh RT, 66% ethanol added with stirring for an additional 1 hour.  A third 
wash was performed for 15 minutes with fresh 66% ethanol and after removing 
the ethanol, the filter papers were washed with acetone for 5 minutes with stirring.  
The filter papers were dried under a heat lamp and placed in scintillation vials 
with 5 mL of Bio-Safe II scintillation cocktail and the radioactivity detected by 
scintillation counting.   
Glycogen phosphorylase was measured by the incorporation of [U-14C]-
glucose into glycogen using [U-14C]-glucose-1-phosphate as the glucosyl donor 
in the presence or absence of 2 mM AMP (46).  A reaction mixture (60 L) 
consisting of 200 mM KF, 100 mM glucose-1P, 10 mg/mL treated rabbit liver 
glycogen (Type III) , -/+ 3 mM AMP pH 6 and [U-14C]-glucose-1-phosphate  for a 
46 
specific activity of ~23 cpm/nmol (usually ~10 Ci in 12 ml) was preheated for 5 
minutes at 30oC.  The reaction mixture without AMP contained 0.15 mg/mL 
caffeine.  Thirty L of either the LSS or the LSP appropriately diluted (see below) 
was added and the reaction mixture incubated at 30oC for various times 
depending on tissue and fraction.  Typically for muscle, the LSS was diluted 1:4 
in homogenization and the LSP, which was resuspended in the original volume, 
was diluted 1:2.  The reaction time was 6.5 minutes.  For brain, the LSS was 
used undiluted and the LSP, resuspended in ½ the original volume, was also 
undiluted.  The reaction time was 15 minutes.  All reactions were stopped by 
spotting 75 L onto 2 cm X 2 cm square 31ET filter paper and immediately 
immersed in -20oC 66% ethanol. Filters were washed as described for the 
glycogen synthase assay. Radioactivity incorporated into glycogen was 
quantified as for glycogen synthase activity using scintillation counting. 
  
7.  Preparation of treated glycogen 
Rabbit liver glycogen, Type III (Sigma) was passed over a mixed bed ion 
exchange resin to remove contaminating ions.  Ten grams of glycogen was 
dissolved in 100 mL of H2O in a glass beaker with stirring.  Aldrich mixed bed 
TMD-8 ion exchange resin (~200 mL bed volume) was washed with 500 mL of 
H2O in a beaker three times with stirring for approximately 10 minutes each.  The 
resin was packed into a column (4.3 cm X 50 cm), and washed with an additional 
1 L of H2O at a free flow rate.  Immediately before applying the glycogen, the flow 
rate was adjusted to ~50 mL/hr., and the glycogen was collected in a beaker.  
The glycogen was precipitated by slowly adding 100% ethanol at -80oC to a final 
concentration of 66% with stirring.  To facilitate the precipitation, 2 drops of 1M 
NaCl were added (~50 L).  The suspension was kept stirring in an ice bath for 
15 minutes and then transferred to Beckmann centrifuge tubes pre-cooled to 4oC.  
The glycogen was centrifuged at 8,000 rpm for 20 minutes at 4oC using a JA.10 
rotor.  The pellet was washed twice with 100% ethanol, collected by 
centrifugation and allowed to dry in a mortar covered with parafilm with holes.  
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The dried glycogen was ground with a pestle, transferred to a 50 mL conical tube 
and stored at 4oC until use.  
 
8.  Western blot analysis 
Samples prepared as above were diluted with 5X loading buffer to 1X and 
boiled for 5 minutes (5X loading buffer: 62.5 mM Tris-PO4 pH 6.8, 50% (w/v) 
glycerol, 6.25% (w/v) SDS, 0.1% (w/v) bromphenol blue and 5% -
mercaptoethanol) and subjected to SDS polyacrylamide gel electrophoresis 
(SDS PAGE) using a 10% polyacrylamide gel.  The gel was run at 200 V until the 
bromphenol blue reached the bottom of the gel.  The proteins were transferred to 
nitrocellulose membranes overnight at 15 volts and stained with Ponceau S to 
assess loading.  The membranes were blocked for 1 hour with 5% non-fat milk 
dissolved in filtered Tris-buffered saline containing Tween 20 (TBST, 10 mM Tris-
HCl, 150 mM NaCl, 0.1% Tween 20 pH 8) and filtered through Miracloth 
immediately before use.  The TBST was filtered through a bottle top, 0.22 m, 
Stericup sterile filter (Millipore).  The membranes were probed for a minimum of 1 
hour at room temperature or a maximum of overnight at 4oC with various 
antibodies diluted appropriately in 2% milk dissolved in TBST and washed 3 X 5-
10 minutes each with TBST before incubation with the secondary antibody.  The 
secondary antibody was incubated with the membranes for 1 hour at room 
temperature followed by washing with TBST 3 times for 5-10 minutes each.  
Detection was by enhanced chemiluminescence and autoradiography.  The 
levels of protein expression were quantitated by densitometric scanning of the 
autoradiogram using Quantity One software (BioRad).  Anti-glycogen synthase, 
anti-glycogen synthase phospho-site 3a, anti phospho-GSK-3, anti-phospho- and 
nonphospho-AMPK, and anti-phospho-eIF2 were from Cell Signaling 
Technology, anti-laforin and anti-branching enzyme antibodies were from Abnova, 
anti-GSK-3 from Invitrogen Corporation, anti-GAPDH antibody was from 
Biodesign, anti-AGL antibody was from Abgent, anti-ubiquitin antibody was from 
Santa Cruz Biotechnology. Anti-glycogenin-1 (143) and anti RGL (61) are as 
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previously described.  Anti-PTG antibodies were a generous gift from Dr. Alan 
Saltiel (University of Michigan, Ann Arbor, MI). 
 
9.  Determination of glycogen concentration 
Total glycogen in skeletal muscle, liver and brain was assayed by slight 
modifications of Suzuki et al. (53).  For skeletal muscle and liver, approximately 
30 mg of frozen powdered tissue was weighed in a 1.5 mL screw cap tube and 
hydrolyzed in 200 L of 30% KOH for 1 hour, cooled on ice and precipitated with 
2 volumes of 100% ethanol at -20oC.  To aid the precipitation of glycogen, 67 L 
of 2% Na2SO4 was added prior to the addition of the ethanol.  After precipitating 
for 1 hour at -20oC, the glycogen was collected by centrifugation at 17500 x g, 
resuspended in 100 L (200 L for liver) of H2O and precipitated again with 2 
volumes of -20oC, 100% ethanol for a minimum of 1 hour at -20oC.  This 
procedure was repeated once more (total of 3 ethanol precipitations) and the 
glycogen pellet dried in a Speed Vac and digested overnight in 100 L of 0.2 mM 
sodium acetate pH 4.8 and 0.3 mg/mL amyloglucosidase.  Glucose equivalents 
were determined by a coupled reaction involving the conversion of glucose to 
glucose-6P by hexokinase followed by the reduction of nicotinamide adenine 
dinucleotide phosphate (NADP+), by glucose-6P dehydrogenase and recording 
the OD at 340 nm.  Typically for muscle, the glycogen digest was diluted 1:2 and 
10L added to a 300 L reaction mix consisting of 300 mM triethanolamine pH 
7.6, 4 mM MgCl2, 0.9 mM NADP+, 2 mM ATP and 2 g/mL glucose-6P 
dehydrogenase (Roche).  The OD 340nm of an aliquot (100L) was recorded 
and to the remaining reaction mix was added 1L hexokinase (diluted with an 
equal volume of (NH4)2SO4 to 750 units/mL) (Roche).  The reaction was allowed 
to proceed for 25-30 minutes at room temperature and the OD 340nm recorded.  
For brain glycogen determination, 40-50 mg of frozen powdered tissue was 
weighed in 1.5 mL screw cap tubes and hydrolyzed in 300 L of 30% KOH for 1 
hour, cooled on ice and precipitated with 2 volumes of -20oC, 100% ethanol.  To 
aid the precipitation of the glycogen, 100 L of 2% Na2SO4 was added prior to 
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the addition of the ethanol.  After precipitating for 1 hour at -20oC, the glycogen 
was collected by centrifugation and resuspended in 100 L of H2O.  Ten volumes 
of a 4:1 methanol:chloroform solution was added and the lipids extracted by 
heating the resulting solution at 80oC for 5 minutes.  After recovery of the 
precipitated glycogen by centrifugation at 17,500 x g for 20 minutes, the lipid 
extraction was repeated and the glycogen again recovered by centrifugation.  
The glycogen pellet was resuspended in 100 L of H2O and precipitated with 2 
volumes -20oC 100% ethanol.  After standing at -20oC for 1 hour, the glycogen 
was collected by centrifugation, dried in a speed vac, digested with 
amyloglucosidase and glucose equivalents quantitated as described above. 
For glycogen determination of the LSS and the LSP, typically, for skeletal 
muscle ~200 L of the LSS and 300 L of the LSP (resuspended in the same 
volume as the original homogenization) was brought to 30% KOH and 
hydrolyzed for 1 hour at 100oC.  Glycogen levels were determined as above with 
the exception that the final digestion volume with amyloglucosidase was 50 L.  
Ten L and 20 L of the LSS and LSP respectively, were used to measure 
glucose equivalents.  For brain homogenates, 200-300 L of the LSS and no less 
than 400 L of the LSP (resuspended in 2/3 the original homogenization volume) 
were used.  Again, the glycogen was purified and quantitated as described above 
for total brain glycogen with the exception that the final amyloglucosidase 
digestion volume was 50 L.  Twenty L of both the LSS and LSP was used to 
determine glucose equivalents.  
 
10.  Glycogen branching determination 
The degree of branching of polysaccharides was analyzed by the protocol 
of Krisman (30) using mouse skeletal muscle glycogen purified for covalent 
phosphate determination (see Experimental Procedures Section 4).  Briefly, 125 
L of an iodine-iodide solution containing 1.5 M KI and 100 mM I2 was added to 
32.5 mL of a saturated solution of CaCl2 and mixed.  Glycogen, 100 L of ~0.5 
mg/mL was added to 600 L of the CaCl2 solution containing the iodine-iodide 
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reagent and incubated for 7 minutes at room temperature, at which point the 
spectrum of the sample was recorded from 400-750 nm in a disposable plastic 
cuvette. 
 
11.  Electron microscopy 
Purified glycogen (15-25 g), whether from whole tissue or from the LSS 
and LSP was spotted on a Formvar coated grid and allowed to settle for 30-60 s, 
at which time a drop of NanoVan (Nanoprobes) was added and wicked off 30 
seconds later.  The glycogen was viewed with a Technia G12 Biotwin 
transmission electron microscope (FEI, Hillsboro, OR) equipped with an AMT 
CCD camera (Advanced Microscopy Techniques, Danvers, MA) at 80 kEV and 
150,000 X magnification at the Indiana University Electron Microscopy Center.  
Particle diameters were measured, and a histogram was constructed depicting 
the size distribution of the particles for different age groups and genotypes. 
 
12.  Ethanol solubility assay 
Purified skeletal muscle glycogen from 9 month old Epm2a-/- mice was 
subjected to treatment with wild type laforin or catalytically inactive C266S laforin 
(see Experimental Procedures Section 3).  The reaction was terminated by 
boiling for 10 minutes in a H2O bath, cooled, and the denatured protein removed 
by centrifugation.  The supernatant was dialyzed overnight against H2O, and the 
glycogen recovered by ethanol precipitation.  This glycogen was also used for 
electron microscopy studies as described above. 
 
13.  Synthesis and purification of [32P]UDP-glucose, [32P]UDP-[2-deoxy]-
glucose and [32P]UDP-[3-deoxy]-glucose 
32P]UDP-glucose, [32P]UDP-[2-deoxy]-glucose and [32P]UDP-[3-
deoxy]-glucose were synthesized enzymatically and purified essentially as in 
(144, 145) (Figure 13).  Briefly, 1-5 mCi of [-32P]-ATP (3000 Ci/mmol) was dried 
under N2 gas and resuspended in a reaction mixture containing 45 mM Tris-HCl, 
pH 7.5, 6 mM MgCl2, 0.8 mM UTP, 0.9 mM DTT, 3 units of UDP-glucose 
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pyrophosphorylase (Sigma), 3 units of inorganic pyrophosphatase (Roche) and 6 
units of phosphoglucomutase (Roche). The reaction was initiated by the addition 
of 5.6 units of hexokinase (Roche) and incubated at 30oC for 3-18 hours and 
then terminated by boiling in a H2O bath for 10 minutes.  For [32P]UDP-glucose 
synthesis, the reaction mixture contained 9 mM glucose and was terminated after 
3-4 hours. For [32P]UDP-[2-deoxy]-glucose and [32P]UDP-[3-deoxy]-glucose 
synthesis, the reaction mixtures contained 20 mM 2-deoxy- glucose and 20mM 
3-deoxy-glucose, respectively and were terminated after ~18 hours.  The 
denatured protein was removed by centrifugation at 17,500 x g and the 
supernatant was added to 5 mg activated charcoal and vortexed vigorously for 2-
3 minutes.  After centrifugation 5000 x g for 1 minute, the pellet was washed 3 
times with 1 mL ice cold H2O, with vigorous vortexing for 30 sec and the 
[32P]UDP-glucose was eluted with 200 L of a 50% (v/v) ethanol solution 
containing 0.16 M ammonium hydroxide by vigorously vortexing for 2-3 minutes 
and centrifugation at 5,000 x g for 1 minute.  The eluent was dried in a Speed 
Vac and the [32P]UDP-glucose and derivatives were resuspended in 100-200 L 
of H2O, aliquoted and stored at -80oC until use. 
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Figure 13.  Synthesis of [32P]UDP-glucose.  [32P]UDP-glucose was 
synthesized enzymatically starting with [-32P]ATP. HK, hexokinase; ATP, 
adenosine triphosphate; PGM, phosphoglucomutase; UGP, UDP-glucose 
pyrophosphorylase; UTP, uridine triphosphate. 
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14.  Thin layer chromatography 
To asses purity of the radio isotopes, ascending thin layer 
chromatography was performed in a solvent consisting of n-propanol:ethyl 
acetate:H2O (7:1:4) using high performance thin layer chromatography (HPTLC) 
silica gel plates (Alltech).  The plates were allowed to dry at room temperature 
and radioactivity visualized by autoradiography. 
 
15.  Phosphorylation of glycogen by glycogen synthase 
A reaction mixture consisting of 62.5 mM Tris-HCl pH 7.6, 8.3 mg/mL 
deionized rabbit liver glycogen, 9 mM glucose-6P, 6.25 mM EDTA and 1.25 M 
[32P]UDP-glucose (50,000-100,000 cpm/pmol) or 1.25 M UDP-[U-14C]glucose, 
(500-2000 cpm/pmol) was preheated to 30oC at which time partially purified D-
form glycogen synthase from rabbit skeletal muscle or recombinant His-tagged 
yeast glycogen synthase was added to a final concentration of 1.0-1.2 g/mL.  
The final concentration of the reaction components were 50 mM Tris-HCl pH 7.6, 
6.7 mg/mL deionized rabbit liver glycogen, 7.2 mM glucose-6P, 5 mM EDTA and 
1 M [32P]UDP-glucose or 1 M UDP-[U-14C]glucose.  The reaction mixture was 
incubated for the indicated time or, if not stated, 30 minutes, and terminated 
either by boiling in a 100oC H2O bath or by the addition of 2 volumes of 100% 
ethanol at -20oC.  Immediately before termination of the reaction, KH2PO4 was 
added to both the 14C and 32P reactions to a final concentration of 50 mM to 
reduce background 32P.  All reactions, whether stopped by boiling or ethanol 
precipitation, were placed at -20oC for a minimum of 1 hr in 66% ethanol 
containing 5-15 mM LiCl to precipitate the radiolabeled glycogen.  After boiling in 
a H2O bath for 2 minutes, the glycogen was recovered by centrifugation at 
17,500 x g for 20 minutes at 4oC and dried in a Speed Vac.  The glycogen pellet 
was redissolved in H2O to a final concentration of 6.67 mg/mL and SDS loading 
buffer added to 1X.  In most cases, the glycogen pellet was redissolved in H2O to 
a final concentration of ~8.3 mg/ml, aliquoted and brought to 6.7 mg/mL by the 
addition of -amylase and amyloglucosidase (final concentration of 300 g/mL 
for each glucosidase and 20 mM NaOAc pH 4.8) or laforin (see Experimental 
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Procedures Section 17).  The reaction was for a minimum of 1 hour at 37-40oC, 
and was terminated by the addition of SDS loading buffer.  After boiling, the 
glycogen (~200-250 g) was subjected to SDS PAGE using 10 % gels (1.5 mm 
plate separation), the gels stained with Commassie blue, destained with 25% 
methanol containing 7% glacial acetic acid, dried with a gel dryer and the 
radioactivity detected using a phosphorimager. 
 
16.  Phosphorylation of glycogen using skeletal muscle extracts 
Rabbit liver glycogen was phosphorylated using skeletal muscle extracts 
from WT and Gys1-/- mice (MGSKO) mice similarly to above with the exception 
that the source of the enzyme was muscle extract.  Approximately 30 mg of 
mouse skeletal muscle was homogenized as above, and 20 L of the LSS (~5 
mg/mL) added to 80 L of a reaction mixture containing 62.5 mM Tris-HCl pH 7.6, 
8.3mg/mL deionized rabbit liver glycogen, 9 mM glucose-6P, 6.25 mM EDTA and 
1.25 M [32P]UDP-glucose (50,000-100,000cpm/pmol) or 1.25 M UDP-[U-
14C]glucose (500-2000 cpm/pmol)The reaction was incubated at 30oC for 30 
minutes and the glycogen was purified, treated with or without glucosidases and 
visualized as above. 
 
17.  Dephosphorylation of 32P-labeled glycogen with laforin 
Phosphorylated glycogen (40 L of an ~8.3 mg/mL solution) whether 
prepared with rabbit skeletal muscle glycogen synthase or recombinant yeast 
glycogen synthase was incubated with 50 g/mL active WT laforin or catalytically 
inactive C266S laforin in phosphatase buffer in a final reaction volume of 50 L 
for a minimum of 1.5 hrs at 37oC.  The reaction was terminated by the addition of 
SDS loading buffer and subjected to SDS PAGE and subsequent 
phosphorimaging to visualize the radiolabeled glycogen. 
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18.  Purification of phosphorylated oligosaccharides from rabbit skeletal 
muscle glycogen  
Approximately 240-250 mg (80-85 mg/mL) of rabbit skeletal muscle was 
digested overnight at 37-40oC with 0.3 mg/mL amyloglucosidase and 0.3 mg/mL 
-amylase containing 1 mM CaCl2, and 10 mM sodium acetate pH 4.8 in a 3 mL 
reaction volume.  After digestion, a precipitate formed which was inferred to be 
glycogenin, as it is a hydrophobic protein (146).  Glycogenin was removed by 
centrifugation at 10,000 x g for 5 minutes at 4oC and the digest was transferred 
to clean Eppendorf tubes and placed in a boiling H2O bath for 10 minutes to 
denature the -amylase and amyloglucosidase.  After cooling, the protein was 
removed by centrifugation at 17,500 x g for 10 minutes at 4oC and the cleared 
supernatant was added to 2 mL (bed volume) of DEAE sepharose resin and 
incubated overnight on a Nutator at 4oC.  Prior to addition of the supernatant, the 
DEAE sepharose resin was washed three times with 10 mL of 10 mM NaOAc 
pH=4.8 for 10 minutes on a Nutator at 4oC.  The resin was poured into a column 
and washed with 20 column volumes of H2O.  The anionic species were eluted 
stepwise (flow rate of ~0.5 mL/min) with 10 mM, 50 mM, 100 mM, 500 mM, and 1 
M ammonium bicarbonate (NH4HCO3).  Four mL of each concentration was used 
and 1 mL fractions were collected.  An aliquot (40-60 L) of each fraction was 
used to measure covalent phosphate (see Experimental Procedures Section 4).  
The remainder was dried in a Speed Vac and redissolved in ~500 L H2O, and 
dried further until there was no visible NH4HCO3.   Typically this procedure was 
repeated 2-3 times to remove all the NH4HCO3.   The fractions containing 
phosphate were dissolved in H2O to a final concentration of 1 mM phosphate and 
stored at -20oC until use. 
 
19.  Dephosphorylation of phosphorylated oligosaccharides purified from 
rabbit skeletal muscle glycogen 
Phosphorylated oligosaccharides (10 L of 1 mM phosphate) were treated 
with either WT laforin (25 g/mL) or C266S laforin (25 g/mL) in 25 mM sodium 
acetate pH 5.5 in a final reaction volume of 20 L overnight at 37oC to ensure 
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completion.  A different buffer was chosen because the components in the 
phosphatase buffer described in Experimental Procedures Section 3 gave a 
strong signal on the HPAEC that eluted from the column around the same 
retention time as glucose.  The reactions were terminated by boiling in a 100oC 
H2O bath for 10 minutes and the precipitated protein removed by centrifugation 
at 17,500 x g for 10 minutes at 4oC, filtered using spin filters and the products 
analyzed as described below. 
 
20.  Analysis of purified phosphorylated oligosaccharides by high 
performance thin layer chromatography (HPTLC) 
Phosphorylated and dephosphorylated oligosaccharides purified from 
glycogen were analyzed by HPTLC on silica gel plates in a solvent system 
consisting of n-propanol:ethyl acetate:H2O (7:1:4). Approximately 3 nmoles 
(based on phosphate) of phosphorylated oligosaccharides were developed using 
ascending thin layer chromatography in the above solvent and stained for sugars 
by dipping the plates in a 95% methanolic solution containing 0.3% N-(1-
Naphthyl)ethylene-diamine dihydrochloride and 5% H2SO4 (for 100 mL: dissolve 
300 mg of N-(1-Naphthyl)ethylene-diamine dihydrochloride in 95 mL methanol 
and 5 mL of concentrated H2SO4). The plates were allowed to dry at room 
temperature and were placed in an oven at 110oC for 10 minutes.  Approximately 
10 nmoles of sugar and sugar phosphate standards were developed in parallel. 
 
21.  Analysis of purified phosphorylated oligosaccharides by high 
performance anion exchange chromatography (HPAEC) 
Phosphorylated oligosaccharides purified from glycogen were analyzed by 
HPAEC on an ICS3000 from Dionex using a PA1 column and detected by pulsed 
amperometric detection.  All samples were filtered using a spin column before 
injection into a 25 L injection loop.  Eluent A consisted of 100 mM NaOH and 
Eluent B 100 mM NaOH containing 1 M sodium acetate.  The fractions were 
eluted with a continuous gradient from 0-75% Eluent B over 60 minutes with a 
flow rate of 0.25 mL/min.  Five to 10 nmoles of phosphorylated oligosaccharides 
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were analyzed (based on phosphate concentration).  Carbohydrate standards, 
maltose, maltotriose, maltotetraose, maltopentaose, maltohexaose, 
maltoheptaose, maltooctaose, glucose-1P, glucose-6P, and glucose-2P were 
analyzed at a concentration of 10-100 M (250 pmoles-2.5 nmoles).    
 
22.  Synthesis of glucose-1,2-cyclic phosphate 
Glucose-1,2-cyclic phosphate was synthesized essentially as described by 
Zmudzka and Shugar (147).  One gram of the disodium salt of glucose-1P was 
dissolved in 5 mL of H2O and converted to the free acid by cation exchange 
chromatography using Dowex (H+) 50W-X8 resin.  The resin was washed with 
H2O and the free acid of glucose-1P was neutralized with pyridine and 
concentrated in a Speed Vac to approximately 10 mL using clean borosilicate 
glass tubes.  Pyridine (30 mL) and 3 g of dicyclohexylcarbodiimide (DCC) were 
added and the solution incubated at 0oC for 48 hours in a round bottom flask at 
which time 10 mL of H2O was added to the reaction and the precipitated 
cyclohexylurea filtered away by vacuum filtration.  The filtrate was extracted 3 
times with an equal volume of diethyl ether and the aqueous phase concentrated 
under vacuum in a Speed Vac to about 5 mL using clean borosilicate glass tubes.  
The insoluble material was removed by vacuum filtration and the filtrate was 
passed through a Dowex (H+) cation exchange resin and rapidly neutralized with 
a saturated solution of barium hydroxide (Ba(OH)2) to pH 8.  The resulting 
solution was concentrated under reduced pressure in a Speed Vac to about 1 mL 
in borosilicate glass tubes, freed from cloudiness by centrifugation at 5,000 x g 
for 5 minutes and 3 mL of acetone added to the supernatant to precipitate a 
white powder.  The solution was centrifuged 5,000 x g for 5 minutes and the 
barium salt of glucose-1,2-cyclic phosphate washed 3 times with 10 mL of 100% 
ethanol at -20oC by mixing well and centrifugation at 5,000 x g for 5 minutes 
followed by 3 washes with an equal volume of acetone.  The barium salt of 
glucose-1,2-cyclic phosphate was dried under reduced pressure in a Speed Vac 
and stored at -20oC until use.  
57 
23.  Synthesis of glucose-2-phosphate 
Glucose-2-phosphate (glucose-2P) was synthesized by acid hydrolysis of 
glucose-1,2-cyclic phosphate and purified as the barium salt (148, 149) (Figure 
14).  The conditions for acid hydrolysis are chosen to be sufficient to open the 
ring and hydrolyze the very labile glucose-1P without hydrolyzing the glucose-2P 
(149).  Therefore 100 mols of glucose-1,2-cyclic phosphate was dissolved in 9 
mL of H2O and preheated to 100oC at which time 1 mL of 1 M hydrobromic acid 
was added and the solution incubated for 5 minutes at 100oC in a 15 mL 
polypropylene conical screw cap tube.  The solution was cooled and a saturated 
solution of Ba(OH)2 was added until the pH was between 9-10.  The solution was 
kept on ice until the barium phosphate formed began to settle at which time the 
precipitate was collected by centrifugation at 10,000 x g for 10 minutes and the 
supernatant saved on ice.  The precipitate was redissolved in 100 mM HBr, the 
pH adjusted to 9 and the solution kept on ice until once again the barium 
phosphate began to settle.  This procedure was repeated for a third time and to 
the combined supernatants was added 3 volumes of cold 100% ethanol.  After 
cooling overnight on ice, the precipitated barium salt of glucose-2P was collected 
by centrifugation at 10,000 x g for 10 minutes, washed with 100% ethanol, dried 
under reduced pressure in a Speed Vac and stored at -20oC until use. 
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Figure 14.  Synthesis of glucose-2-phosphate.  Glucose-2P was synthesized 
by cyclization of glucose-1P with dicyclohexylcarbodiimide (DCC) in aqueous 
pyridine at oC for 48 hours, followed by mild acid hydrolysis of the labile cyclic 
phosphate.  HBr, hydrobromic acid. 
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24.  Matrix assisted laser desorption ionization time of flight mass 
spectrometry (MALDI-TOF-MS) analysis of phosphorylated 
oligosaccharides 
MALDI-TOF-MS analysis was performed by the Complex Carbohydrate 
Research Center, The University of Georgia.  Briefly, an aliquot (2 L, 1 mM  
phosphate) of purified phosphorylated oligosaccharides were analyzed by 
MALDI/TOF-MS.  The matrix was 2’,4’,6’-trihydroxyacetophenone monohydrate 
(THAP, 0.5 M 2,4,6 THAP in ethanol:0.1 M diammonium hydrogen citrate in 
H2O : 2:1 (v/v)).  The matrix solution (1 L) was deposited first on the target and 
then an equal volume of the sample was deposited.  All spectra were obtained 
using a Microflex LRF (Bruker).  MALDI-TOF-MS analysis was performed in the 
reflector negative ion mode.  Positive ion mode, using -dihydroxybenzoic acid 
(DHBA, 20 mg/mL solution in 50% methanol:H2O was tried also but the sample 
produced stronger signals in negative ion mode with THAP matrix.   
 
25.  Nuclear magnetic resonance (NMR) spectroscopy 
 The phosphorylated oligosaccharides were deuterium-exchanged by 
lyophilization from D2O, dissolved in D2O, and transferred to an NMR tube with 
magnetic susceptibility plugs matched to D2O (Shigemi).  The pD of the sample 
was 5.9.  Proton-proton and proton-carbon correlated spectra were acquired on a 
Varian Inova 600 MHz spectrometer equipped with a 3-mm cryoprobe or a 
Varian Inova-800 MHz spectrometer, equipped with a 5-mm cryoprobe.  Proton-
phosphorous correlated spectra were acquired on a Varian Inova 500 MHz 
spectrometer, equipped with an 8-mm XH room temperature probe.  All spectra 
were taken at 25oC.  Chemical shifts were referenced to internal acetone [(1H) = 
2.218 ppm, (13C) = 33.0 ppm] (150).  All experiments except the 1H-31P 
correlated spectra were acquired with standard Varian pulse sequences.  For 1H-
31P correlated experiments, the regular gHMQC and HMQC-TOCSY experiments 
were modified for 31P in the X channel, using a  pulse of 13 ms at a level of 60 
dB, and a 3JH-P coupling constant of 7 Hz.  Chemical shifts were referenced to 
59 
external 85% phosphoric acid [(31P) = 0.00 ppm]. Additional acquisition 
parameters are listed in Table 1. 
 
 
 
 
 
experiment SFRQ DFRQ SW SW1 NT NI AT MIX NP 
proton 600  5040  32  1998  10070
1H-1H gCOSY 600  5040 5040 8 512 203  1024 
1H-1H TOCSY 800  3721 3721 32 128 138 100 512 
1H-1H ROESY 800  3721 3721 32 128 138 300 512 
1H-13C 
gHSQC 
600 150 5040 10555 256 100 150  756 
1H-31P 
gHMQC 
500 200 3470 8000 360 32 400  1388 
1H-31P 
HMQC-
TOCSY 
500 200 3470 3000 400 24 300 40 1041 
 
Table 1.  NMR acquisition parameters.  Abbreviations used: SFRQ, 
spectrometer frequency for proton nucleus in Hz, DFRQ, decoupler frequency for 
heteronucleus (13C or 31P) in Hz, SW, spectral width in the directly detected 
dimension (1H) in Hz, SW1, spectral width in the indirectly detected dimension 
(13C or 31P) in Hz, NT number of transients, nNI, number of increments, AT, 
acquisition time in ms,MIX, Mixing (spinlock) time in ms, np: number of points in 
the directly detected dimension. 
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RESULTS 
 
1.  Laforin is a Glycogen Phosphatase 

1.1  Laforin dephosphorylates glycogen and amylopectin in vitro 
Our initial attempts to identify a substrate for laforin were primarily focused 
on sugar phosphate metabolites such as glucose-6P and glucose-1P, with no 
success (data not shown).  During the course of these studies a report by Worby 
et al. (113) demonstrated that laforin was capable of dephosphorylating 
amylopectin (113).  In addition to glucose, -1,4-linked polysaccharides like 
amylopectin and mammalian glycogen contain small amounts of covalent 
phosphate.  In amylopectin ~0.25% by weight of the molecule contains 
phosphate, corresponding to about 1 phosphate every 150 glucose residues.  
The values for mammalian glycogen vary depending on tissue and species, but 
are nonetheless relatively small compared to the amount of glucose.  In our 
hands, rabbit muscle glycogen contains 4-5 times more phosphate than rabbit 
liver glycogen.  In muscle, a molecule of phosphate is present approximately 
every 650 glucoses, which corresponds to about 0.07% of the polysaccharide 
weight.  In liver this value is about 1 phosphate every 3,000 glucose residues.  
Worby et al. (113) attempted to measure dephosphorylation of commercially 
available rabbit liver glycogen by laforin but were unsuccessful, possibly because 
of the lack of assay sensitivity and/or the low phosphate content of liver glycogen.  
We initially confirmed the observation that amylopectin is a substrate for 
recombinant laforin (Figure 15A & B).  Some 80-90% of the phosphate was 
released in a time dependent manner.  Varying the amylopectin concentration 
indicated a saturable process that followed a hyperbolic curve.  We then 
analyzed rabbit skeletal muscle glycogen purified by relatively mild conditions 
(see Experimental Procedures Section 1).  This glycogen contained 0.38% by 
weight of protein as judged by the Bradford protein determination assay.  SDS 
PAGE and Coomassie staining revealed the presence of a 38 kDa protein that 
was only apparent after the glycogen had been hydrolyzed with -amylase (data 
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Figure 15.  Laforin dephosphorylates amylopectin and rabbit skeletal 
muscle glycogen in vitro.  A. Time dependent release of phosphate from 
potato amylopectin (0.5 mg/ml) by purified, recombinant laforin (2.5 g/ml).  B. 
Concentration dependence of the rate of dephosphorylation of amylopectin by 
laforin.  The reaction was for 15 minutes in the presence of 2.5 g/ml laforin.  
C. Time dependent release of phosphate from rabbit skeletal muscle glycogen 
(5 mg/ml) by purified, recombinant laforin (25 g/ml).  D.  Concentration 
dependence of the rate of dephosphorylation of rabbit skeletal muscle 
glycogen by laforin. The reaction was for 40 min in the presence of 25 g/ml 
laforin.   
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not shown).  Western analysis using anti glycogenin antibody demonstrated that 
the protein was glycogenin (data not shown).  Analysis of total phosphate content 
by acid hydrolysis and detection of inorganic phosphate indicated that the 
glycogen contained 0.07% covalent phosphate by weight.  Laforin released 20–
25% of the total phosphate present, and the glycogen concentration dependence 
of the reaction was close to hyperbolic (Figure 15C & D). Unlike amylopectin, 
glycogen is believed to exist as a series of concentric shells of glucose residues 
(Figure 16B) and phosphate in the interior layers may not be accessible to laforin 
in the intact glycogen molecule. Therefore, after phosphate release had reached 
a maximum, we added the glycogen-degrading enzymes, -amylase and 
amyloglucosidase, to disrupt the glycogen structure.  Most of the remaining 
phosphate was now released and was by inference present in the inner tiers of 
the molecule (Figure 16A).  Exposure of glycogen to the glucosidases in the 
absence of laforin did not release inorganic phosphate, and likewise treatment of 
laforin with the glucosidases led to no phosphate release (data not shown).  
 
1.2  Glycogen dephosphorylation requires the carbohydrate binding 
domain of laforin 
The laforin mutant C266S, in which a critical active site residue is mutated 
(Figure 11), did not hydrolyze phosphate from glycogen confirming that 
phosphate release was not an artifact and was an enzyme-catalyzed reaction 
(Figure 17B).  Some Lafora disease mutations are located in the glycogen 
binding domain and, with one of these, W32G, previous work has demonstrated 
that the enzyme does not bind glycogen yet retains significant activity towards 
the artificial phosphatase substrate p-nitrophenyl phosphate (pNPP) (101, 107).  
Recombinant W32G laforin was partially active towards pNPP but was unable to 
dephosphorylate glycogen (Figure 17A & B) demonstrating that laforin action 
requires binding to glycogen by this non-catalytic domain.  This finding is 
consistent with the idea that laforin is associated with glycogen during its 
metabolism, monitoring and opposing the excessive introduction of phosphate. 
63 
 
0
2
4
6
8
10
WT C266S W32G
Ph
os
ph
at
as
e 
A
ct
iv
ity
 
(n
m
ol
/m
in
/m
g)
0
1
2
3
4
5
WT C266S W32G
Ph
os
ph
at
as
e 
A
ct
iv
ity
 
( m
ol
/m
in
/m
g)
A BpNPP glycogen
 
Figure 17.  Glycogen dephosphorylation requires the carbohydrate 
binding domain of laforin.  A. WT laforin and W32G laforin are active 
towards pNPP.  Mutation at the active site (C266S) eliminated activity.  B. WT 
laforin releases phosphate from rabbit skeletal muscle glycogen.  Mutation at 
the active site (C266S) essentially eliminated activity. Mutation in the 
carbohydrate binding domain (W32G), which is known to eliminate binding to 
polysaccharides, also abolished laforin’s ability to dephosphorylate glycogen. 
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Figure 16.  Dephosphorylation of glycogen in the presence of glycogen 
hydrolyzing enzymes.  A. Dephosphorylation of rabbit skeletal muscle 
glycogen in the presence of -amylase and amyloglucosidase.  Glycogen (5 
mg/ml) dephosphorylation by laforin (25 g/ml) was allowed to proceed until 
the reaction was essentially complete, at which time -amylase (0.3 mg/ml) 
and amyloglucosidase (0.3 mg/ml) were added.  Subsequent phosphate 
release was monitored.  B. Model for glycogen structure.  Glycogen is 
believed to exist as a series of concentric shells of glucose residues, so that 
inner tiers would not be on the surface of the molecule.  A full size molecule 
would consist of twelve tiers. 
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2.  Analysis of Epm2a-/- Mice 
 
2.1  Glycogen and glycogen phosphate levels increase with age in the 
absence of laforin   
Mice with the Epm2a gene disrupted develop many of the characteristics 
of Lafora disease (151).  The animals had Lafora bodies in muscle and brain, 
impaired behavioral responses, and ataxia, and they ultimately underwent 
myoclonic seizures.  Lafora disease is a progressive disorder and in the Epm2a-
/- mice neurological symptoms are only apparent in older, 9 month old, animals; 
however  Lafora bodies begin to develop around 3 months of age.  We therefore 
compared young animals, 3 months of age, with mice 9-12 months old, beginning 
with the measurement of glycogen and glycogen phosphate content.  Analysis of 
muscle glycogen isolated from the 3 month  animals showed no difference in 
total glycogen levels between wild type and Epm2a-/- mice (Figure 19A open 
bars) and an approximately four-fold increase in the phosphate content (Figure 
18A, open bars).  In the older animals, there was a three-fold elevation in total 
glycogen content (Figure 19A, filled bars) and a further increase in phosphate to 
around six times that present in wild type animals (Figure 18A, filled bars).  
Phosphate content of wild type glycogen was unchanged as animals aged from 3 
to 9-12 months.  A similar trend was observed in liver glycogen phosphate levels.  
At 3 months of age, there was an approximately 30% increase in liver glycogen 
phosphate (Figure 18B, open bars).  As the animals aged to 9-12 months, 
glycogen phosphate levels increased to 4 times that of age-matched wild type 
controls (Figure 18B, filled bars).  Glycogen phosphate levels were significantly 
lower as the WT mice aged from 3 to 9-12 months of age, possibly due to the 
high turnover of the glycogen in the liver as compared to muscle (see 
Discussion).  Brain glycogen levels were already increased at 3 months and 
progressed to a five-fold elevation in the old animals (Figure 19B).  Because of 
the much lower amounts of glycogen recoverable from brain, it was not feasible 
to measure phosphate content.  The greater sensitivity of brain glycogen 
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Figure 18.  Skeletal muscle and liver glycogen phosphate levels are 
increased in Epm2a-/- mice.  Glycogen was purified from muscle and liver 
for analysis of covalent phosphate.  A. Skeletal muscle glycogen phosphate 
levels in 3 month (open bars) and 9-12 month (filled bars) WT and Epm2a-/- 
mice.  *p< 0.001 vs WT, # p< 0.01 vs 3 month Epm2a-/-, (n=7-8).  B. Liver 
glycogen phosphate levels in 3 month (open bars) and 9-12 month (filled 
bars) WT and Epm2a-/- mice.  £p< 0.05 vs 3 month WT, *p< 0.05 vs WT, #p< 
0.05 vs 3 month Epm2a-/-, (n=6-8). 
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Figure 19.  Skeletal muscle and brain glycogen levels increase with age 
in Epm2a-/- mice.  Total glycogen content was analyzed from 3 month and 
9-12 month old animals.  A. Skeletal muscle glycogen levels in 3 month 
(open bars) and 9-12 month (filled bars) WT and Epm2a-/- mice.  *p< 0.001 
vs WT and 3 month Epm2a-/-, (n=11-15).  B. Brain glycogen content in 3 
month (open bars) and 9-12 month (filled bars) WT and Epm2a-/- mice.  *p= 
0.0001 vs WT, #p< 0.002 vs 3 month Epm2a-/-, (n=3-4).
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accumulation in the absence of laforin could reflect differences in brain glycogen 
metabolism and explain the potentially more serious consequences in this tissue. 
 
2.2  Age-dependent changes in chemical and physical properties of 
glycogen in Epm2a-/- mice  
Lafora disease is characterized by poorly branched glycogen-like 
polymers in the Lafora bodies (89-91).  We therefore monitored the degree of 
branching of glycogen purified from laforin deficient mice by recording the visible 
absorption spectrum in the presence of iodine.  Iodine intercalates into 
polysaccharide helices to give a characteristic spectrum whose absorption 
maximum is influenced by the degree of branching and hence the length of 
uninterrupted helical segments (152).  This technique readily distinguishes wild 
type mouse glycogen from amylopectin which has one -1,6-linkage on average 
every ~30 glucoses and whose absorption spectrum maximum is at a much 
higher wavelength (Figure 20A, red).  Mammalian glycogen typically has 
branches every ~12 glucose residues.  The iodine spectra of muscle glycogen 
from 3 month or 9-12 month old wild type mice are super-imposable, with 
absorption maximum around 470 nm, indicating no change in branching with age 
in WT animals (Figure 20A & B).  Muscle glycogen from 3 month old Epm2a-/- 
mice had an iodine spectrum slightly, but significantly, shifted to longer 
wavelength (Figure 20A, green, & B).  However, the spectrum for 9-12 month old 
knockout animals was dramatically altered, such that it was approaching that of 
amylopectin and indicative of a substantial reduction in the number of branches 
(Figure 20A, blue & B).  Removal of the phosphate by laforin treatment did not 
alter the iodine spectrum (data not shown).  In liver there were no significant 
alterations in the iodine spectrum of glycogen purified from young or old Epm2a-
/- mice (data not shown). 
Poorly branched glucose polymers, like amylopectin, are less soluble in 
water than highly branched polysaccharides.  Indeed, during isolation (see 
Experimental Procedures Section 4), it was more difficult to dissolve precipitated 
glycogen from the 9-12 month Epm2a-/- mice than glycogen from any of the 
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Figure 20.  Glycogen becomes poorly branched with age in Epm2a-/- 
mice.  A. Iodine spectra of skeletal muscle glycogen (50-75 g/mL) purified 
from WT and Epm2a-/- mice.  Amylopectin is shown for reference.  B. 
Quantitation of A.  3 month old animals are depicted with open bars and 9-12 
month old animals with filled bars.  The wavelength at maximum absorbance 
indicates the degree of branching of polysaccharides.  *p< 0.002 vs WT, #p< 
0.0001 vs 3 month Epm2a-/-, (n=3-8). 
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Figure 21.  Glycogen phosphate contributes to glycogen solubility in 
ethanol.  Skeletal muscle glycogen (5 mg/mL) purified from a 9 month old 
Epm2a-/- mice that was treated with catalytically inactive laforin (C266S) (i) or 
active laforin (ii), and brought to 66% (v/v) ethanol.  (iii) Addition of LiCl to (i).  
(iv) Addition of LiCl to (ii).  (v) Addition of LiCl to a 66% ethanol solution 
without glycogen (v). 
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other mouse groups analyzed.  Likewise, after storage at -20oC, thawing of 9-12 
month mouse glycogen solution resulted in a precipitate that required heating to 
re-dissolve.  Similar treatment of glycogen from wild type or 3 month old Epm2a-
/- mice did not result in precipitated material. 
Polysaccharides like glycogen are insoluble in ethanol, a property that is 
useful for their separation from ethanol soluble constituents.  Thus, as part of our 
normal isolation protocol of glycogen from tissues (see Experimental Procedures 
Section 4), we utilize precipitation in 66% (v/v) ethanol.  In the course of this work, 
we observed that muscle glycogen from Epm2a-/- mice, regardless of age, was 
much more soluble in 66% ethanol than wild type glycogen and did not come 
readily out of solution (data not shown).  Addition of trace amounts of a 
chaotropic salt, like LiCl, used to ensure complete precipitation of 
polysaccharides from ethanol, was effective in precipitating glycogen from both 
the 3 month and the 9-12 month Epm2a-/- mice.  Glycogen from 9-12 month 
Epm2a-/- mice was exposed under aqueous conditions to either the catalytically 
inactive C266S mutant laforin or wild type laforin followed by addition of ethanol 
to 66% (v/v).  Treatment with inactive laforin recapitulated the results described 
for glycogen from tissue extracts, with the glycogen remaining in solution (Figure 
21C, i).  Treatment with active laforin, conditions which remove most of the 
phosphate, resulted in a polysaccharide that precipitated normally (Figure 21C, ii).  
Addition of LiCl to both samples hastened precipitation, although the 
phosphorylated glycogen formed more flocculent material that, under gravity, 
pelleted at a slower rate (Figure 21C, iii & iv).  The visible material was not salt 
since it was absent in the control sample lacking any glycogen (Figure 21C, v). 
 
2.3  Age dependent changes in glycogen structure in Epm2a-/- mice   
The high molecular weight of glycogen makes it large enough to be 
analyzed by electron microscopy and the literature contains numerous examples.  
Analysis of the glycogen purified from the muscle of wild type mice by 
transmission electron microscopy indicated particles reminiscent of these 
structures, whether from old or young animals (Figure 22A & B).  Glycogen from 
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Figure 22.  Age-dependent changes in glycogen structure in Epm2a-/- 
mice.  Electron micrographs of skeletal muscle glycogen purified from: A. 3 
month old WT; B. 9-12 month old WT; C. 3 month old Epm2a-/-, D. 9-12 
month old Epm2a-/-; E. Size distribution of skeletal muscle glycogen 
particles purified from WT and Epm2a-/- mice.
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3 month old Epm2a-/- mice had generally a similar appearance, although 
perhaps with a tendency to slightly smaller particles (Figure 22C).  In contrast, 
glycogen from the 9-12 month old mice had a strikingly distinct appearance, with 
a more defined boundary, less granularity and a more even density (Figure 22D).  
Furthermore, many fields had large regions where particles appear to have 
coalesced or aggregated, either before or during preparation of the grids.  The 
size distribution of the particles was estimated by measuring apparent particle 
diameter.  Glycogen particles from 3 month old wild type mice had an average 
diameter of 27.1 nm, which is in the range reported for native muscle glycogen 
particles (153).  Interestingly, with age, there appeared to be a shift in the 
population to a slightly larger size (average 35.1 nm) but retaining the 
approximately Gaussian distribution seen in the younger animals.  Glycogen 
particles from the 3 month old knockout animals, as noted, were smaller, with 
average diameter 24.2 nm, but still normally distributed.  The comparable 
analysis of the particles from old Epm2a-/- mice was hampered by the presence 
of the large conglomerates.  Although individual particles were visible, their 
dimensions could not be estimated.  From counting particles in regions outside of 
the conglomerates, it was apparent that there was much greater variability in size, 
with many particles of diameter well beyond that anticipated for a normal 
glycogen particle (Figure 22D).  This could be due to a different density of the 
polysaccharide or more likely an aggregation of individual molecules that cannot 
be resolved by this analysis.   
Compared with the other samples analyzed, the glycogen from the old 
knockout mice was characterized by having the highest phosphate content and 
much reduced branching.  Thus, purified muscle glycogen from the 9-12 month 
old Epm2a-/- animals was subjected to treatment with laforin to remove  
phosphate and, in a parallel control, treatment with the catalytically inactive 
laforin mutant C266S.  After removing protein and buffer, the glycogen was 
visualized by electron microscopy.  Glycogen from the control sample had an 
appearance comparable to that shown in Figure 22D (Figure 23A).  Treatment of 
9-12 month old glycogen with active laforin caused a significant change in 
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Figure 23.  Effect of phosphate removal on skeletal muscle glycogen from 
9-12 month old Epm2a-/- mice.  Electron micrographs of glycogen treated with 
A. the catalytically inactive laforin (C266S) or B. active WT laforin.  
 
 
72 
individual appearance tending more to that of wild type (Figure 23B).  However, 
the granularity of the normal particles was not completely restored.  Since the 
removal of phosphate by laforin did not affect branching (previous section), we 
conclude that the phosphate is primarily responsible for the abnormal 
morphology of the glycogen from the 9-12 month old animals, in particular the 
presence of larger particles and aggregates. 
With the possibility that abnormal glycogen phosphorylation might affect 
the aggregation of glycogen, at least in the samples from older Epm2a-/- mice, 
we wondered whether our standard sample preparation for enzyme analysis, in 
which a low speed centrifugation is included to remove gross cellular debris from 
tissue extracts, may have actually removed some of the glycogen.  This 
separation is not an issue for samples directly processed for measurement of 
glycogen.  We found that in extracts from the muscle of 9-12 month old Epm2a-/- 
mice, about 60% of the glycogen was recovered in the low speed pellet (LSP), 
compared with ~25% for wild type muscle (Figure 24A).  In brain extracts, over 
75% of the glycogen was in the pellet from knockout mouse extracts (Figure 24B).  
The increased glycogen in the old knockout mice was associated with the LSP as 
the glycogen level in the low speed supernatant (LSS) was the same as wild type.  
Glycogen was purified from the LSS and LSP fractions of muscle extracts of the 
9-12 month old Epm2a-/- animals for analysis by electron microscopy (Figure 
24C & D).  During this procedure, it was noted that the LSP glycogen was 
significantly harder to dissolve in water than the LSS fraction.  The pellet fraction 
was highly enriched for the morphologically abnormal structures described in 
Figure 22, whereas in the supernatant the particles were predominantly of more 
wild type appearance.  The glycogen in the pellet also had significantly higher 
glycogen phosphate content (Figure 24E).  The phosphorylation of the LSS 
glycogen was, in absolute terms, comparable to that of the whole glycogen 
fraction of 3 month old Epm2a-/- mice (see Figure 18A, open bars).  Analysis of 
glycogen branching by iodine spectra indicated that the pellet was enriched for 
poorly branched glycogen, with an absorption maximum close to that of 
amylopectin (Figure 24F).  In these old knockout mice, it appears that low speed 
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Figure 24.  Fractionation of glycogen from 9-12 month old Epm2a-/- mice.  
Total skeletal muscle or brain extracts from 9-12 month old WT and Epm2a-/- 
mice were subjected to low speed centrifugation to generate supernatant (LSS) 
and pellet (LSP).  A. Percentage of total muscle glycogen, in the LSP.  *p< 0.05, 
(n=6).  B. Percentage of total brain glycogen in the LSP.  *p< 0.005, (n=3).  C. 
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centrifugation can effectively separate a polyglucosan fraction from normal 
glycogen that remains in the supernatant. 
 
2.4  Analysis of glycogen metabolizing enzymes and related proteins in 9-
12 month old Epm2a-/- mice   
We extended our analysis of glycogen metabolism in the old Epm2a-/- 
mice, quantitating some potentially relevant proteins and also taking into account 
the partitioning of the glycogen between the LSS and LSP.  In wild type mice, 
most laforin is present in the LSS in muscle and brain (Figure 25A & 26A).  As 
judged by Western analysis, total glycogen synthase protein level (LSS plus 
LSP) was increased by ~50% in the muscle (Figure 25A) and ~2.5-fold in brain 
(Figure 26A) of knockout animals and this elevation could be attributed to an 
increase in the protein associated with the LSP.  There was in fact a slight 
decrease in the soluble glycogen synthase protein.  Glycogen synthase activity 
measured in the presence of glucose-6P, usually taken as a measure of total 
glycogen synthase (25), however, was statistically unchanged between 
genotypes in either the LSS or LSP fractions (Figure 27B,D & 28B,D).  In Epm2a-
/- muscle extracts (Figure 27B & D) or brain extracts (Figure 28B & D), the 
activity in the LSP fractions was lower than in the LSS, despite the presence of 
as much or more glycogen synthase protein in the LSP (Figure 25A & 26A).  In 
other words, the measured glycogen synthase specific activity was reduced in 
the LSP.  In contrast, the activity associated with the LSP fraction of wild type 
mice was commensurate with the relatively small amount of glycogen synthase 
protein present.  The reason for the unexpectedly low specific activity in the LSP 
fractions, muscle or brain, of the glycogen synthase of the knockout mice is not 
immediately obvious.  One possibility would be the occurrence of some stable 
and novel modification of the protein.  Alternatively, the activity assay in this 
fraction may somehow be inaccurate.  This result is also consistent with the in 
vitro observation that purified rabbit muscle glycogen synthase binds more 
effectively to the abnormal glycogen isolated from old Epm2a-/- muscle (Figure 
29).  The -/+ glucose-6P activity ratio has been used as a kinetic index of 
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Figure 25.  Analysis of glycogen metabolizing enzymes and related 
proteins in skeletal muscle of 9-12 month old Epm2a-/- mice.  Muscle 
extracts WT and Epm2a-/- mice were analyzed.  A. Glycogen synthase (GS) 
protein levels in the LSS and the LSP of muscle extracts.  B. Glycogen 
debranching enzyme (AGL) and branching enzyme (BE) protein levels in 
muscle extracts.  Muscle PTG protein levels in the high speed centrifugation 
glycogen pellet.  C. Glycogenin (GN) protein levels in the LSP and the HSP of 
muscle treated or not with -amylase.  D.  Ubiquitinated proteins in the LSS and 
LSP.   
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Figure 26.  Analysis of glycogen metabolizing enzymes and related 
proteins in brain of 9-12 month old Epm2a-/- mice.  Brain extracts from WT 
and Epm2a-/- mice were analyzed.  A. Glycogen synthase protein levels in the 
LSS and the LSP.  B. Glycogen debranching enzyme (AGL) and branching 
enzyme (BE) protein levels in the LSS.  PTG protein levels in the high speed 
centrifugation glycogen pellet of brain extracts.  C. Ubiquitinated proteins in 
the LSS and LSP. 
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glycogen synthase inactivation by reversible phosphorylation.  In muscle, but not 
brain, there was a significant reduction in the activity ratio in the Epm2a-/- 
samples in both fractions (Figure 27A,C & 28A,C).   
Based on Western blotting, the levels of branching enzyme (BE) and 
debranching enzyme (AGL) were not greatly changed in extracts of muscle 
(Figure 25B) or brain (Figure 26B) from Epm2a-/- mice.  Small levels of both 
proteins were detectable in the LSP with a small increase in the knockout 
animals tracking with the elevated levels of glycogen in this fraction.  However 
quantitation of total protein (LSS+LSP) showed no differences between WT and 
knockout mice (data not shown).  PTG is a type 1 protein phosphatase regulatory 
subunit (64) that has been implicated in laforin action, first as a protein capable of 
interacting with laforin (103) and secondly as a potential target for a malin-laforin 
ubiquitylating complex, leading to its proteosomal degradation (117, 118).  PTG 
associates with glycogen and, with the available antibodies, we can only detect 
PTG when enriched in high speed glycogen pellets.  Analysis of PTG protein 
levels revealed, if anything, a decrease in PTG protein in the muscle of Epm2a-/- 
mice (Figure 25B) and no change in the brain (Figure 26B).  
Glycogenin is the self-glucosylating initiator protein of glycogen synthesis 
(154-156) which is thought to remain covalently attached to glycogen.  As such, 
its level will index the number of glycogen molecules present.  Glycogenin can 
only be detected by Western blotting once glycogen has been degraded by 
treatment with -amylase (Figure 25C).  Consistent with this idea, the large 
majority of the glycogenin is only detected after -amylase digestion.  In these 
experiments, the glycogenin level essentially correlates with the amount of 
glycogen present, as analyzed in the LSP of the knockout mice where there is 
more glycogen (Figure 25C).  The high speed pellet concentrates the glycogen 
present in the LSS.  Analysis of glycogenin protein levels in this fraction revealed 
no changes between the WT and Epm2a-/- mice.  If the measured glycogen level 
in the different fractions is normalized to the amount of glycogenin, there is no 
great variation.  This ratio is increased in the LSP fraction from the Epm2a-/- 
mice, but only by ~60%.  The main conclusion from this analysis is that the 
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Figure 27.  Skeletal muscle glycogen synthase activity in the LSS and 
LSP of 9-12 month old Epm2a-/- mice.  Skeletal muscle extracts WT and 
Epm2a-/- mice were analyzed.  A. Glycogen synthase activity ratio in the LSS 
of WT (open bars) and Epm2a-/- (filled bars) mice.  *p< 0.05, (n=3).  B. Total 
glycogen synthase activity measured in the presence of glucose-6P in the LSS 
of WT (open bars) and Epm2a-/- (filled bars) mice.  C. Glycogen synthase 
activity ratio in the LSP of WT (open bars) and Epm2a-/- (filled bars) mice.  D. 
Total glycogen synthase activity measured in the presence of glucose-6P in 
the LSP of WT (open bars) and Epm2a-/- (filled bars) mice.  *p< 0.05, (n=3). 
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Figure 28.  Brain glycogen synthase activity in the LSS and LSP of 9-12 
month old Epm2a-/- mice.  Brain extracts from WT and Epm2a-/- mice were 
analyzed.  A. Glycogen synthase activity ratio in the LSS of WT (open bars) 
and Epm2a-/- (filled bars) mice.  B. Total glycogen synthase activity measured 
in the presence of glucose-6P in the LSS of WT (open bars) and Epm2a-/- 
(filled bars) mice.  C. Glycogen synthase activity ratio in the LSP of WT (open 
bars) and Epm2a-/- (filled bars) mice.  D. Total glycogen synthase activity 
measured in the presence of glucose-6P in the LSP of WT (open bars) and 
Epm2a-/- (filled bars) mice.  
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morphologically abnormal glycogen in the old knockout mice consists of glycogen 
molecules whose molecular mass is not greatly different from wild type. 
A pathological hallmark of many neurodegenerative disorders, including 
Lafora disease, is the presence of ubiquitin-positive, intracellular inclusion bodies 
in regions of the brain (157).  Western analysis of skeletal muscle revealed a 
remarkable increase in ubiquitin positive proteins in the LSP of the old Epm2a-/- 
mice (Figure 25D).  The signal was comparable between genotypes in the LSS 
and analysis of ubiquitin positive proteins in brain, failed to reveal any noticeable 
changes between the WT and Epm2a-/- animals (Figure 26D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29.  Glycogen synthase binds more effectively to the abnormal 
glycogen isolated from 9-12 month old Epm2a-/- muscle.  Purified rabbit 
muscle glycogen synthase (GS, I-form) was incubated with purified muscle 
glycogen from 9 month old WT and Epm2a-/- mice and subjected to high 
speed centrifugation to pellet glycogen.  S, supernatant after centrifugation 
at 100,000 x g; P, pellet after centrifugation at 100,000 x g. 
81 
2.5  Analysis of glycogen metabolism in 3 month old Epm2a-/- mice   
Our characterization of the 3 month old Epm2a-/- is not as thorough as in 
the older animals.  In brain, glycogen levels are elevated in the knockout animals 
as early as 3 months of age (Figure 19B, open bars).  Total skeletal muscle 
glycogen levels in the 3 month old Epm2a-/- mice are relatively normal compared 
to WT, although there is a trend for an increase in the knockout animals that 
didn’t quite reach statistical significance (p=0.06, Figure 19A, open bars).  The 
major biochemical change observed at this age was a 4 fold increase in the 
covalent phosphate content of skeletal muscle glycogen in the Epm2a-/- animals 
(Figure 18A, open bars), with a corresponding increase in ethanol solubility (data 
not shown).  Morphologically, the muscle glycogen granules in the 3 month old 
Epm2a-/- mice are relatively normal when viewed under the electron microscope 
(Figure 22C).  Although this glycogen is somewhat poorly branched as judged by 
the iodine spectra (Figure 20A & B), the physico-chemical properties of the 
polysaccharide are for the most part, comparable to those of WT glycogen.  
Distribution of muscle glycogen between the LSS and the LSP displayed a 
similar trend to the older Epm2a-/- animals.  Approximately 60-65% of the 
glycogen was recovered in the LSP after centrifugation of muscle extracts of the 
Epm2a-/- mice (Figure 30A & B).  The glycogen synthase activity ratio (-/+ 
glucose-6P), as well as total glycogen synthase activity measured in the 
presence glucose-6P was unchanged in the knockout mice in both the LSS and 
the LSP (Figure 30C-F).  Based on Western analysis, the level of AGL was 
unchanged in the Epm2a-/- in the LSS with no detectable protein in the LSP 
(Figure 31).  As early as 3 months of age, the Epm2a-/- mice exhibit a 
redistribution of glycogen synthase protein from a soluble LSS to an insoluble 
LSP fraction (Figure 31).  
During the preparation of this thesis, Moreno et al. (158) reported that a 
functional laforin-malin complex promotes the ubiquitination of AMP-activated 
protein kinase (AMPK), a heterotrimeric serine/threonine protein kinase that acts 
as an energy sensor.  This ubiquitination occurred through the formation of lysine 
-63 linked ubiquitin chains which did not target AMPK for proteosomal 
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Figure 30.  Skeletal muscle glycogen and glycogen synthase activity in 3 
month old Epm2a-/- mice.  Skeletal muscle extracts of WT and Epm2a-/- 
mice were analyzed.  A. Glycogen levels in the LSS (open bars) and LSP 
(filled bars) of WT and Epm2a-/- mice.  *p= 0.0078 vs WT LSP, (n=3).  B. 
Percentage of glycogen in the LSP.  **p= 0.004, (n=3).  C. Glycogen synthase 
activity ratio in the LSS, (n=3).  D. Total glycogen synthase activity in the LSS 
measured in the presence of glucose-6P, (n=3).  E. Glycogen synthase activity 
ratio in the LSP, (n=3).  F. Total glycogen synthase activity in the LSS 
measured in the presence of glucose-6P, (n=3).  
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degradation.  However, the authors suggested that this modification increases 
the steady-state levels of at least the -subunit of AMPK, possibly because it 
alters the subcellular distribution of the protein.  AMPK is a trimer of three 
different subunits, ,  and .  AMPK is the catalytic subunit and contains a 
highly conserved kinase domain located at the N terminus of the protein (159).  
AMPK and AMPK are regulatory subunits and the latter contains a 
carbohydrate binding domain that associate with glycogen and has been 
proposed to be a sensor of glycogen levels (160).   AMPK is regulated by 
allosteric activation by AMP and by the phosphorylation of Thr172 within the 
catalytic domain of the α-subunit by upstream kinases (161).  Western analysis of 
the -subunit of AMPK in the 3 month old Epm2a-/- mice revealed no changes 
between genotypes in the LSS.  The level of AMPK in the LSP was also 
unchanged in the knockout animals.  These results are inconsistent with the 
model of Moreno et al. (158), as loss of laforin would disrupt the laforin-malin 
complex and lysine ubiquitination of AMPK resulting in lower levels of AMPK, or 
possibly an alteration in the distribution between the LSS and the LSP.  
Furthermore, phosphorylation of AMPK at Thr172 in the -subunit, taken as a 
measure of protein kinase activity, was unaffected by disruption of the Epm2a 
gene (Figure 31).   
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Figure 31.  Analysis of glycogen metabolizing enzymes and related 
proteins in 3 month old Epm2a-/- mice.  Skeletal muscle extracts from WT 
and Epm2a-/- mice were analyzed.  AGL, glycogen synthase (GS), P-AMPK, 
AMPK and laforin protein levels in the LSS and LSP of WT and Epm2a-/- 
mice.  GAPDH is shown as a loading control.   
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3.  Generation and Analysis of Epm2b-/- Mice  

3.1  Preamble 
Dr. DePaoli-Roach’s laboratory and our laboratory have recently 
developed and initially characterized mice in which the second gene involved in 
Lafora disease, Epm2b has been deleted.  The data presented below were 
generated by a number of individuals in both laboratories.  My contributions 
included: glycogen synthase and phosphorylase activity measurements, 
glycogen determinations, glycogen phosphate determinations, data collection 
and participation in the preparation of the manuscript that was recently published 
(96).  The mice were generated and characterized under the leadership of Dr. 
Anna DePaoli-Roach.  Processing of tissue was done by Anna DePaoli-Roach, 
Dyann M. Segvich, and Catalina Meyer.  RTPCR and exercising of mice were 
performed by Jose M. Irimia who also helped with the histology.  Western blot 
analysis and genotyping were performed by Anna DePaoli-Roach and Dyann M. 
Segvich.  The manuscript was written by Peter Roach and Anna DePaoli-Roach. 
 
3.2  Generation of Epm2b-/- mice  
Disrupted ES C57BL/6N (10571D-E2) cells were purchased from the 
Knockout Mouse Project Repository (KOMP), University of California, Davis.  The 
strategy for the disruption was to replace the complete Epm2b coding region plus 
391 nucleotides of 3’ UTR with a cassette containing the LacZ and the neo genes.  
The LacZ gene was fused in frame at the Epm2b ATG (Figure 32A).  After 
expansion and confirmation of targeting by PCR analyses (Figure 32B), the cells 
were injected into C57Bl/6J blastocysts and the injected blastocysts were 
implanted in the uterus of pseudo-pregnant C57Bl/6J females for generation of 
chimeric mice.  PCR genotyping of the chimeric mice showed that one male was 
positive for the disruption and was mated with C57Bl/6J females to test for 
germline transmission.  Germline transmission of the disrupted allele gave 
heterozygous Epm2b-/+ mice in a C57/Bl6 background.  Progeny from crosses of 
heterozygous mice generated animals for characterization.  Since we have been 
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Figure 32.  Targeted disruption of Epm2b.  A. Strategy for the distruption of 
the Epm2b gene.  Diagram of the Epm2b locus and targeted disruption of the 
coding region.  Arrowheads indicate the position of the oligonucleode primers 
used for PCR genotyping.  B. 5’ and 3’ PCR genotyping.  The wild type and the 
disrupted alleles are indicated.  C, E. Malin and laforin transcript levels.  Malin 
and laforin mRNA levels were determined in skeletal muscle of 3 month old 
mice.  **p< 0.01 vs WT, (n=4).  ND indicates not detectable.  D. -galactosidase 
expression.  Shown is a representative Western blot of -galactosidase 
expression in skeletal muscle and brain of WT, heterozygous and homozygous 
null Epm2b mice, (n=8). 
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unable to obtain usable antibodies against mouse malin, we adopted several 
independent approaches to assure deletion.  Standard PCR directed at both the 
5’- and 3’-ends of the insertion clearly distinguished the wild type and mutant 
alleles (Figure 32B).  Quantitative PCR was applied to determine message levels 
and did not detect malin message in Epm2b-/- mice (Figure 32C).  Finally, the 
gene disruption strategy places -galactosidase under the control of the malin 
promoter.  Therefore, the presence of -galactosidase marks the targeted 
deletion of Epm2b in tissues that express malin.  Samples from brain and muscle 
of Epm2b-/+ and Epm2b-/- mice were positive for -galactosidase by Western 
blotting whereas no signal was detected in the wild type mice (Figure 32D).  
From all of these criteria, we conclude that the Epm2b-/- mice indeed carry a 
disruption in both alleles of the gene.  We also used quantitative PCR to analyze 
the laforin mRNA level and found no change in the Epm2b-/- mice (Figure 32E). 
 
3.3  Epm2b-/- mice develop Lafora bodies by 3 months of age 
 A characteristic feature of Lafora disease is the presence of Lafora bodies 
in tissues.  Therefore we analyzed various tissues for their presence.  Sections 
from brain, skeletal muscle, heart and liver of 3 month old wild type and knockout 
mice were treated with diastase and then stained with periodic acid/Schiff 
(PASD) to visualize -amylase resistant polysaccharide. PASD positive 
structures, indicative of Lafora bodies, were visible in most areas of the brain.  
They were most abundant in the cerebellum (Figure 33A) and were also plentiful 
in the hippocampus (Figure 33C) and cortex (data not shown) of Epm2b-/- 
animals.  Comparable structures were absent in corresponding sections from 
wild type littermates (Figure 33B & D).  Though less abundant than in brain, 
Lafora bodies were also readily detectable in heart muscle from knockout mice 
(Figure 33E) but not wild type littermates (Figure 33F).  We have yet to complete 
a systematic survey of skeletal muscle but it is apparent that Lafora bodies are 
much more scarce in muscle than in brains or even hearts from Epm2b-/- mice at 
this age.  We found some Lafora bodies in soleus muscle (Figure 33G) but not in 
wild type controls (Figure 33H).  The lower incidence of Lafora bodies in skeletal
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Figure 33.  Lafora bodies in tissues of Epm2b-/- mice.  Sections of brain, heart 
and skeletal muscle from 3 month old mice were stained with periodic 
acid/Schiff/diastase (PASD) to visualize -amylase resistant polysaccharide, 
indicated by arrows.  A. Cerebellum, Epm2b-/-; B. Cerebellum, wild type; C. 
Hippocampus, Epm2b-/-; D. Hippocampus, wild type; E. Heart, Epm2b-/-; F. Heart, 
wild type; G, soleus muscle, Epm2b-/-; H. soleus muscle, wild type. 
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muscle as compared with brain is consistent with the lesser degree of glycogen 
synthase and laforin redistribution to the insoluble LSP in these tissues (see 
Results Section 3.4).  No Lafora bodies were detected in the livers of Epm2b-/- 
mice (data not shown). 
 
3.4  Glycogen, glycogen metabolizing enzymes and related proteins in 3 
month old Epm2b-/- mice. 
Our systematic analysis of the Epm2a-/- mice found no evidence to 
support the imbalance hypothesis for the formation of Lafora bodies.  Perhaps 
more important was the fact that glycogen synthase activity was unchanged and 
there were no significant alterations in any of the potential laforin-malin targets.  
Therefore, we extended our analyses of glycogen metabolism to the Epm2b-/- 
mice with emphasis on the levels of proteins proposed to be targets of malin, as 
in vivo substrates of the E3 ubiquitin ligase should be elevated in its absence.  A 
small, but significant, increase in total glycogen was observed in muscle and 
brain from Epm2b-/- mice (Figure 34A & 35A).  Low speed centrifugation of 
tissue extracts separates glycogen into the soluble supernatant (LSS) and the 
insoluble pellet (LSP).  In muscle, the distribution of glycogen was unchanged 
(Figure 34B & C) but in brain there was a significant increase in the proportion of 
insoluble glycogen in tissue from Epm2b-/- mice (Figure 35B & C).  Glycogen 
synthase total activity and -/+ glucose-6P activity ratios were unchanged in the 
knockout animals (Figure 36A-D & 37A-D), although in brain there was a trend to 
increased total activity in the LSP (Figure 37D).  These results were confirmed by 
Western blotting with anti-glycogen synthase antibodies (Figure 40A & 41A), and 
in the case of brain the increased proportion of glycogen synthase in the LSP 
was statistically significant.  Glycogen phosphorylase total activity, activation 
state (-/+ AMP activity ratio) and distribution between soluble and insoluble 
fractions in muscle and brain were unaffected by loss of the Epm2b gene (Figure 
38A-D & 39A-D).  The knockout animals did however display a significant 
increase in total phosphorylase activity in the LSP (Figure 39D).  The level of the 
other metabolic enzyme analyzed debranching enzyme, was also unaltered in 
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Figure 34.  Glycogen levels in skeletal muscle of Epm2b-/- mice.  Total 
glycogen levels and distribution of glycogen between the LSS and the LSP from 
3 month old male WT, Epm2b-/+ and Epm2b-/- mice was analyzed.  A. Total 
skeletal muscle glycogen levels.  *p< 0.05 vs WT, (n=8).  B. Percentage of 
skeletal muscle glycogen in the LSP, (n=4).  C. Skeletal muscle glycogen levels 
in the LSS (open bars) and LSP (filled bars), (n=4).   
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Figure 35.  Glycogen levels in brain of Epm2b-/- mice.  Total glycogen levels 
and distribution of glycogen between the LSS and the LSP from 3 month old male 
WT, Epm2b-/+ and Epm2b-/- mice was analyzed.  A. Total brain glycogen levels.  
*p< 0.05 vs WT, (n=8).  B. Percentage of brain glycogen in the LSP.  **p< 0.01 vs 
WT and Epm2b-/+, (n=6).  C. Brain glycogen levels in the LSS (open bars) and 
LSP (filled bars).  *p< 0.05 vs WT LSP, (n=6). 
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Figure 36.  Glycogen synthase activity in skeletal muscle of Epm2b-/- mice.  
Skeletal muscle from 3 month old male WT, Epm2b-/+ and Epm2b-/- mice was 
analyzed.  A. Skeletal muscle glycogen synthase (GS) -/+ glucose-6P (G6P) 
activity ratio in the LSS, (n=8).  B. Total skeletal muscle GS activity measured in 
the presence of G6P in the LSS, (n=8).  C. Skeletal muscle GS -/+ G6P activity 
ratio in the LSP, (n=8).  D. Total skeletal muscle GS activity in the LSP measured 
in the presence of G6P, (n=8).   
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Figure 37.  Glycogen synthase activity in brain of Epm2b-/- mice.  Brain from 
3 month old male WT, Epm2b-/+ and Epm2b-/- mice was analyzed.  A. Brain GS -
/+ G6P activity ratio in the LSS, (n=8).  B. Total brain GS activity in the LSS 
measured in the presence of G6P, (n=8).  C. Brain GS activity ratio in the LSP -/+ 
G6P, (n=8).  D. Total brain GS activity in the LSP measured in the presence of G6P, 
(n=8).   
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knockout animals (Figure 40A & 41A).  In brain extracts, the signal by Western 
blotting was weak, and so the enzyme was enriched by high speed centrifugation 
of the LSS to produce a glycogen pellet.  AGL levels in this pellet were the same 
in wild type and knockout mice (Figure 41B).  Therefore, the only potentially 
significant changes associated with Epm2b disruption in these analyses was a 
slight increase in total glycogen and an enrichment of glycogen and glycogen 
synthase in the insoluble fraction in brain.   
The type 1 protein phosphatase glycogen-binding subunit, PTG, has been 
proposed to be a target for malin-mediated ubiquitylation and degradation (117, 
118).  In order to detect PTG, it was necessary to prepare a high speed glycogen 
pellet.  From analysis of this fraction, there was no change in PTG level in the 
Epm2b-/- mice (Figure 40C).  We also analyzed the level of another glycogen-
associated PP1 targeting subunit, RGL/GM (53) that is found in striated muscle, 
and observed no alteration in the Epm2b-/- mice (Figure 40B).  As noted in the 
Introduction, GSK-3 was also considered a candidate to be a laforin substrate 
(104).  We therefore analyzed GSK-3 total protein and phosphorylation of the 
inhibitory N terminal site.  Neither parameter was affected by loss of the Epm2b 
gene, in either muscle or brain extracts (Figure 40B & 41C).  We also analyzed 
the phosphorylation state of the eukaryotic initiation factor alpha (eIF2), a 
marker for endoplasmic reticulum (ER) stress.  No detectable changes were 
observed in the Epm2b-/- animals (Figure 40C). 
 Previous work has implicated laforin as a malin target (105) and has also 
suggested that malin and laforin function as a complex (122).  Analysis of muscle 
extracts indicated a trend towards an increased distribution of laforin to the 
insoluble LSP (Figure 40A).  However, from analysis of brain, there was a large 
increase in total laforin protein and a major, statistically significant redistribution 
of laforin to the LSP accompanied by clear depletion of the soluble LSS fraction 
in the Epm2b-/- mice (Figure 41A).  In wild type animals, more than 90% of the 
laforin was in the soluble LSS fraction (Figure 41A & F) but in the knockout 
animals ~90% of the laforin was present in the insoluble LSP fraction (Figure 41A 
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& G).  This result is the most striking biochemical difference that we have 
observed so far from study of the Epm2b knockout mice. 
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Figure 38.  Glycogen phosphorylase activity in skeletal muscle of Epm2b-
/- mice.  Skeletal muscle from 3 month old male WT, Epm2b-/+ and Epm2b-/- 
mice was analyzed.  A. Skeletal muscle phosphorylase (Ph) -/+ AMP activity 
ratio in the LSS, (n=8).  B. Total skeletal muscle Ph activity in the LSS, 
measured in the presence of AMP, (n=8).  C. Skeletal muscle Ph -/+AMP 
activity ratio in the LSP, (n=8).  D. Total skeletal muscle Ph activity in the LSP, 
measured in the presence of AMP, (n=8).  
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Figure 39.  Glycogen phosphorylase activity in brain of Epm2b-/- mice.  
Brain from 3 month old male WT, Epm2b-/+ and Epm2b-/- mice was analyzed.  A. 
Brain phosphorylase (Ph) -/+ activity ratio in the LSP, (n=8). B. Total brain Ph 
activity in the LSS, measured in the presence of AMP, (n=8).  C.  Brain Ph -/+ 
AMP activity ratio in the LSP, (n=8).  D.  Total brain Ph activity in the LSP, 
measured in the presence of AMP.  *p< 0.05 vs WT, (n=8). 
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Figure 40.  Glycogen metabolizing enzymes and related proteins in 
skeletal muscle of Epm2b-/- mice.  Skeletal muscle from 3 month old male 
WT, Epm2b-/+ and Epm2b-/- mice were analyzed.  A. Distribution of AGL, GS 
and laforin protein levels in skeletal muscle LSS and LSP.  Representative 
Western blots are shown from n=8.  Comparable amounts of samples of the 
LSS and LSP were loaded.  B. GSK-3, phospho-GSK-3, eIF2, phospho-eIF2 
and RGL protein levels in the LSS.  Representative Western blots are shown 
from (n=4).  Same amounts of samples were loaded.  GAPDH is used as 
loading control.  C. PTG protein levels in the HSS and the HSP.  Samples in the 
HSP pellet were enriched 5-times with respect to the HSS in order to allow 
detection.  D. Quantitation of GS protein levels in the LSS, expressed as the 
ratio of protein in the LSS to the total protein (LSS + LSP), (n=8).  E. 
Quantitation of GS protein levels in the LSP, expressed as the ratio of protein in 
the LSS to the total protein (LSS + LSP), (n=8).  F. Quantitation of laforin protein 
levels in the LSS, expressed as the ratio of protein in the LSS to the total protein 
(LSS + LSP), (n=8).  G. Quantitation of laforin protein levels in the LSP, 
expressed as the ratio of protein in the LSS to the total protein (LSS + LSP), 
(n=8).  H. Quantitation of PTG protein levels in the HSP normalized to WT 
protein levels, (n=4). 
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Figure 41.  Glycogen metabolizing enzymes and related proteins in brain 
of Epm2b-/- mice.  Skeletal muscle from 3 month old male WT, Epm2b+/- and 
Epm2b-/- mice were analyzed.  A.  Distribution of AGL, GS and laforin protein 
levels in brain LSS and LSP. Representative Western blots are shown from 
(n=5-8).  LSP of AGL and GS are enriched ~2.5-fold as compared to LSS 
because of the low protein concentration in the pellet fraction whereas LSP of 
laforin are enriched only by 50%.  B. AGL protein levels in the HSP enriched 
2.5-fold with respect to the LSS, (n=4).  C. GSK-3 and phospho-GSK-3 protein 
levels in the LSS, (n=4).  D. Quantitation of GS protein levels in the LSS, 
expressed as the ratio of protein in the LSS to the total protein (LSS + LSP), 
normalized for equal sample loading.  **p= 0.0002, (n=8).  E. Quantitation of GS 
protein levels in the LSP, expressed as the ratio of protein in the LSS to the total 
protein (LSS + LSP), normalized for equal sample loading.  **p= 0.0002, (n=8). 
F. Quantitation of laforin protein levels in the LSS, expressed as the ratio of 
protein in the LSS to the total protein (LSS + LSP), normalized for equal sample 
loading.  **p< 0.0001, (n=5).  G. Quantitation of laforin protein levels in the LSP, 
expressed as the ratio of protein in the LSS to the total protein (LSS + LSP), 
normalized for equal sample loading.  **p< 0.0001, (n=5).  
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3.5  Effect of AMPK activation on glycogen metabolizing enzymes 
Solaz-Fuster et al. (116) have proposed that AMPK phosphorylates laforin, 
controls its association with malin and thereby regulates laforin and malin targets.  
AMPK was also reported to phosphorylate the PTG protein phosphatase subunit 
and target it for degradation by the malin-laforin complex (120).  Muscle AMPK 
was therefore activated in vivo by exercising wild type mice to exhaustion on a 
treadmill.  Glycogen was significantly depleted by this exercise regimen (Figure 
42C) with concomitant activation of glycogen synthase, as judged by the -/+ 
glucose-6P activity ratio (Figure 42A) and Western analysis of the 
phosphorylation of site 3a (Figure 42D).  A six-fold increase in the activation state 
of AMPK was observed as judged by the ratio of phospho-AMPK to total AMPK 
(Figure 42E).  Under these conditions, no changes were observed in the protein 
levels of glycogen synthase, debranching enzyme, laforin and RGL (Figure 42D & 
E).  Interestingly PTG protein levels were increased in response to exercise, 
opposite to what would be expected if AMPK phosphorylation targeted it for 
degradation (Figure 42F).  This result is also consistent with activation of 
glycogen synthase (Figure 42A).  We therefore find no evidence to support a role 
for AMPK in degradation of these proteins via malin or any other mechanism. 
 
3.6  Glycogen phosphate levels are unchanged in skeletal muscle and liver 
of the Epm2b-/- mice 
Our hypothesis is that Lafora bodies are formed by excessive glycogen 
phosphorylation that eventually alters the physico-chemical properties of the 
polysaccharide resulting in a loss of solubility.  This hypothesis is supported by 
our analysis of the Epm2a-/- mice and the observation that glycogen phosphate 
levels are elevated.  Analysis of muscle glycogen phosphate levels in the 
Epm2b-/- mice revealed no differences between genotypes (Figure 43A), 
consistent with the fact that Lafora bodies have not been observed in the majority 
of skeletal muscle sections analyzed by PASD staining.  Lafora bodies were only 
detected in the soleus muscle of the Epm2b-/- mice, which represents a small 
fraction of the total skeletal muscle.  Furthermore, Lafora bodies were detected in 
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Figure. 42.  Effect of AMPK activation on glycogen metabolizing enzymes 
and related proteins in skeletal muscle of exercised mice.  Skeletal 
muscle of 3 month old WT male mice exercised to exhaustion were analyzed.  
A. GS -/+ G6P activity ratio in the LSS of basal and exercised mice.  **p< 
0.01, (n=3).  B. Total GS activity in the LSS measured in the presence of G6P 
of basal and exercised mice, (n=3).  C. Skeletal muscle glycogen levels in the 
LSS (open bars) and LSP (filled bars) of basal and exercised mice, (n=3).  D. 
Western blots of phosphorylated GS (site 3a), total GS and RGL in basal and 
exercised mice, and quantitation of GS site 3a phosphorylation.  **p< 0.01, 
(n=3).  E. Western blots of phosphorylated AMPK, total AMPK, AGL and 
laforin, and quantitation of AMPK phosphorylation in basal and exercised mice 
**p< 0.01, (n=3).  F. PTG protein levels in the HSS and HSP of basal and 
exercised mice. HSP samples are enriched 4-fold with respect to the HSS.   
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a limited number of cells in soleus.  Therefore it is unlikely that our 
measurements would be sensitive enough to detect alterations in glycogen 
phosphate levels associated with such a small fraction of the muscle positive for 
Lafora bodies.  Consistent with the lack of Lafora bodies in liver sections, 
glycogen phosphate levels were normal in liver glycogen analyzed from the 
Epm2b-/- mice (Figure 43B).  Due to the low quantity of brain glycogen, it was 
not feasible to measure covalent phosphate levels. 
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Figure 43.  Glycogen phosphate levels in Epm2b-/- mice.  Glycogen was 
purified from skeletal muscle and liver for analysis of covalent phosphate.  A.  
Skeletal muscle glycogen phosphate levels of 3 month old WT (white bar), 
Epm2b-/+ (grey bar) and Epm2b-/- (black bar) mice, (n=9-10).  B. Liver 
glycogen phosphate levels of 3 month old WT (white bars) and Epm2b-/- (black 
bars) mice, (n=8). 
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4.  The Incorporation of Phosphate into Glycogen 
 
4.1  Synthesis of [32P]UDP-glucose, [32P]UDP-[2-deoxy]-glucose and 
[32P]UDP-[3-deoxy]-glucose 
Lomako et al. (4) proposed that a UDP-glucose:glycogen:glucose-1-
phosphotransferase transferred the  phosphate from UDP-glucose into 
glycogen when rabbit skeletal muscle extracts were incubated with [-32P]UDP-
glucose and glycogen.  However, the enzyme was never identified or 
characterized at the molecular level.  In light of these results, we synthesized [-
32P]UDP-glucose in an attempt to identify the enzyme responsible for 
phosphorylating glycogen.  [-32P]UDP-glucose was synthesized enzymatically 
as described under Experimental Procedures (Figure 13) and purified using acid 
washed charcoal.  Starting with [-32P]ATP, UDP-glucose can be produced by the 
combined actions of hexokinase, phosphoglucomutase and UDP-glucose 
pyrophosphorylase.  The purification is based on the fact that sugars do not bind 
activated charcoal, but nucleotides bind with high affinity.  Given that UDP-
glucose contains both a sugar and a nucleotide moiety, it can be purified from 
unreacted components of the reaction mixture by binding to charcoal and eluting 
under alkali conditions, sufficient to remove UDP-glucose from the charcoal 
without eluting non-sugar based nucleotides.  HPTLC and autoradiography 
revealed the presence of one radiolabeled species that had an identical Rf value 
as UDP-[U-14C]glucose (Figure 44A) and unlabelled UDP-glucose (data not 
shown).  Treatment of [-32P]UDP-glucose with UDP-glucose pyrophosphatase, 
a NUDIX hydrolase that hydrolyses the pyrophosphate bond of UDP-glucose, 
generated glucose-132P (Figure 44A & B).  The reaction is dependent on a 
divalent cation and was terminated with equimolar amounts of EDTA (see 
Results Section 7.1).  Furthermore incubation of [-32P]UDP-glucose with 
glycogen synthase in the presence of rabbit liver glycogen resulted in the 
complete consumption of [-32P]UDP-glucose and a product that migrated with a 
similar Rf value as [32P]UDP (Figure 45).  [32P]UDP-[2-deoxy]-glucose and 
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Figure 44.  Synthesis of [-32P]UDP-glucose.  [-32P]UDP-glucose was 
synthesized enzymatically and purified using acid washed charcoal.  A. 
HPTLC and visualization by autoradiography of [-32P]UDP-glucose treated 
with and without UDP-glucose pyrophosphatase (UGPPase).  Standard 
UDP-[U-14C]glucose and [U-14C]glucose-1P are shown.  B. The reaction 
catalyzed by UGPPase.   
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[32P]UDP-[3-deoxy]-glucose were also synthesized as above with the exception 
that the starting product was 2-deoxy-glucose and 3-deoxyglucose instead of 
glucose, respectively.  Both UDP-glucose derivatives migrated at the same Rf 
value as [-32P]UDP-glucose during HPTLC.  Although less pure than [-
32P]UDP-glucose, these derivatives were also consumed when incubated with 
glycogen synthase in the presence of glycogen (Figure 45). 
 
Figure 45  Reactivity of [-32P]UDP-glucose and derivatives towards 
glycogen synthase.  HPTLC and visualization by autoradiography of [-
32P]UDP-glucose, [32P]UDP-[2-deoxy]-glucose and [32P]UDP-[3-deoxy]-
glucose treated with or without glycogen synthase.  Radiolabeled UDP-
glucose was consumed upon treatment with glycogen synthase 
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4.2  Glycogen synthase phosphorylates glycogen by transferring the -
phosphate from UDP-glucose into glycogen 
In plant starch, C6 and C3 phosphomonoesters are formed by a unique 
set of dikinase enzymes, found only in plants, by transfer of the -phosphate in 
ATP to C3 and C6 glucose hydroxyls in amylopectin (8).  Extensive bioinformatic 
analysis of mammalian genomes has failed to reveal any analogous enzymes.  
However, we demonstrate that glycogen synthase transfers the -phosphate 
from UDP-glucose into glycogen.  Traditionally, glycogen synthase activity is 
measured by the incorporation of [U-14C]glucose from UDP-[U-14C]glucose using 
a filter paper assay (142).  By this procedure, 14C-labeled glycogen precipitates 
on filter papers when exposed to ethanol.  The unreacted isotope is removed by 
extensive washing and the 14C-labeled glycogen is quantified by scintillation 
counting.  In our initial studies using purified rabbit skeletal muscle glycogen 
synthase to elongate exogenously added glycogen in the presence of [32P]UDP-
glucose, using the filter paper assay, we noticed that the [32P]UDP formed 
bound to the filter papers (data not shown).  Therefore we resorted to an 
additional purification step.  The large molecular weight of glycogen does not 
allow it to enter polyacrylamide gels when subjected to SDS PAGE.  The 
unreacted metabolites, such as UDP, will migrate through the gel leaving only the 
glycogen in the well.  This method has been used successfully in the past to 
visualize 14C-labeled glycogen (162).  By this method we were able to 
demonstrate that the incorporation of phosphate into glycogen by glycogen 
synthase using [32P]UDP-glucose was time dependent (Figure 46B) and the 
rate of incorporation of phosphate, was in relative terms, equal to that of 14C 
glucose incorporation using UDP-[U-14C]glucose as the glucosyl donor (Figure 46 
A-C).  The absolute rate of phosphate incorporation was ~1 phosphate molecule 
introduced every 10,000 glucoses incorporated into glycogen.  In an attempt to 
confirm that the radio-labeled spot on the gel was glycogen, and not an artifact of 
the reaction, the polysaccharide was digested with -amylase and 
amyloglucosidase to hydrolyze the glycosidic linkages.  Treatment with 
107 
 
 
Figure 46.  Glycogen synthase incorporates the -phosphate of UDP-
glucose into glycogen during synthesis.  A 10% polyacrylamide gel was 
subjected to phosphorimaging to visualize radiolabeled glycogen.  A. 
Phosphorimage depicting the time dependent incorporation of 14C glucose into 
glycogen using UDP-[U-14C]glucose as the glucosyl donor.  B. Time 
dependent incorporation of 32P into glycogen using [-32P]UDP-glucose as the 
phosphoryl donor.  C. Relative quantitation of A. and B.  D. Digestion of 
radiolabeled glycogen with the glycogen hydrolyzing enzymes -amylase and 
amyloglucosidase.  Arrows indicate the bottom of the well, and arrow heads 
the bottom of the stacking gel. 
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glucosidases eliminated all the radiolabel from both the 14C and 32P labeled 
glycogen. 
Muscle glycogen synthase knockout mice, MGSKO, which lack the Gys1 
gene, do not accumulate glycogen in skeletal muscle and have no detectable 
glycogen synthase protein as judged by Western blotting (163).  Extracts from 
muscle of these mice catalyzed minimal formation of 14C-labeled glycogen 
(Figure 47, left panel).  When extracts of wild type mice were incubated with [-
32P]UDP-glucose, we observed high molecular 32P-labeled material of the same 
mobility as the 14C-labeled glycogen and which was also substantially reduced by 
treatment with glucosidases (Figure 47).  Interestingly, formation of high 
molecular weight material was not above background when the extract came 
from MGSKO mice (Figure 47, right panel).  We conclude first that 32P can be 
incorporated into glycogen from [-32P]UDP glucose by enzyme(s) present in 
mouse muscle and secondly that the primary enzyme responsible is glycogen 
synthase. 
 
4.3  Laforin removes phosphate incorporated by glycogen synthase   
The UDP-glucose: glycogen glucose-1-phosphotransferase described by 
Lomako et al. (5) was proposed to transfer the -phosphate of UDP-glucose into 
glycogen with the formation a C1-O-P-O-C6 bridging phosphodiester.  Perhaps 
the most obvious mechanism for the incorporation of phosphate into glycogen 
catalyzed by glycogen synthase would be through the formation of a C1-O-P-O-
C4 phosphodiester.  This is based on the notion that the non-reducing C4-OH in 
the acceptor glycogen particle is thought to act as a nucleophile, attacking the C1 
carbon of glucose in UDP-glucose with the subsequent formation of an -1,4-
glycosidic linkage.  We originally hypothesized that the 4-OH of glycogen would 
attack the electrophilic -phosphate of UDP-glucose forming a C1-O-P-O-C4 
phosphodiester linkage necessitating the action of a phosphodiesterase prior to 
laforin action to remove the phosphate.  In our in vitro characterization of laforin 
action, we were unable to detect activity towards the commercially available p-
nitrophenolphosphocholine or p-nitrophenyl phenylphosphonate, two commonly 
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Figure 47.  Phosphorylation of glycogen using mouse skeletal muscle 
extracts.  Extracts from WT and MGSKO mice were used.  Phosphorimage 
depicting the incorporation of [U-14C]glucose (left) and 32P (right) into glycogen 
from UDP-[U-14C]glucose and [-32P]UDP-glucose respectively using mouse 
skeletal muscle extracts as the source of the enzyme.  Treatment with -
amylase and amyloglucosidase is shown to confirm incorporation of radioactivity 
into glycogen.  Arrows indicate the bottom of the well, and arrow heads the 
bottom of the stacking gel. 
 
 
Figure 48.  Laforin hydrolyzes phosphate introduced by glycogen 
synthase.  14C labeled glycogen (left panel) and 32P labeled glycogen (right 
panel was prepared, purified by ethanol precipitation and subjected to 
treatment with either catalytically inactive C266S, laforin (CS) or active (WT) 
laforin.  Arrows indicate the bottom of the well, and arrow heads the bottom of 
the stacking gel. 
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used chromogenic phosphodiesterase substrates. An interesting 
phosphodiesterase candidate comes from examination of the human proteins 
containing carbohydrate binding domains.  The CAZy database (www.cazy.org) 
lists a total of 37 human genes encoding proteins with predicted carbohydrate 
binding modules (CBM), grouped in four families (164).  CBM20 has three entries, 
laforin, genethonin and an uncharacterized protein KIAA1434.  KIAA1434 has a 
C terminal domain with similarity to glycerophosphoryl diester diesterases 
(GDPDs).  We obtained the cDNA of this protein and subcloned it into pET28a 
and expressed the protein in bacteria followed by purification by affinity 
chromatography using Ni-NTA agarose.  After incorporating 32P into glycogen 
with glycogen synthase, we wondered whether the 32P could be hydrolyzed by 
laforin in the presence of KIAA1434.  Surprisingly laforin was able to hydrolyze 
the 32P label whether KIAA1434 was included or not (data not shown).  
Incubation of 32P labeled glycogen with either WT laforin or catalytically inactive 
C266S laforin clearly demonstrated that laforin was capable of removing the 
majority of the 32P label incorporated by glycogen synthase (Figure 48, right 
panel), without affecting 14C labeled glycogen that was prepared in a parallel 
experiment (Figure 48, left panel) and that the catalytic activity was required.  
Further evidence to support the notion of phosphomonoesters in glycogen comes 
from our in vitro observations that laforin can remove the majority of the 
phosphate in rabbit muscle glycogen in the presence of the glycogen degrading 
enzymes -amylase and amyloglucosidase (Figure 16A). With this in mind we 
sought to determine the chemical nature of the phosphate linkage in glycogen 
using rabbit skeletal muscle glycogen as a convenient source. 
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5.  Purification and Analysis of Phosphorylated Oligosaccharides from  
Rabbit Skeletal Muscle Glycogen 
 
5.1  Purification of phosphorylated species from glycogen 
Purified rabbit muscle glycogen contains 0.07% covalent phosphate by 
weight, which corresponds to approximately 1 phosphate every 650 glucose 
residues.  Using this glycogen, we attempted to identify the chemical nature of 
the phosphate and more specifically the hydroxyl in glucose to which the 
phosphate is attached.  Rabbit muscle glycogen was digested with -amylase 
and amyloglucosidase and the anionic species were bound to DEAE sepharose 
resin.  After extensive washing to remove glucose and neutral oligosaccharides, 
negatively charged species were eluted with ammonium bicarbonate and 
fractions analyzed for covalent phosphate by acid hydrolysis and detection of 
inorganic phosphate release by the Malachite Green method (140).  Of the 20 
fractions collected, seven contained a significant amount of covalent phosphate 
(labeled A-G, Figure 49).   
 
5.2  Analysis of phosphorylated species by high performance thin layer 
chromatography (HPTLC) 
The phosphorylated species collected by DEAE sepharose 
chromatography were subjected to high performance thin layer chromatography 
(HPTLC) analysis and were positive for carbohydrate as judged by reaction with 
N-(1-Naphthyl)ethylene-diamine dihydrochloride, a sensitive carbohydrate 
specific stain (Figure 50A).  Each fraction analyzed by this method generated a 
single species that upon phosphate hydrolysis by laforin treatment caused a 
prominent change in the migration pattern of the oligosaccharides (Figure 50A).  
Removal of phosphate from the majority of the fractions resulted in a smear from 
the origin as well as three distinct species, that when developed with 
carbohydrate standards, migrated at similar Rf values as maltotriose, 
maltotetraose and maltopentaose (Figure 50B).  This solvent system is unable to 
resolve monosaccharide phosphates from disaccharide phosphates, as glucose-
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6P and lactose-1P have similar Rf values (Figure 50B).  Therefore it is not 
unreasonable to assume that the single species observed before 
dephosphorylation by laforin is a complex mixture of phosphorylated 
oligosaccharides that are not resolved by this method.   
 
5.3  Analysis of phosphorylated oligosaccharides by high performance 
anion exchange chromatography (HPAEC) 
Carbohydrates such as glucose have no charge at neutral pH but in alkali 
conditions, the sugar acquires a negative charge and can be separated by anion 
exchange chromatography.  Therefore, we analyzed the phosphorylated 
oligosaccharides by high performance anion exchange chromatography 
(HPAEC).  By this method the phosphorylated oligosaccharides eluted between 
25-30 min (Figure 51B), retained by the column more than a series of 
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Figure 49.  DEAE sepharose purification of phosphorylated species from 
glycogen.  Anionic species from digested glycogen were bound to DEAE 
sepharose resin, eluted stepwise with increasing concentrations of 
NH4HCO3 .and analyzed for covalent phosphate.  The chromatogram depicts 
the amount of phosphate in each fraction collected.  Fractions 1-4, 10 mM 
NH4HCO3; Fractions 5-8, 50 mM NH4HCO3; Fractions 9-12, 100 mM 
NH4HCO3; Fractions 13-16, 500 mM NH4HCO3; Fractions 17-20, 1000 mM 
NH4HCO3. 
 
113 
 
 
Figure 50.  High performance thin layer chromatography analysis of 
phosphorylated oligosaccharides purified from glycogen.  A. Analysis of 
DEAE sepharose fractions containing covalent phosphate.  The fractions were 
either treated with catalytically inactive C266S laforin (-) or catalytically active 
WT laforin (+), developed by HPTLC and stained with N-(1-Naphthyl)ethylene-
diamine dihydrochloride to visualize sugars.  B. HPTLC analysis of Fraction E 
treated with inactive laforin (-) or active laforin (+). Malto-oligosaccharide and 
sugar phosphate standards are shown.  G1, glucose; G2, maltose; G3, 
maltotriose; G5, maltopentaose; G6, maltohexaose; G7, maltoheptaose; G8, 
maltoocatose; G6P, glucose-6P; L1P, lactose-1P. 
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Figure 51.  Analysis of purified phosphorylated oligosaccharides by high 
performance anion exchange chromatography (HPAEC).  Approximately 
5-10 nmoles (based on phosphate) of Fraction E from the DEAE sepharose 
column was analyzed after treatment with catalytically inactive C266S laforin 
or active WT laforin.  A. HPAEC analysis of oligosaccharide standards.  
Abbreviations as in Figure 50.  B. Phosphorylated oligosaccharides  treated 
with catalytically inactive laforin.  C. Phosphorylated oligosaccharides treated 
with active laforin.  D. Overlay of A, B and C.  
115 
malto-oligosaccharide standards (Figure 51A), as would be expected for 
phosphorylated species.   Treatment with laforin changed the elution profile 
producing a somewhat more complex mixture (Figure 51C).  A series of peaks 
with retention times matching those of maltotriose, matotetraose, maltopentaose 
and maltohexaose were observed in the chromatogram (Figure 51D).  This trend 
was observed in all fractions collected by DEAE sepharose chromatography 
(Figure 49) when treated with laforin and analyzed by HPAEC (data not shown).  
Given the highly branched nature of glycogen it is probable that the peaks 
produced after laforin treatment that do not correspond to the standard linear 
malto-oligosaccharides are branched oligosaccharides for which we do not have 
suitable standards.  
Treatment of the phosphorylated oligosaccharides with alkaline 
phosphatase, a non specific phosphatase, produced many of the species 
produced by laforin treatment (Figure 52D & E).  Alkaline phosphatase activity 
was not as efficient as laforin action as judged by the remaining area under the 
curve of the starting material after phosphate removal (Figure 52C & D).  
Interestingly, alkaline phosphatase treatment produced maltose, whereas the 
smallest oligosaccharide produced by laforin dephosphorylation was maltotriose, 
perhaps indicating specificity of laforin action based on chain length of the 
substrate.  Incubation of the phosphorylated oligosaccharides with a non specific 
phosphodiesterase, snake venom phosphodiesterase, had no effect on the 
retention time on all fractions analyzed (data not shown).   
 
5.4  Analysis of phosphorylated oligosaccharides by MALDI-TOF-MS 
Further analysis of these fractions by matrix assisted laser desorption 
ionization time of flight mass spectrometry (MALDI-TOF-MS) confirmed a 
complex mixture of oligosaccharides, each containing a phosphate (Figure 53).  
Mass analysis indicated the presence of oligosaccharides varying in length from 
3 glucoses plus a phosphate to 18 glucoses plus a phosphate in five of the 
fractions collected by anion exchange chromatography using DEAE sepharose. 
This methodology is only capable of identifying absolute mass quantities and the 
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Figure 52.  Alkaline phosphatase treatment of phosphorylated 
oligosaccharides.  HPAEC analysis of phosphorylated oligosaccharides 
treated with laforin and alkaline phosphatase  A. malto-oligosaccharide 
standards.  Abbreviations as in Figure 50.  B. Phosphorylated 
oligosaccharides from fraction E treated with catalytically inactive C266S 
laforin.  C. Phosphorylated oligosaccharides from fraction E treated with 
C266S laforin.  D. Phosphorylated oligosaccharides from fraction E treated 
with calf intestinal alkaline phosphatase.  E. Overlay of A-D. 
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structure of these oligosaccharides cannot be determined from these analyses. 
However, our HPAEC analyses suggest that these oligosaccharide phosphates 
are not just linear, non-branched sugars, but a mixture of branched 
oligosaccharides which would not be resolved by mass analysis. 
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Figure 53.  MALDI-TOF-MS analysis of phosphorylated 
oligosaccharides.  MALDI/TOF-MS analysis was performed in the reflector 
negative ion mode using THAP as matrix.  Two nmoles of sample E was 
analyzed.   
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6.  Identification of the Phosphate Linkage in Glycogen  

6.1  Acid hydrolysis of glycogen and phosphorylated oligosaccharides  
Mild acid hydrolysis to cleave glycosidic bonds is used in carbohydrate 
chemistry to identify structural components of polysaccharides (165).  
Amylopectin, for example is hydrolyzed in 0.7M HCl for 3 hours at 100oC to 
hydrolyze glycosidic linkages and the products can be analyzed enzymatically or 
chromatographically to determine the resulting monosaccharide phosphate 
structure.  In an effort to detect glucose-6P in rabbit skeletal muscle glycogen, we 
hydrolyzed the polysaccharide under acidic conditions and attempted to measure 
glucose-6P levels enzymatically using glucose-6P dehydrogenase and 
spectrophotometrically determining the reduction of NADP+ to NADPH.  During 
these studies, we observed a rapid reduction in NADP+ followed by a slow and 
steady increase in the rate of NADPH formation (Figure 54A).  The amount of 
glucose-6P, taken as the theoretical saturation point of the initial burst in activity, 
accounted for about 25-30% of the total phosphate in glycogen.  Since the 
reaction never went to completion at the time points analyzed, we wondered 
whether the high concentration of glucose present in the reaction mix after 
hydrolysis was being oxidized by glucose-6P dehydrogenase, albeit at a much 
slower rate.  Using a reaction mixture consisting of glucose, initiated a reduction 
in NADP+ catalyzed by glucose-6P dehydrogenase, suggesting that the enzyme 
has glucose dehydrogenase activity (Figure 54B).  When a mixture of glucose 
and glucose-6P were incubated with glucose-6P dehydrogenase, there was a 
rapid reduction of NADP+ followed by a slow and steady increase in the rate of 
NADPH formation (Figure 54B), reminiscent of the acid hydrolyzed glycogen 
sample (Figure 54A).  Whether this activity is from glucose-6P dehydrogenase or 
from contaminating glucose dehydrogenase is not clear at the moment but this 
activity has been reported (166).  In fact the authors warned about measuring 
glucose-6P levels in the presence of high concentrations of glucose.   
In light of these results and the lack of specificity for substrates of glucose-
6P dehydrogenase, we resorted to chromatographic analysis of acid hydrolyzed 
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phosphorylated oligosaccharides.  Our preliminary experiments involved 
hydrolysis in 2M trifluoroacetic acid (TFA) at 100oC for 4 hours and resulted in 
complete hydrolysis of the glycosidic linkages and produced glucose-6P as 
judged by HPAEC (Figure 55A).  Although we had evidence of glucose-6P 
production after acid hydrolysis of both glycogen and the phosphorylated 
oligosaccharides, glucose-6P is considerably more stable to acid treatment than 
glucose-1P (data not shown).  We wondered whether our hydrolysis conditions 
were also hydrolyzing phosphate groups that may be attached at other positions 
of the glucose ring   The only commercially available glucose phosphates are 
glucose-1P and glucose-6P, so we synthesized glucose-2P from glucose-1,2-
cyclic phosphate with the rationale of determining whether glucose-2P is stable 
under the conditions used for acid hydrolysis of glycosidic linkages in the 
phosphorylated oligosaccharides.  Glucose-1,2-cyclic phosphate was 
synthesized by the cyclization of glucose-1P with dicyclohexylcarbodiimide 
(DCC) in aqueous pyridine (147).  It was originally discovered that the reaction of 
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Figure 54.  Glucose-6P dehydrogenase has glucose dehydrogenase 
activity.  A. Time dependent reduction of NADP+ by glucose-6P 
dehydrogenase in the presence of acid hydrolyzed rabbit muscle glycogen.  B. 
Time dependent reduction of NADP+ by glucose-6P dehydrogenase in the 
presence of glucose (▼), glucose-6P (●) and glucose + glucose-6P (○).   
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Figure 55.  Acid hydrolysis of phosphorylated oligosaccharides.  All 
samples were analyzed by HPAEC.  A. Approximately 10 nmoles of 
phosphorylated oligosaccharides were subjected to acid hydrolysis in 2 M TFA 
at 100oC for 4 hours.  Under these conditions, the phosphorylated 
oligosaccharides were hydrolyzed to glucose and glucose-6P.  B. HPAEC 
analysis of glucose-2P detected contaminating glucose-1P.  C. HPAEC 
analysis of mildly acid hydrolyzed glucose-2P (100 mM HCl, 5 minutes, 
100oC).  Under these conditions glucose-2P was stable and glucose-1P was 
hydrolyzed to glucose.  D. Glucose-2P is hydrolyzed to glucose under 
conditions used to hydrolyze the phosphorylated oligosaccharides (2 M TFA at 
100oC for 4 hours). 
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DCC with ribonucleoside ‘2’,(3’) phosphate esters which possessed adjacent cis 
hydroxyls formed five membered ribonucleoside 2’,3’ cyclic phosphates (167)  
The product of cyclization of glucose-1-phosphate with DCC depends entirely on 
the stereochemistry of the adjacent hydroxyl groups relative to the phosphate 
ester.  Cyclization is possible when the relationship of a phosphate ester to the 
adjacent hydroxyl group is axial to equatorial or equatorial to equatorial (168).  -
D-glucose-1P, for example contains a hydroxyl at the 2 position of the pyranose 
ring that lies equatorial (cis) to the phosphate ester, and therefore reaction with 
DCC will result in the formation of glucose-1,2-cyclic phosphate.  In contrast, -
D-mannose-1-phosphate, in which the 2 hydroxyl and the phosphate ester lie 
axial (trans) does not undergo cyclization with DCC (168).  Reaction of DCC with 
glucose-1P produced glucose-1-2-cyclic phosphate that was purified as the 
barium salt in about 60-70% yield.  Hydrolysis of glucose-1-2-cyclic phosphate in 
100 mM HBr for 5 min at 100oC produced glucose-2P and glucose-1P; the latter 
is very labile under these conditions and was further hydrolyzed to glucose and 
inorganic phosphate.  Glucose-2P was purified as the barium salt and analysis 
by HPAEC revealed the presence of 2 peaks, one minor peak of glucose-1P and 
a major peak corresponding to glucose-2P (Figure 55B), that was confirmed by 
NMR spectroscopy (data not shown).  Acid hydrolysis, (5 min, 100oC, 100mM 
HCl) converted the acid labile glucose-1P to glucose and inorganic phosphate, 
without affecting the glucose-2P (Figure 55C).  However, subjecting glucose-2P 
to the acidic conditions required to hydrolyze glycosidic linkages in a parallel 
experiment to that of the phosphorylated oligosaccharides of Figure 55A, 
hydrolyzed the glucose-2P to glucose (Figure 55D).  These results in addition to 
the observation that phosphoryl group migration can occur under acid conditions 
(169) prompted us to explore other methodologies to determine the position of 
the phosphate group in glycogen. 
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6.2  Determination of the phosphate position in glycogen by NMR 
spectroscopy  
Although the phospho-oligosaccharide mixture is heterogeneous in terms 
of polymerization state, it is homogeneous in the sense that it consists primarily 
of glucose or glucose-phosphate residues.  It was therefore amenable to analysis 
by NMR spectroscopy.  Several spin systems were detected by 1H-1H COSY and 
TOCSY and 1H-13C HSQC.  The spectra were dominated by a group of similar 
spin systems belonging to 4--Glc-(1→4) residues.  Other spin systems present 
included those of 4--Glc-(1→6), terminal -Glc-(1→4), terminal -Glc-(1→6), 
and  and  reducing end residues that appeared to be mostly 4,6-linked (i. e. a 
branching residue glycosylated in both the 4 and the 6 positions), judging by their 
H-1 chemical shifts (170) (Table 2).  In addition, two spin systems were identified, 
each with one proton resonance uncharacteristically far downfield for glucose, 
suggesting substitution by phosphate (Figure 56). On the basis of the 
connectivities established by the COSY, TOCSY, and ROESY experiments and 
the carbon chemical shifts determined by the HSQC experiment, one of these 
downfield signals appeared to be H-2 of a terminal glucose residue and the other 
H-3 of a 4-linked glucose.  To confirm substitution by phosphate, we acquired a 
1H-31P gHMQC spectrum, which showed two peaks, confirming substitution at 
the 2-OH and the 3-OH positions by phosphate (Figure 57).  We also acquired a 
1H-31P HMQC-TOCSY spectrum to ascertain that these two protons belong to the 
spin systems previously assigned.  This spectrum showed the expected 
correlations of each of the peaks detected in gHMQC with their neighboring 
protons (Figure 58). 
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 Residue  1 2 3 4 5 6 NOE 
I t--Glc-2-P-(1→?) 1H 5.69 4.00 3.76 3.50 3.69 3.83/3.77  
  13C 100.0 77.3 74.8 72.0 75.0 63.3  
II t--Glc-(1→4) 1H 5.59 3.58 3.65 3.43 3.66 3.83/3.77 IV-4 
  13C 101.3 74.2 75.4 72.1 75.4 63.3  
III 4--Glc-(1→4) 1H 5.40 3.60 3.97 3.64 3.84 3.83/3.77 IIIn-1-4a 
  13C 102.2 74.1 76.0 79.7 73.8 63.3  
IV 4--Glc-3-P-(1→4) 1H 5.35 3.75 4.46 3.81 3.87 n.d.b III-4, VII-4, or VIII-4 
  13C 102.4 74.6 79.9 76.4 73.8 n.d.  
V 4,6--Glcred 1H 5.22 3.55 3.96 3.64 3.93 3.98/3.83  
  13C 94.6 74.2 76.0 79.7 72.7 69.7  
VI t--Glc-(1→6) 1H 4.99 3.54 3.74 3.44 3.86 n.d.  
  13C 101.5 74.7 74.2 72.1 73.8 n.d.  
VII 4--Glc-(1→6) 1H 4.95 3.59 4.01 3.63 3.85 n.d.  
  13C 100.7 74.1 73.0 80.6 74.0 n.d.  
VIII 4,6--Glcred 1H 4.65 3.25 3.77 3.62 3.60 3.97/3.73  
  13C 98.5 76.7 78.9 80.6 77.3 68.8  
 
Table 2.  Chemical shift assignments of phosphorylated oligosaccharides.   athe next residue in the 
chain, bnot determined. 
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Figure 56.  1H-1H TOCSY NMR spectrum of phosphorylated 
oligosaccharides.  A sample of phosphorylated oligosaccharides (Fraction C + 
D + E + F) was analyzed by 1H-1H TOCSY NMR.  The spectrum was acquired 
at 25 oC and 18.7 T with a 1-s relaxation delay and 3.7 kHz spectral width, 100 
ms spinlock time, 0.138 s acquisition time, 128 increments, and 32 transients 
per increment.  
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Figure 57.  1H-31P gHMQC NMR spectrum of phosphorylated 
oligosaccharides.  A sample of phosphorylated oligosaccharides (Fraction C + 
D + E + F) was analyzed by gHMQC.  The 1H-31P gHMQC spectrum was 
acquired with an 8.0 kHz spectral width in F1, 0.4 s acquisition time, 32 
increments, and 360 transients per increment. The signal marked with an 
asterisk is probably from a terminal glucose-2P residue linked in a different 
position but could not be clearly identified due to its low abundance. 
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Figure 58.  1H-31P HMQC-TOCSY NMR spectrum of phosphorylated 
oligosaccharides.  A sample of phosphorylated oligosaccharides (Fraction C + 
D + E + F) was analyzed by 1H-31P HMQC-TOCSY NMR.  The 1H-31P HMQC-
TOCSY spectrum was acquired with a 3.0 kHz spectral width in F1, 0.3 s 
acquisition time, 40 ms spinlock time, 24 increments, and 400 transients per 
increment.  Phosphorus decoupling was turned on during acquisition using the 
GARP-1 decoupling sequence.  The signal marked with an asterisk is probably 
from a terminal glucose-2P residue linked in a different position but could not be 
clearly identified due to its low abundance. 
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7.  Mechanism of Phosphate Incorporation by Glycogen Synthase 
 
7.1  Cyclic phosphate formation 
Perhaps the most obvious mechanism for the incorporation of phosphate 
into glycogen by glycogen synthase would be through the formation of a C1-O-P-
O-C4 linkage.  However, our data strongly suggest the occurrence of 
phosphomonoesters in glycogen.  First of all, NMR analysis suggests the 
presence of phosphate at the C2 and C3 hydroxyls with no detectable C1, C4 or 
C6 phosphates.  Furthermore, the NMR analysis suggests that these phosphates 
are monoesters.  Secondly, our phosphorylated oligosaccharides are hydrolyzed 
by laforin, which in our hands has no phosphodiesterase activity, or alkaline 
phosphatase. Finally, laforin is capable of removing phosphate that has been 
incorporated by glycogen synthase.  How is phosphate incorporated as a 
monoester by glycogen synthase during elongation of the polymer?  Insight into 
the mechanism may come from an unexpected observation during our studies of 
UGPPase specificity for UDP-glucose.  The reaction catalyzed by UGPPase 
(Figure 44B) is a metal dependent hydrolysis of the pyrophosphate bond in UDP-
glucose.  During the course of studying the enzyme’s effects on [-32P]UDP-
glucose, we noticed that in the presence of Mg2+ or Mn2+, UDP-[U-14C]glucose 
and [-32P]UDP-glucose would decompose to a species that, when analyzed by 
HPTLC, migrated slightly faster than UDP-glucose (Figure 59).  This species was 
completely consumed by UGPPase treatment of the [32P]UDP-glucose but only 
partially in the reaction mix containing the UDP-[U-14C]glucose (Figure 59).  The 
latter is most likely due to the amount of substrate in the respective reactions, as 
the reaction containing UDP-[U-14C]glucose had more substrate and was 
terminated prior to completion.  Nevertheless, analysis of unlabelled UDP-
glucose in the presence of Mg2+ revealed that the unknown species had no 
detectable UV absorption and contained carbohydrate, as judged by reactivity 
towards N-(1-Naphthyl)ethylene-diamine dihydrochloride (data not shown).  
Addition of equimolar amounts of EDTA or removing the divalent cation from the 
reaction mix prevented the formation of the species.   
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Figure 59.  The formation of glucose-1,2-cyclic phosphate (fast ester) from 
UDP-glucose.  UDP-[U-14C]glucose and [32P]UDP-glucose were treated with 
or without 100 g/mL UGPPase in 50 mM Tris-HCl, pH 8.8 containing 10 mM 
MgCl2.  The reaction was terminated by boiling in a water bath and the products 
analyzed by HPTLC.  In contrast, the chromatogram of Figure 44 was 
terminated by the addition of equimolar amounts of EDTA, essentially 
eliminating the presence of fast ester.  
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 Glucose,-1,2-cyclic phosphate (Figure 60A) was first described by Leloir, 
in the early 1950’s as a contaminant in the enzymatic synthesis of UDP-glucose, 
that he termed “fast ester” (171).  In addition to being prepared by reaction of 
glucose-1P with DCC (see Results Section 6.1), glucose-1,2-cyclic phosphate 
can be prepared by the metal ion or base catalyzed decomposition of UDP-
glucose (172).  We wondered whether cyclic phosphodiester formation during 
elongation of glycogen by glycogen synthase might be the phosphoryl donor 
responsible for phosphorylating glycogen.  Our initial attempts to introduce 
phosphate into glycogen with glycogen synthase from [-32P]UDP-glucose in the 
presence of Mg2+ resulted in high background 32P on the gel, most prominently in 
the well where glycogen resides.  However the 32P in the well was not glycogen 
as it was insensitive to glucosidase treatment. (data not shown).  Furthermore,  
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Figure 60.  The structure of glucose-1,2-cyclic phosphate and glucose 1,3-
cyclic phosphate.  A. Glucose-1,2-cyclic phosphate is a five membered cyclic 
phosphate thought to form by the alkali and/or metal dependent decomposition 
of UDP-glucose.  B.  Glucose-1,3-cyclic phosphate is a seven membered cyclic 
phosphate. 
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we wondered whether the formation of glucose-1,2-cyclic phosphate or glucose-
1,3-cyclic phosphate (Figure 59B) in the active site of glycogen synthase, 
independent of divalent cations, would allow for phosphate to be incorporated at 
the C2 or the C3 hydroxyls (Figure 66, see Discussion).  In the event of the 
possible formation of a five membered cyclic phosphate ring or a six membered 
cyclic phosphate ring, the formation of the five membered ring would be favored 
(168).  This is consistent with the preferential degradation of UDP-glucose to 
glucose-1,2-cyclic phosphate rather than glucose-1,3-cyclic phosphate, 5 and 6 
membered cyclic phosphates respectively.  However, [32P]UDP-[2-deoxy]-
glucose undergoes cyclization in the presence of Mn2+ at alkaline pH as judged 
by HPTLC (Figure 61).  Loss of the C2-OH would most likely cause cyclization to 
 
 
Figure 61.  Cyclic phosphate formation from UDP-glucose derivatives.  
Incubation of [32P]UDP-glucose, [32P]UDP-[2-deoxy]-glucose  and [32P]UDP-
[3-deoxy]-glucose with Mn2+ results in the formation of cyclic phosphates as 
monitored by HPTLC.  The addition of EDTA strongly inhibits cyclic phosphate 
formation by chelating the Mn2+. 
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occur between the anomeric carbon and C3, forming a stable six membered 
cyclic phosphate.  This is inferred because six-membered cyclic phosphates are 
more stable than seven membered cyclic phosphates (173), which would form 
between the C1 and C4/C6 hydroxyls.  Likewise, cyclization of [32P]UDP-[3-
deoxy]-glucose produced [32P]glucose-1,2-cyclic phosphate (Figure 61).  In 
addition to the formation of cyclic phosphates, the presence of Mn2+ also caused 
a notable change in the migration pattern of other 32P labeled species.  However, 
this may be an artifact since a precipitate of Mn(OH)2 formed during the reaction 
in the samples without EDTA (Figure 61).  Nevertheless, both UDP-glucose 
derivatives are capable of undergoing cyclization under these conditions. 
Interestingly, when these radioactive isotopes are incubated with glycogen 
synthase using glycogen as the acceptor, [32P]UDP-[3-deoxy]-glucose 
incorporates significantly more 32P than [32P]UDP-[2-deoxy]-glucose and even 
more than [32P]UDP-glucose (Figure 62).  The product of all three reactions was 
degraded by glucosidase treatment indicating that it was polysaccharide and that 
both UDP-glucose analogs could act as phosphate donors during glycogen 
synthesis.  Why the three nucleotide sugars led to different phosphate 
incorporation is not immediately obvious.  It is possible that loss of the hydroxyl 
at C2 forces cyclization at C3 while loss of the C3 hydroxyl forces the formation 
of a cyclic phosphate between C1 and C2 resulting in different kinetics of 
incorporation, also with respect to the normal UDP-glucose substrate. 
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Figure 62.  Glycogen synthase incorporates phosphate into glycogen 
using [32P]UDP-[2-deoxy]-glucose and [32P]UDP-[3-deoxy]-glucose.  
Glycogen synthase incorporates 32P into glycogen using [32P]UDP-glucose, 
[32P]UDP-[2-deoxy]-glucose and [32P]UDP-[3-deoxy]-glucose as the 
phosphate donors.  The arrow indicates the bottom of the well and the arrow 
head indicates the bottom of the stacking gel. 
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DISCUSSION 
 
1.  Laforin as a Glycogen Phosphatase 
 The first report of the presence of covalent phosphate in glycogen was in 
the early 1980’s, (6) almost 125 years after the original discovery of the 
polysaccharide.  The fact that covalent phosphate has been overlooked for all 
these years is a testimony to the low levels present in the glycogen molecule.  
The frequency of phosphorylation in rabbit muscle glycogen is around 1 
phosphate every 650 glucoses residues. The average number of phosphates per 
glycogen molecule would of course depend on size.  For example, a normal 
glycogen molecule of 9 tiers would have a diameter of ~31 nm and ~15,000 
glucose residues (174).  Such a particle would contain on average ~25 
phosphate groups.  Covalent phosphate in plant starch has been well studied, 
and starch metabolism is influenced by genetic depletion of the enzymes 
involved in starch phosphate metabolism.  Although glycogen and amylopectin 
share the chemistry of their polymerization and branching linkages, their 
structures are quite different (175).  Amylopectin has a generally higher 
molecular weight and is significantly less branched (1 in ~30 residues) than 
glycogen (1 in ~12 residues).  Whereas glycogen is believed to be formed of 
concentric tiers of glucose residues (Figure 2), amylopectin has a more extended 
conformation that includes semi-crystalline regions of unbranched glucose chains 
lined up in parallel (176).  This difference likely accounts for the fact that most of 
the phosphate in amylopectin is readily released by laforin, and is presumably 
superficial and available, while only a fraction of the phosphate is accessible on 
the surface of the glycogen molecule and phosphate from the inner tiers cannot 
be accessed until the structure is disrupted by hydrolyzing enzymes.   
On the model of Gunja-Smith et al. (2)  there are approximately equal 
numbers of A chains (unbranched) and B chains (branched), and there is a 
uniform distribution of chain lengths.  Furthermore, each B chain has two chains 
attached to it, and all the unbranched chains are on the outermost tier.  
Assuming random distribution of phosphate, a full size glycogen molecule of 12 
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tiers, containing 55,000 glucose residues, with a frequency of phosphorylation of 
1/650 would have about 85 phosphates, of which half would be located on the 
unbranched A chains of the outer most tier.  In this hypothetical particle, laforin 
would release 25% of the total phosphate or ~21 phosphates.  Only when the 
structure is disrupted by hydrolyzing enzymes would the remaining phosphate be 
removed.  Perhaps this result suggests that phosphate is not equally distributed 
throughout the particle.  If we assume that all phosphates on the A chains are 
sterically accessible to laforin, and the amount hydrolyzed is an absolute 
measure of the phosphate on the A chains, then the inner 11 tiers would contain 
75% of the phosphate, far from equally distributed considering the inner 11 tiers 
would contain 50% of the glucose.  It is interesting that the rate of phosphate 
release from both amylopectin and glycogen is saturable by substrate and 
follows approximately hyperbolic kinetics.  The apparent Km's for amylopectin and 
glycogen were 1.5 mg/ml and 4.5 mg/ml respectively.  For glycogen with Mr 107, 
the Km would be 0.45 M.  Expressed in terms of covalent phosphate 
concentrations, the values would be 47.3 M and 42.5 M for amylopectin and 
glycogen, respectively.  However, if only 25% of the glycogen phosphate is 
assumed to be accessible, the Km would be reduced to ~10 M.  Nonetheless, 
these Km values are quite close to each other and would be consistent with some 
commonality in the reaction mechanism for phosphate removal from both 
polysaccharides.  However, interpreting the kinetics of polysaccharide 
dephosphorylation by laforin is complex.  First, both glycogen and amylopectin 
are polydisperse.  Secondly, the analysis is complicated by the fact that laforin 
contains a carbohydrate binding domain separate from the catalytic site and that 
laforin activity requires a functional carbohydrate binding domain.  In fact, if the 
inhibition of laforin pNPPase activity by polysaccharide (107) reflects binding, 
then even at the lowest substrate concentrations of Figures 14B and D, virtually 
all of the laforin would be bound.  Thus, simple enzyme kinetic formulations may 
not be applicable. 
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2.  Lafora Disease Mouse Models 
Lafora disease is a progressive disorder and patients are relatively normal 
until they develop neurological symptoms starting in their teenage years with 
rapid progression and subsequent death within about 10 years (89-91).  
Therefore a molecular explanation for LD must account for the gradual nature of 
its onset and subsequent course, despite the fact that any genetically determined 
defects in proteins will be present from birth.  Currently, a prevailing hypothesis is 
that the symptoms of the disease accompany the accumulation of the Lafora 
bodies which, in neurons, leads to cell death and the associated epilepsy, 
myoclonus, ataxia and other symptoms.  Lafora bodies contain abnormally 
branched deposits of the normal cellular storage compound, glycogen (177, 178).  
In our studies of Epm2a-/-, mice we have observed age-dependent changes in 
the properties of glycogen that parallel the course of the disease and can explain 
its progressive nature.  Based on these data, we believe that the initial 
hyperphosphorylation of glycogen in Epm2a-/- animals leads to altered physico-
chemical properties that do not grossly affect the normal synthesis and 
degradation cycle of the polysaccharide.  With time, the glycogen develops into a 
polysaccharide whose branching structure is substantially altered to form an 
insoluble polymer, with the characteristics of polyglucosan.  We envisage a 
threshold in glycogen phosphorylation beyond which the glycogen is destined to 
become the insoluble polyglucosan that results in the pathology of the disease.   
The frequency of phosphorylation measured for muscle glycogen from 
wild type mice, regardless of age, was around 1 per 1500 glucose residues.  The 
value we reported for rabbit muscle glycogen was 1 per 650, which is similar to 
previous values cited in the literature (4, 5).  This difference could be species 
related or could result from differences in the isolation protocols.  In any case, 
phosphorylation is relatively rare and, in the 3 month old Epm2a-/- mice, is only 
increased to 1 in ~375 glucose residues.  The average number of phosphates 
per glycogen molecule in mice, assuming 9 tiers (diameter of 30.6 nm and 
15,386 glucose residues) would be ~10 which would increase to ~40 in young 
Epm2a-/- mice.  It is difficult to conceive how addition of such a relatively small 
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number of charged groups could alone cause a dramatic change in ethanol 
solubility, especially as the phosphates are probably not all located on the 
outermost tiers of the molecule.  More importantly, one might postulate that 
increased phosphorylation would actually make the polymer less soluble in a less 
polar solvent like ethanol.  Phosphorylation is clearly responsible for the 
increased ethanol solubility since its removal with laforin reverts the solubility 
properties to that of wild type glycogen (Figure 21).  We propose that the 
phosphates elicit a global change in glycogen structure.  Experimental 
determination of glycogen structure is hampered by the fact that the polymer is 
polydisperse with respect both to size and to exact branching structure.  However, 
there is a strong expectation that glycogen, like amylopectin, will contain 
polyglucose helices.  A crystal structure of a cycloamylose has been determined 
(179).  This molecule is a 26 residue cyclic polymer of glucose in -1, 4- linkages 
(cyclomaltohexicosaose) that adopts a structure with two antiparallel polyglucose 
helices in which the glucose oxygen atoms are oriented towards the exterior 
surface and the carbon skeletons of the glucoses line the interior of the helix 
(Figure 63).  While this molecule maintains the helical structures by constraints 
not present in native glycogen or amylopectin, it is not unreasonable to propose 
that some of the structural features occur in the native polysaccharides.  It is 
notable in the cycloamylose structure that the helices are stabilized by intra-
helical hydrogen bonding mediated by the physically adjacent 6', 2' and 3' 
hydroxyls (Figure 63).  From inspection of the structure, it is apparent that the 
introduction of phosphate groups to virtually any glucose hydroxyl group would 
disrupt the local hydrogen bonding, destabilize the secondary structure, and 
potentially expose the more hydrophobic faces of the glucose residues to solvent.  
We propose that the glycogen molecule can maintain its compact structure with a 
low number of phosphorylations but that, past some threshold, too many helices 
lose their regular structure, resulting in altered packing of the polyglucose chains 
and global disruption of the structure of the molecule.  In this situation, the 
ethanol solubility is actually enhanced by the disruption of the secondary 
structure caused by phosphorylation. 
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Figure 63.  Crystal structure of v-amylose.  View of the ideal left-handed, 
single-stranded v-amylose helix constructed on the basis of the central 6 
glucoses in the four helical parts of the two symmetry-independent CA26 
molecules in the triclinic unit cell.  All C(6)–O(6) groups are oriented (2) 
gauche, hydrogen bonds O(3)n…O(2)n+1 and O(6)n…O(2) n+6; O(6)n…O(3) n+6; 
drawn in blue.  Adapted from Gessler et al. 96, 4246-4251. (1999) PNAS.  
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 The glycogen purified from 9-12 month old Epm2a-/- mice has properties 
consistent with the formation of Lafora bodies.  As the knockout mice age from 3 
to 9-12 months, the increase in glycogen phosphorylation is relatively small but is 
accompanied by a major decrease in branching, acquisition of water insolubility, 
development of gross morphological abnormalities as observed by electron 
microscopy, and a tendency to aggregate.  Aggregation is inferred from the 
appearance of large conglomerated structures by electron microscopy and also 
the fact that low speed centrifugation of tissue extracts recovers the majority of 
the glycogen in the pellet fraction.  Normal glycogen particles in tissue extracts 
require high speed centrifugation (for example, 100,000 x g for 2 hours) to be 
removed from aqueous solution.  Thus, the low speed centrifugation 
operationally defines two populations of glycogen particles.  The glycogen 
particles present in the LSP are larger, have an altered iodine spectrum, are 
water insoluble and have an abnormal appearance by electron microscopy, as 
compared with the polysaccharide that remains in the supernatant which 
behaves more like normal glycogen.  Based on the amount of covalently 
attached glycogenin, which essentially provides a count of the number of 
glycogen molecules present, the actual sizes of the glycogen molecules in the 
two fractions are not greatly different, only some 60% larger in the LSP fraction.  
This relatively small increase cannot explain the large change in hydrodynamic 
properties allowing sedimentation by low speed centrifugation and argues for the 
presence of aggregates in the LSP.  In other words, the glycogen particles in the 
LSP must be formed of multiple, individual glycogen molecules.  Both 
aggregation and water insolubility likely contribute to the formation of Lafora 
bodies.  The insolubility can be attributed primarily to the reduced branching of 
the polysaccharide and is unaffected by dephosphorylation in vitro with laforin 
(data not shown).  Aggregation requires the presence of the phosphate since its 
removal reverses much of the abnormal morphology seen by electron 
microscopy (Figure 23A & B).  However, aggregation must also depend on the 
poorly branched structure since it is not observed with glycogen from the young 
Epm2a-/- animals, even though significant hyperphosphorylation has already 
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occurred.  Thus, aberrant glycogen phosphorylation may be viewed as necessary 
but not sufficient for Lafora body formation in this model.  How phosphorylation 
and reduced branching combine to favor aggregation of glycogen molecules in 
tissues is not clear at this time.  
A major question in Lafora research is how loss of function of laforin or 
malin contributes to the generation of Lafora bodies.  The first reported laforin 
substrate was the protein kinase GSK-3 (104, 180) that regulates glycogen 
synthase activity.  However, not all reports support this hypothesis (3, 113, 138) 
which is also inconsistent with the observation that glycogen synthase -/+ 
glucose-6P activity ratio is not increased in Epm2a-/- or the Epm2b-/- animals 
and perhaps more importantly, the phosphorylation state of GSK3 is unchanged 
in both animal models.  We favor the hypothesis that a primary function of laforin 
in vivo is as a glycogen phosphatase.  It focuses on the idea that LD is 
essentially a metabolic disorder and that laforin is a glycogen metabolic enzyme.  
It could in fact be viewed as part of a repair or corrective mechanism, such as 
exists for the synthesis of other biopolymers, like DNA.  Normal glycogen 
contains low levels of covalent phosphate and laforin will limit phosphorylation to 
what has evolved to be a structurally tolerated level.  In the absence of functional 
laforin, as in the Epm2a-/- mice or LD patients, the usual cycles of glycogen 
synthesis and degradation in the various tissues initially proceed relatively 
normally but with time the glycogen gradually accumulates structural defects that 
set it on the course to develop into polyglucosan.  
Defects in malin must also result in accumulation of polyglucosan.  Malin 
could function in concert or upstream of laforin in the control of glycogen 
phosphorylation, resulting in an essentially identical mechanism to that proposed 
for laforin.  Alternatively, it could regulate glycogen phosphorylation 
independently of laforin, for example down-regulating enzyme(s) responsible for 
introducing phosphate into glycogen.  Finally, it could function to limit the 
transition from normally branched glycogen to polyglucosan.  From our initial 
analyses of the Epm2b-/- mice, we favor the idea that malin prevents laforin 
sequestration in an insoluble fraction.  Simple binding of malin and laforin could 
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be sufficient to maintain laforin in the soluble compartment to remove excessive 
phosphate from glycogen.  Malin could actively oppose the formation of 
abnormally structured glycogen, as a positive regulator of laforin activity or by an 
unknown laforin-independent mechanism.  Alternatively, rather than affecting the 
formation of abnormal glycogen, malin could prevent accumulation by promoting 
its disposal to lysosomes.  In any event, the accumulation of structurally aberrant 
glycogen would disproportionately bind laforin which is known to interact 
preferentially with poorly branched polysaccharides like amylopectin (107) and 
polyglucosan (95). 
Most Lafora research has focused on ways in which malin and laforin 
function to limit the transition from normally branched glycogen to polyglucosan 
and several potential malin targets have been proposed.  Biochemically, malin 
has been shown to act as an E3 ubiquitin ligase (105) and studies with cultured 
cells have implicated multiple proteins as targets for malin action, including 
glycogen synthase, debranching enzyme, PTG and laforin (105, 117-119).  In 
studies of hepatocytes (116) and neurons (117), the groups of Guinovart and de 
Cordoba proposed that a malin-laforin complex ubiquitylated the type 1 
phosphatase regulatory subunit PTG and, in neurons, also glycogen synthase, 
leading to their degradation.  Worby et al. (118) also reported that malin targets 
PTG for degradation in a laforin-dependent manner.  Impaired degradation of 
either glycogen synthase or PTG should result in increased glycogen elongating 
activity, either by directly increasing glycogen synthase levels or, in the case of 
PTG, by increased targeting of PP1 to glycogen causing dephosphorylation and 
activation of glycogen synthase.  An imbalance between elongating and 
branching activity has long been proposed as a potential mechanism for 
polyglucosan formation (181).  If a functional laforin-malin complex targets these 
proteins for degradation by ubiquitylation, as proposed, one would expect their 
levels to be elevated when laforin or malin activity is defective, as in Lafora 
patients with EPM2A and EPM2B mutations or in mice with the Epm2a or the 
Epm2b gene disrupted.  From our analysis of the Epm2a-/- and Epm2b-/- mice 
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we find no evidence for changes in the levels of debranching enzyme or PTG, 
arguing against laforin-malin dependent degradation in normal animals.   
The results with glycogen synthase in the Epm2a-/- mice were more 
complex.  At 3 months of age the Epm2a-/- mice have normal glycogen levels 
and a slight redistribution of glycogen synthase to the insoluble LSP. In the older 
animals total glycogen levels were significantly elevated in muscle and brain, and 
the majority of this glycogen was recoverable in the LSP/polyglucosan fraction as 
abnormally structured polysaccharide.  Glycogen synthase protein, judged by 
Western blot, was significantly elevated in this fraction as compared with wild 
type samples.  This result is also consistent with the in vitro observation that 
purified glycogen synthase binds more effectively to the abnormal glycogen 
isolated from old Epm2a-/- muscle.  This increase in glycogen synthase could be 
consistent with laforin-dependent breakdown of glycogen synthase by malin.  
However, it is not a unique explanation since our experience with several 
genetically modified mouse models indicates that glycogen content correlates 
with glycogen synthase protein level.  Binding to glycogen itself appears to 
stabilize glycogen synthase.  For example, overexpression of another PP1 
regulatory subunit, RGL/GM, leads to increased glycogen in muscle and elevated 
glycogen synthase protein (52).  Decreased glycogen levels, as observed in RGL 
knockout (53) or PTG knockout (DePaoli-Roach, unpublished data) animals, 
were associated with decreased glycogen synthase.  The question then is 
whether the elevated glycogen synthase in the Epm2a-/- mice is secondary to 
the increased glycogen levels or the cause of the glycogen over-accumulation?  
In any event, the results from the old Epm2a-/- mice are confounding with 
respect to the enzymatic imbalance theory of polyglucosan formation in LD 
because the glycogen synthase recovered in the LSP has low activity.  
Normalizing activity in the presence of glucose-6P to the protein detected by 
Western blot, indicates a 2-3 fold decrease in specific activity in the LSP of 
Epm2a-/- mice compared to the LSS.  Simplistically, these activity measurements 
do not indicate an enzymatic imbalance towards elongating activity in the 
knockout animals.  The assessment is unchanged if activities determined in the 
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absence of glucose-6P are considered.  The caveat would be if the enzyme 
assays, for some reason, do not reflect the true activity of the glycogen synthase 
in the LSP of the Epm2a-/- animals.  One idea would be that association of 
glycogen synthase with the insoluble polyglucosan aggregates effectively 
removes the enzyme from the soluble phase, limiting our ability to measure 
activity by traditional assays, but in vivo allowing for effective elongation and 
synthesis of the glycogen.  A different possibility would be that some 
unrecognized, stable modification of the enzyme is able to reduce activity, even 
in the presence of glucose-6P, an eventuality that would argue against the 
imbalance hypothesis.  In the 3 month old Epm2b-/- mice, glycogen synthase 
total activity and -/+ glucose-6P activity ratios were unchanged, although in brain 
there was a trend to increased total activity in the LSP, consistent with our 
observations of the 3 month old Epm2a-/- mice.  These results were confirmed 
by Western blotting with anti-glycogen synthase antibodies, and in the case of 
brain the increased proportion of glycogen synthase protein in the LSP was 
statistically significant.  
An alternative mechanism for polyglucosan formation in Epm2a-/- mice 
would be loss of control of the branching/debranching system.  The debranching 
enzyme, AGL, was proposed to be a malin target by Cheng et al. (119).  Defects 
in malin function, then, should correlate with elevated AGL protein which the 
authors proposed would lead to less branched glycogen.  The AGL protein level 
was unchanged in muscle or brain of Epm2a-/- and the Epm2b-/- mice arguing 
against increased debranching activity accounting for polyglucosan formation in 
this model.  In any event, based on the two stage degradation of glycogen by 
phosphorylase and debranching enzyme, excessive AGL activity should only 
reduce branching frequency if phosphorylase, an abundant enzyme, becomes 
limiting.  During synthesis, reduced branching enzyme activity could also 
potentially lead to impaired glycogen branching but in previous analyses of young 
Epm2a-/- (3) and C266S over-expressing mice (138), there was no evidence for 
a major decrease in branching enzyme activity in knockout animals. Our 
systematic analysis of glycogen metabolism in the Epm2a-/- and the Epm2b-/- 
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mice do not support the enzymatic imbalance hypothesis as being the 
predominant initial defect in the formation of Lafora bodies.  Our model for Lafora 
body formation envisions a transition from relatively normal glycogen metabolism 
to a state in which incremental damage to glycogen molecules, triggered by 
hyperphosphorylation, leads to abnormal glycogen structure that in the long term 
becomes insoluble, poorly branched, aggregates of polyglucosan that can 
explain the formation of Lafora disease. 
 
3.  The Incorporation of Phosphate into Glycogen and the Chemistry of the 
Phosphorylation 
The synthesis of biological polymers in nature, in many instances, is prone 
to errors by the polymerizing enzyme.  The cell exhausts a great deal of energy 
in order to repair these mistakes, usually by recruiting “repair” proteins.  The 
classic example is that of errors that occur during DNA replication, although 
errors in protein synthesis and the transcription of DNA to mRNA are also 
common (182-185).  Incorporation of an incorrect nucleotide by DNA polymerase 
is rare, with a frequency of about 1 error every 100,000 nucleotides (186).  At first 
glance, this rate seems almost negligible but in the case of humans with 6 billion 
base pairs in each diploid cell, this would account for ~120,000 errors every time 
the cell divides.  Obviously, this is not the case due to the various DNA repair 
proteins which monitor the DNA for mistakes and repair them.  Here we add 
another biopolymer, glycogen, to the list of those polymers prone to errors by 
their respective polymerizing enzymes.   
Our in vitro and in vivo data support the notion that glycogen 
phosphorylation drives the formation of Lafora bodies and the subsequent 
neurological phenotype in Lafora patients.  Therefore, understanding how the 
phosphate is incorporated and where the phosphate resides in the polymer is of 
fundamental importance not only for Lafora disease, but also for glycogen 
metabolism in general.  We propose that phosphate incorporation into glycogen 
by glycogen synthase represents an enzymatic error not unlike mistakes in DNA 
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synthesis.  As with DNA, we suggest that there is an evolved repair mechanism, 
in this case based on the action of the laforin phosphatase. 
In vivo evidence for the incorporation of phosphate into glycogen by 
glycogen synthase comes from studies of mice exercised to exhaustion on a 
treadmill (J.M. Irimia unpublished observations).  Exhaustive exercise in mice 
decreases muscle glycogen to about 20% of the normal value with a concomitant 
decrease in the total phosphate content of the glycogen.  During recovery and 
subsequent glycogen synthesis, the total glycogen phosphate levels increase at 
a rate of about 1 phosphate every 6,500 glucoses, similar to our in vitro rate of 
phosphate incorporation by glycogen synthase.  It is important to distinguish 
between the rate of phosphate incorporation and the density of basal 
phosphorylation or the frequency of phosphorylation.  Glycogen synthase 
incorporates phosphate at a rate of 1 Pi every 5,000-10,000 glucose residues.  
However, the glycogen molecule has a density of basal phosphorylation of 1 
phosphate every 1,500 glucose residues in mouse skeletal muscle for example.  
Although total phosphate levels increase during glycogen synthesis in the 
exercised mice, the density of phosphate (molPi / mol glc) decreases.  This 
would be expected if only 1 phosphate is being incorporated approximately every 
6,500 glucoses (Figure 64) and the basal density of phosphorylation in WT mice 
is about 1 phosphate every 1,500 glucoses.  These data are consistent with 
phosphate being introduced in vivo during glycogen synthesis.  Interestingly, the 
phosphate density never reaches the levels present in the basal, non exercised 
mice, even after a week of rest.   We believe that this is due to the fact that 
glycogen synthase has not been through enough rounds of synthesis required to 
introduce phosphate back to basal levels.  Perhaps an alternative explanation 
would be that during basal glycogen metabolism, only the outer tiers of the 
glycogen molecule are being turned over and the phosphate incorporated on the 
outer tier is rapidly hydrolyzed by laforin.  Only after substantial depletion of 
glycogen such as after a bout of exercise, would the particle be degraded to an 
extent that the phosphate introduced during the subsequent re-synthesis by 
glycogen synthase would reside in the inner tiers of the molecule, shielded from 
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Figure 64.  Linear model for phosphate metabolism in glycogen.  A. Normal 
glycogen contains a basal level of phosphorylation.  In mice, the frequency is 
about 1 Pi every 1500 glucose residues.  B. After exhaustive exercise, mouse 
glycogen is depleted to about 20% the basal levels, total phosphate levels 
decrease due to laforin action but the density of phosphate increases slightly as 
the number of glucoses removed by phosphorylase must exceed the number of 
phosphates removed by laforin.  C. In the recovery period, glycogen is 
synthesized and glycogen synthase incorporates phosphate at a rate of 1 Pi 
every 5000-10000 glucose residues.  Although the total amount of phosphate 
increases, the density of phosphate decreases as the incorporation of glucose is 
far greater than that of phosphate.  Only when glycogen synthase has gone 
through multiple rounds of synthesis will phosphate levels reach basal levels. 
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laforin action.  In other words, the basal level of phosphorylation is restricted to 
the inner tiers of the particle or the B chains, consistent with laforin only being 
able to remove 25% of the phosphate from the intact glycogen molecule.  
Nevertheless, depletion of 80% of the glycogen in mouse muscle after exercise, 
assuming all glycogen molecules are degraded equally, would remove the two 
outer tiers plus about 50% of the third outermost tier of the molecule.  However, 
Shearer and Graham (153) have suggested that different pools of glycogen 
granules appear to be degraded preferentially depending on exercise conditions, 
and whether or not this is dependent on the degree of phosphorylation of 
different pools of glycogen is unknown.   
It is also of interest to note that liver glycogen phosphate levels decrease 
as mice age.  Liver glycogen is turned over much more frequently than muscle 
glycogen, as the glucose stored as glycogen in the liver is mobilized to the 
bloodstream in the fasted state.  The decrease in the frequency of 
phosphorylation as mice age may be explained by the same reasoning described 
for muscle glycogen after depletion by exercise.   
The UDP-glucose: glycogen glucose-1-phosphotransferase described by 
Lomako et al. (5) was proposed to transfer the -phosphate of UDP-glucose into 
glycogen with the formation a C1-O-P-O-C6 bridging phosphodiester.  Perhaps 
the most obvious mechanism for the incorporation of phosphate into glycogen 
catalyzed by glycogen synthase would be through the formation of a C1-O-P-O-
C4 phosphodiester.  This is based on the idea that the non-reducing C4-OH in 
the acceptor glycogen molecule is thought to act as a nucleophile, attacking the 
C1 carbon of UDP-glucose with the subsequent formation of an -1,4-glycosidic 
linkage.  Our original hypothesis was that the C4-OH of glycogen would attack 
the electrophilic -phosphate of UDP-glucose forming a C1-O-P-O-C4 
phosphodiester linkage.  However, there is no evidence that laforin has 
phosphodiesterase activity.  In our in vitro characterization of laforin action, we 
were unable to detect activity towards the commercially available p-
nitrophenolphosphocholine or p-nitrophenyl phenylphosphonate, two commonly 
used chromogenic phosphodiesterase substrates.  Therefore, we originally 
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Figure 65.  Proposed mechanism of glycogen polymerization catalyzed by 
glycogen synthase.  An unknown amino acid in the active site of glycogen 
synthase acts as a nucleophile (Nu:) and attacks the anomeric carbon of UDP-
glucose with the release of UDP.  A basic residue (B:) deprotonates and 
activates the C4-OH making the oxygen a good nucleophile.  Attack at C1 
displaces the enzyme and forms an -1,4-glycosidic linkage.   
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hypothesized that there must be a phosphodiesterase that would hydrolyze the 
phosphodiester bond and that laforin would then remove the phosphomonester.  
An interesting phosphodiesterase candidate was the putative glycerophosphoryl 
diester diesterases, KIA1434, that additionally contained a CBM20, but our 
unexpected observation that laforin could hydrolyze phosphate incorporated by 
glycogen synthase, avoids the necessity for a phosphodiesterase such as 
KIAA1434 to remove glycogen synthase incorporated phosphate.   
Our initial attempts at determining the phosphate position of glycogen 
using acid hydrolysis were somewhat misleading since glucose-6P was detected 
in two separate experiments.  The phenomenon of phosphoryl migration under 
acidic conditions has been observed in xylose phosphates (169) and our results 
suggest that this migration phenomenon also occurs in glucose.  Acid hydrolysis 
of glycogen and subsequent determination of glucose-6P enzymatically via 
glucose-6P dehydrogenase revealed the presence of glucose-6P in the 
polysaccharide.  Similarly, acid hydrolysis of the phosphorylated 
oligosaccharides prepared by the enzymatic hydrolysis of glycogen produced 
glucose-6P as judged by HPAEC.  Nonetheless, glucose-6P was not detected by 
NMR spectroscopy analysis of the phosphorylated oligosaccharides, supporting 
the idea of phosphoryl group migration in glucose phosphates during acid 
hydrolysis.   
Glycogen synthase normally transfers the glucosyl moiety of UDP-glucose 
to the non-reducing end of the glycogen particle.  Mechanistically, an active site 
amino acid is thought to act as a nucleophile attacking the anomeric carbon, 
displacing UDP.  A basic amino acid deprotonates the C4-OH of the acceptor 
glycogen molecule, thus making the non-reducing end of glycogen a nucleophile.  
Attack at the anomeric carbon recovers the stereochemistry with the formation of 
an -1,4-glycosidic linkage (Figure 65).  How the -phosphate is incorporated at 
the 2-OH and the 3-OH is speculative at this time but we propose that a similar 
mechanism exists involving the spontaneous formation of glucose-1,2-cyclic 
phosphate and/or glucose-1,3-cyclic phosphate in the active site (Figure 66). 
Nucleophiilic attack at C1 of the cyclic phosphate would open the ring and the 
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Figure 66.  Proposed mechanism for the incorporation of phosphate at the 
C2-OH and the C3-OH in glycogen.  We propose that during catalysis, one 
UDP-glucose molecule for every 5000-10000 that enters the active site of 
glycogen synthase breaks down to form glucose-1,2-cyclic phosphate (left) or 
glucose-1,3-cyclic phosphate (right).  The active site nucleophile breaks the 
unstable cyclic phosphate by attack on C1.  The activated 4-OH attacks the 
anomeric carbon forming an -1,4-glycosidic linkage.  By this mechanism, 
phosphate would be introduced at the C2 and C3 hydroxyls in glycogen by 
glycogen synthase. 
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activated C4-OH at the non-reducing end of glycogen would form an -1-4-
linkage (Figure 66).  We propose that a small fraction of UDP-glucose will form a 
mixture of glucose-1,2-cyclic phosphate and glucose-1,3-cyclic phosphate, the 
former possibly being more prone to attack by a nucleophile at C1 due to the fact 
the five membered cyclic phosphates are less stable than six membered cyclic 
phosphates (168, 173).   
 It is perhaps not uncommon for enzymes to make mistakes.  Most errors 
would go unnoticed, not affecting the cell’s chance of survival in any way.  If 
hexokinase, for example “accidently” phosphorylates one glucose-1P molecule 
for every 10,000 rounds of catalysis with glucose, the mistake would have 
virtually no impact on the survival of the cell.  In the case of DNA synthesis, 
however, these mistakes could have profound impact on the survival of not only 
the cell but the organism.  Therefore, evolution has found ways to correct these 
mistakes through repair proteins.  Our data suggest that this is true for glycogen 
as well.  The inadvertent incorporation of phosphate into glycogen during 
glycogen synthesis, over time, has profound implications for glycogen structure 
and metabolism, as highlighted in patients with Lafora disease.  It is interesting, 
and perhaps very informative, that through evolution laforin is found for the most 
part, only in vertebrates.  Do errors in glycogen synthesis only affect species that 
live long enough?  Our attempts to measure total phosphate in the budding yeast, 
S. cerevesiae were unsuccessful, as we could never purify the glycogen 
sufficiently to remove contaminating material.  Nonetheless, treatment with laforin 
was unable to release any detectable inorganic phosphate (data not shown), 
quite possibly because yeast glycogen does not contain significant levels of 
phosphate.  One possibility could be that yeast do not live long enough for 
glycogen synthase to catalyze enough rounds of synthesis to incorporate 
detectable levels of phosphate.  However, throughout evolution, multicellular 
eukaryotes such as vertebrates lived long enough for phosphate to accumulate in 
the glycogen molecule and subsequently become toxic to the cell.  Natural 
selection would favor those species that were able to “repair” their glycogen by 
removing the phosphate via laforin. 
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 A characteristic feature of Lafora bodies is that the frequency of -1,6-
glycosidic linkages is reduced.  The mechanism by which phosphate affects 
branching of glycogen is speculative at this time.  It remains to be seen if 
substrate specificity of the branching enzyme may be hindered by the presence 
of phosphate in a polysaccharide helix.  There is precedent for this idea, as the 
glycogen hydrolyzing enzymes -amylase and amyloglucosidase are not capable 
of quantitatively degrading glycogen to glucose.  Perhaps this is due to the 
phosphate disrupting the secondary structure of a chain making phosphorylated 
regions of the polysaccharide resistant to enzymatic hydrolysis.  In the cell, 
phosphorylated glycogen may prevent the branching enzyme from binding and 
forming an -1,6-glycosidic linkage.  Furthermore, it seems likely that glycogen 
phosphorylase will not be able to degrade past a phosphate during 
glycogenolysis.  Phosphorylase is thought to degrade glycogen through transfer 
of a molecule of inorganic phosphate to the anomeric carbon at the non-reducing 
end, making glucose-1P a good leaving group with subsequent phosphorolysis.  
Incorporation of phosphate at the 2 or 3 hydroxyls would likely, for steric reasons, 
prevent the transfer of inorganic phosphate to C1, thus preventing glycogen 
degradation.  Furthermore, phosphorylase may not be active towards a 
phosphorylated chain, as the secondary structure would be altered and binding 
may not be feasible.  The end result would be an increase in total glycogen in the 
absence of laforin.   
In summary, we envision a glycogen damage/repair process (Figure 67) 
that involves the transfer of the -phosphate of UDP-glucose to the 2-OH and the 
3-OH of a glycogen molecule during polymerization by glycogen synthase.  
Excessive phosphorylation “damages” the glycogen molecule by altering the 
physico-chemical properties of the polysaccharide that, if not “repaired” by laforin 
action, results in the formation of Lafora bodies in patients with Lafora disease.
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Figure 67.  The metabolism of the covalent phosphate in glycogen.  We envision a glycogen damage/repair 
process.  During glycogen synthesis, glycogen synthase transfers the -phosphate of UDP-glucose to glycogen with 
the formation of C2 and C3 phosphomonoesters.  In the absence of the glycogen phosphatase laforin, such as in 
patients with Lafora disease, glycogen becomes excessively phosphorylated.  The increase in phosphate disrupts 
the physico-chemical properties of the polysaccharide and with time, leads to the formation of Lafora bodies.  We 
propose that laforin is a glycogen repair protein that repairs the damage incurred by glycogen synthase. 
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